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ABSTRACT 
 
DETERMINING THE ROLE OF AUTOPHAGY IN HER2/neu-INDUCED MAMMARY TUMOR 
DORMANCY AND RECURRENCE 
 
Samantha L. Dwyer 
Lewis A. Chodosh, M.D., Ph.D. 
 
Mortality from breast cancer is principally due to tumor recurrence.  Recurrent breast 
cancers arise from the pool of residual tumor cells, termed minimal residual disease, that survive 
treatment and may exist in a dormant state for up to 20 years following treatment of the primary 
tumor.  As recurrent breast cancer is typically a fatal disease, understanding the mechanisms 
underlying dormant tumor cell survival is a critical priority in breast cancer research.  Using a 
HER2/neu inducible bitransgenic mouse model, we demonstrate that the survival and recurrence 
of dormant mammary tumor cells is dependent on autophagy.  We find that autophagy is induced 
in vivo following HER2/neu down-regulation and remains activated in dormant residual tumor 
cells.  Using genetic and pharmacological approaches we demonstrate that inhibition of 
autophagy by chloroquine administration, Atg5 or Atg7 knockdown, or deletion of a single allele of 
the tumor suppressor Beclin 1 is sufficient to inhibit mammary tumor recurrence and that 
autophagy inhibition in dormant mammary tumor cells in vivo results in their death.  Together, our 
findings establish a pro-tumorigenic role for autophagy in tumor dormancy and recurrence, 
demonstrate that dormant tumor cells are uniquely reliant upon autophagy for their survival, and 
reveal that targeting dormant residual tumor cells by inhibiting autophagy is sufficient to impair 
tumor recurrence.  Additionally, we found that the mTOR inhibitor rapamycin delayed mammary 
tumor recurrence in this same mouse model by decreasing the survival of dormant mammary 
tumor cells.  These studies identify pharmacological targets for a cellular state that is resistant to 
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commonly used anti-neoplastic agents and suggest that autophagy inhibition as well as mTOR 
inhibition may be particularly effective in the context of dormant minimal residual disease. 
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CHAPTER I:  Autophagy and Breast Cancer Recurrence 
 2 
   
BREAST CANCER RECURRENCE 
 
Epidemiology 
Breast cancer is the leading cause of cancer mortality in women worldwide1.  It is also the 
most frequently diagnosed malignancy in females in both economically developed and developing 
countries.  In 2008, an estimated 1.38 million new cases of breast cancer were diagnosed and 
approximately 460,000 deaths from breast cancer were reported.  In the United States, 232,340 
new cases and 39,620 estimated deaths from breast cancer are expected in 2013, making this 
disease the most commonly diagnosed cancer in all women and the most common cause of 
cancer death in women ages 20 to 59.  It is estimated that 1 in 8 women in the United States will 
develop invasive breast cancer within their lifetime.  Nevertheless, there has been a steady 
decrease in mortality from breast cancer since 1975 largely due to early detection through 
mammography and improved therapies2.   
There are multiple risk factors associated with the development of breast cancer.  First, 
gender is a predominant risk factor for the development breast cancer as women are more than 
100 times more likely to be diagnosed with the disease than men2.  Beyond gender, age has the 
greatest influence on breast cancer risk.  The probability of a woman developing breast cancer 
increases exponentially with age: before the age of 39 the risk of developing breast cancer is 
approximately 0.5%, whereas this increases to 6.65% by 70 years of age.  Lifestyle is also 
associated with the risk of breast cancer.  Reproductive factors including nulliparity, increasing 
age at first full-term pregnancy, decreasing duration of lactation, and recent use of 
postmenopausal hormone therapy each have been associated with an increase in a woman’s risk 
of developing breast cancer3.  In addition, women who are obese, physically inactive, smoke 
tobacco, or consume large quantities of alcohol are also more likely to be diagnosed with breast 
cancer4-7. 
Family history and genetic susceptibility are also important factors that determine a 
women’s risk of developing breast cancer.  Approximately 5-10% of breast cancer cases are 
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hereditary8.  A woman with a mother, sister, or daughter with breast cancer has an approximately 
two-fold excess risk of developing this disease9.  Having multiple affected first-degree relatives 
further increases the risk.  Additionally, inheritance of genetic mutations predisposes a woman to 
developing breast cancer.  Mutations in BRCA1 and BRCA2 genes can increase a women’s risk 
up to 85%10.  Increased risk of being diagnosed with breast cancer is also associated with 
mutations in p53, PTEN, LKB1, and CDH1. 
 Despite 5-year survival rates approaching 90% in women diagnosed with breast cancer2, 
recurrent breast cancer is almost always fatal and is the primary cause of mortality from this 
disease.  Breast cancer can recur at local, regional, or distant sites, with the majority of 
recurrences appearing within 2 to 5 years after surgical removal of the primary tumor and 
administration of adjuvant therapy11.  However, breast cancer patients can relapse up to 25 years 
following treatment of the primary disease.  This is preferentially seen in women with tumors that 
express estrogen receptor (ER-positive), as the risk for relapse for these patients continues up to 
20 years after initial treatment12.   
Prognostic factors have been identified that predict recurrence-free survival in breast 
cancer patients, including lymph node status, histological grade, tumor size, ER status, and 
HER2/neu status.  Based on these factors, patients are considered at highest risk of breast 
cancer relapse if they have positive lymph node involvement (> 3), high grade (> 2), or large 
tumor size (> 3 cm) 13-15.  Estrogen receptor status is also a strong indicator of recurrence risk as 
ER-positive patients tend to have more favorable outcomes.  Lastly, women with tumors that 
over-express or amplify the receptor tyrosine kinase HER2/neu are at high risk of breast cancer 
recurrence independent of other prognostic factors12,16,17.  Despite the identification of these 
prognostic factors associated with relapse, the mechanisms of breast cancer recurrence are 
presently unknown.  As recurrence is the primary cause of breast cancer-related death, 
understanding this stage in tumor progression is necessary to improve the treatment and survival 
of women diagnosed with this disease. 
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HER2/neu Amplification and Breast Cancer Recurrence 
Human epidermal growth factor receptor 2 (HER2), also known as neu or ErbB2, is 
amplified or overexpressed in approximately 30% of breast cancers (termed HER2/neu-
positive)16,18,19.  Overexpression of HER2/neu in mammary tumor cells independently predicts 
decreased recurrence-free survival, breast cancer-related survival, and overall survival, making it 
a marker of aggressive disease that is associated with poor patient outcome12,16,17,20.  
Additionally, HER2/neu expression in human breast cancers is correlated with age greater than 
50, large tumor size, and high histological grade, each of which are factors that predict poor 
prognosis.   
HER2/neu is a member of the transmembrane ErbB receptor tyrosine kinase family, 
which also includes EGFR (ErbB1), HER3 (ErbB3), and HER4 (ErbB4).  In a ligand-dependent or 
independent manner, homo- and heterodimerization of ErbB family members occurs, which 
triggers autophosphorylation of the intracellular domain of these receptors.  This, in turn, induces 
downstream signaling pathways such as the phosphatidylinositol 3-kinase (PI3K)-protein kinase 
B (Akt)-mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK) 
pathways to regulate cell growth, survival, and differentiation.  Constitutive downstream signaling 
results as a consequence of HER2/neu being highly expressed and accumulating at the 
membrane in HER2/neu-positive breast cancers21,22.  HER2/neu is the preferred dimerization 
partner of the other ErbB family members and has no known ligand20,23. 
Two FDA-approved therapies exist that target HER2/neu in breast cancer.  Trastuzumab 
(Herceptin) is a humanized monoclonal antibody directed against the extracellular domain of 
HER2/neu24.  Lapatinib is a small molecule ATP-competitive kinase inhibitor that affects both 
EGFR and HER2/neu in a reversible manner25.  These treatments have each shown clinical 
benefit in HER2/neu-positive breast cancer patients.  For example, trastuzumab administered in 
the adjuvant setting to women with HER2/neu-positive breast cancer improved disease-free 
survival (odds ratio [OR] = 0.69) and overall survival (OR = 0.78) in addition to decreasing the risk 
of locoregional (OR = 0.53) and distant recurrence (OR = 0.62)26.  Lapatinib in combination with 
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capecitabine increased the overall response rate in HER2/neu-positive patients from 14% (seen 
with capecitabine alone) to 24%27.  Unfortunately, there are women diagnosed with HER2/neu-
positive breast cancer that never respond HER2-targeted therapies20,23.  Additionally, many 
HER2/neu-positive breast cancers progress after initially responding to trastuzumab or lapatinib, 
resulting in recurrent disease and death.   
Multiple mechanisms of resistance to inhibitors of HER2/neu have been proposed20,23.  
Recurrent tumor cells have been shown to express a truncated form of HER2/neu that lacks the 
trastuzumab-binding domain (p95HER2), rendering them resistant to trastuzumab28.  Loss of the 
phosphatase and tensin homolog (PTEN) or p27Kip1 expression, over-expression of the IGF-1R 
or c-MET receptor tyrosine kinases, and mutations in PIK3CA, which encodes the 110 kDa 
catalytic subunit of PI3K, have each been implicated in resistance to trastuzumab29-34.  
Understanding how mammary tumor cells survive HER2/neu targeted therapies and ultimately 
recur is extremely important for the successful treatment and prevention of breast cancer 
recurrence. 
 
Tumor Dormancy and Recurrence 
Mortality from breast cancer is principally due to recurrence following a period of clinical 
remission after primary treatment.  During this period of remission, disseminated tumor cells can 
be detected in the blood or bone marrow of patients more than 20 years after primary diagnosis35.  
This state in which cancer cells persist, but do not manifest themselves clinically, is defined as 
dormancy.  It is these dormant tumor cells that ultimately result in recurrent breast cancer.  
Despite the importance of residual tumor cells in breast cancer progression, little is known about 
the mechanism of survival of dormant tumor cells. 
The concept of tumor dormancy originated from clinical studies suggesting that the length 
of time from remission to recurrence was not consistent with a continuous tumor cell growth 
model.  However, these recurrence kinetics could be explained if tumor cells experienced periods 
of interrupted growth, or dormancy36-38.  Since the initial description of this phenomenon in the 
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clinic, two distinctly different modes of dormancy have been characterized: tumor mass dormancy 
and cellular dormancy.  First, tumor mass dormancy consists of dormant micrometastases that 
are small, undetectable tumors that do not increase in size because tumor cells undergo an equal 
rate of proliferation and apoptosis.  Micrometastases will remain in this state until they can recruit 
new blood vessels, an event known as the “angiogenic switch,” or until they can evade the 
immune system39-41.  In contrast, cellular dormancy involves solitary dormant tumor cells that 
have survived primary treatment.  These dormant tumor cells are quiescent and exist in the 
absence of proliferation and apoptosis41,42. 
It is unclear whether these two distinct types of dormancy are mutually exclusive, but 
there is little evidence of tumor mass dormancy in the clinic.  Cellular dormancy, on the other 
hand, has been observed in breast cancer patients.  Minimal residual disease can be detected in 
the bone marrow and predicts poor prognosis43.  Characterization of these disseminated tumor 
cells (DTCs) has proven difficult as they are very rare, but the residual tumor cells able to be 
recovered were found to be quiescent as they do not stain for the proliferation marker Ki6744,45.  
Therefore, DTCs found in breast cancer patients can be classified as cellular dormancy.  These 
solitary dormant cells are also of interest because they may be protected from conventional 
chemotherapies that rely on cell cycle progression to exert their cytotoxic effects46.  Therefore, 
dissecting the mechanism used by solitary dormant tumor cells to survive is necessary for the 
development of therapies that can prevent breast cancer recurrence.    
Preclinical models for studying dormancy have been described and are beginning to 
provide insights into the molecular mechanisms that regulate tumor dormancy46-53.  First, the 
Folkman group generated mouse models of tumor mass dormancy by injecting multiple tumor 
cells lines subcutaneously into immunocompromised mice54.  They then analyzed tumor growth, 
proliferation of tumor cells, and vascularization of tumors.  Some cell lines, termed non-
angiogenic, formed macroscopic tumors that remain dormant for prolonged periods of time before 
recruiting a blood supply and growing more rapidly.  It was later found that during angiogenesis, 
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expression of the Notch ligand DII4 by endothelial cells was increased55.  This induced Notch3 
signaling in dormant tumor cells and promoted proliferation and escape from dormancy. 
The immune system has been implicated in promoting tumor dormancy as well.  In a 
model of BCL-1 B cell lymphoma, CD8+ T cells maintained tumor cells in a dormant state56.  
Additionally, immunosurveillance mediated by cytostatic CD8+ T cells limited the outgrowth of 
dormant tumor cells in a mouse model of melanoma57. 
The microenvironment has also been shown to positively regulate tumor dormancy 
through decreased β1 integrin signaling both in vitro and in vivo58-61.  Using an in vitro 3-
dimensional culture system that models dormancy, it was found that the addition of fibronectin or 
type I collagen to the extracellular matrix (ECM) activated β1 integrin signaling and induced the 
proliferation of dormant tumor cells.  Proliferation was mediated by Src kinase and focal adhesion 
kinase (FAK) activation in tumor cells downstream of β1 integrin.  FAK then activated extracellular 
signal-regulated kinase (ERK), which induced phosphorylation of myosin light chain (MLC) by 
MLC kinase and resulted in cytoskeleton reorganization.  ERK activation further promoted cellular 
proliferation by causing the translocation of p27Kip1 to the cytoplasm.  Conversely, inhibition of 
β1 integrin signaling maintained tumor cells in a dormant state. 
Lastly, a model using human epidermoid carcinoma HEp3 cells in the chick embryo has 
been used to identify molecular mechanisms of tumor dormancy.  The failure of HEp3 cells to 
establish interactions with the ECM induces quiescence in this system as well62,63.  Down-
regulation of urokinase receptor (uPAR) was observed in dormant HEp3 cells.  The interaction 
between uPAR and α5β1 integrins in the ECM was therefore reduced, consequently decreasing 
FAK-ERK signaling while increasing the activity of p38.  The reduced ratio of ERK to p38 activity 
resulted in the induction of dormancy.  In contrast, increased uPAR expression in proliferative 
HEp3 cells induced α5β1 integrins, activated FAK-ERK signaling, and decreased p38 activity. 
Further exploring mechanisms of dormancy using the chick embryo system, the unfolded 
protein response (UPR) was found to be activated by p38 in dormant HEp3 cells64-66.  Pancreatic 
endoplasmic reticulum kinase (PERK)-eukaryotic initiation factor 2α (eIF2α) signaling contributed 
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to quiescence in these cells by down-regulating cyclin D1 and cyclin D3.  Additionally, the UPR 
was found to promote the survival of dormant HEp3 cells.  Inhibition of PERK sensitized dormant 
HEp3 cells to glucose deprivation and chemotherapy.  ATF6α-Rheb-mTOR signaling also 
promotes survival as knockdown of ATF6α or Rheb induced apoptosis of dormant HEp3 cells67. 
 
Inducible HER2/neu Bitransgenic Mouse Model of Breast Cancer Dormancy and 
Recurrence 
Little is known about the biology of solitary dormant tumor cells, primarily due to the 
difficulty in finding, isolating, and analyzing dormant tumor cells in vivo.  To address this gap, we 
have developed a genetically engineered mouse model for mammary tumor dormancy and 
recurrence68-71.  This model accurately recapitulates key features of the natural history of breast 
cancer as it occurs in women.  This model consists of inducible MMTV-rtTA;TetO-neu (MTB/TAN) 
bitransgenic mice that conditionally express the HER2/neu oncogene in mammary epithelial cells 
in a doxycycline-dependent manner.  Following primary tumor development, oncogene down-
regulation by doxycycline withdrawal results in the regression of primary mammary tumors to a 
non-palpable state due to a phenomenon termed “oncogene addiction.”  However, a small 
population of residual tumor cells survives oncogene down-regulation and remains dormant within 
residual lesions in the mammary gland.  These residual tumor cells are quiescent and resemble 
the cellular dormancy observed in women with breast cancer44,45.  After a variable latency period, 
residual cells give rise to rapidly growing recurrent tumors that result in the death of the animal.  
Additional studies from our laboratory have generated and characterized an inducible tumor cell 
line from this model that also becomes dormant following HER2/neu down-regulation and recurs 
when orthotopically transplanted into the mammary glands of immunocompromised mice.  In this 
thesis, each of these doxycycline-dependent inducible mouse models has been used to 
investigate the function of autophagy in mammary tumor dormancy and recurrence. 
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AUTOPHAGY 
 
Autophagy, also referred to as macroautophagy, is an evolutionarily conserved catabolic 
process involving the degradation of organelles and proteins through the lysosome72-74.  Upon 
signaling from inside or outside the cell, a double-membraned structure called the phagophore 
encloses cytoplasmic contents, thereby creating the autophagosome.  This vesicle is unique to 
this process, and its visualization by electron microscopy allows for identification of cells 
undergoing autophagy75.  The autophagosome then fuses with the lysosome where hydrolytic 
enzymes degrade the enclosed organelles and proteins, allowing their components to be recycled 
back to the cytoplasm and reused.  Autophagy is often non-selective and engulfs the cytoplasm in 
a random manner.  However, autophagy can specifically target ubiquitinated proteins, 
mitochondria, and peroxisomes for degradation. 
 
Autophagy Machinery 
Autophagy was first studied in Saccharomyces cerevisiae, where 35 autophagy-related 
(Atg) genes have been identified76.  Mammalian orthologs of many of these Atg genes exist and 
have been found to play similar roles.  The majority of Atg proteins are involved in 
autophagosome biogenesis, a multistep process that involves initiation and elongation of the 
phagophore73,74.  Initiation of phagophore formation is controlled by two Atg gene-containing 
complexes.  First, the ULK1/Atg1 complex is composed of Unc-51-like kinase 1 (ULK1) or its 
homolog ULK2, Atg13, focal adhesion kinase family interacting protein of 200 kDa (FIP200), and 
Atg10177,78.  This complex is present regardless of the status of autophagy within a mammalian 
cell.  ULK1 is a serine/threonine kinase that, once activated, phosphorylates Atg13, Atg101, and 
itself to initiate autophagy by translocating to the developing membrane.  The exact function of 
this complex during autophagosome formation is still unclear as relevant targets of ULK1 are 
unknown74.  ULK1 is considered the major Atg1 homolog as ULK2 has redundant function79.   
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The second complex that regulates autophagosome initiation is the Class III PI3K 
complex80-83.  This particular PI3K complex consists of Vps34 (the PI3 kinase), Beclin 1/Atg6, 
Barkor/Atg14, and p150/Vps15.  When present within this complex, Vps34 is active and produces 
phosphatidylinositol-3-phosphate (PI-3-P) that is then incorporated into the autophagosome.  The 
precise role for this molecule in autophagosome formation is unclear, but it is proposed that 
essential PI-3-P effector proteins, such as WIPI-1/Atg18, are recruited to the phagophore 
membrane73.  Additional members of this PI3K complex, such as Ambra-1, UVRAG, and Bif-1, 
bind Beclin 1 and positively regulate autophagosome formation84-86.  Conversely, proteins that 
bind Beclin 1, such as the anti-apoptotic proteins Bcl-2 and Bcl-XL, can disrupt formation of the 
PI3K complex, decrease Vps34 activity, and inhibit autophagy87.   
The origin of the membranes that comprise the phagophore is uncertain.  They may be 
generated de novo or arise from cellular organelles such as the endoplasmic reticulum (ER), 
mitochondria, Golgi apparatus, or plasma membrane73,74.  The next step in autophagosome 
formation, elongation of the membrane, most likely involves input from these organelles as well.  
Atg9L1 is a transmembrane protein that shuttles between the trans-Golgi network and the 
phagophore, possibly to carry membranes for expansion of the autophagosome88. 
Elongation of the phagophore also involves two ubiquitin-like conjugation reactions.  In 
the first of these reactions, the ubiquitin-like protein Atg12 is covalently linked to Atg5 by the E1 
ubiquitin activating enzyme-like protein Atg7 and the E2 ubiquitin conjugating enzyme-like protein 
Atg1089.  This Atg12-Atg5 conjugate then interacts with Atg16L1 to form a tetrameric complex that 
is required for elongation of the double membranes89,90.  This complex is always present within 
the cell and is necessary for the subsequent ubiquitin-like conjugation reaction, cleavage and 
lipidation of microtubule-associated protein 1 light chain 3 (LC3/Atg8)91. 
The LC3 ubiquitin conjugation reaction is also required for elongation of the 
phagophore92.  Upon induction of autophagy, the LC3 precursor is cleaved at its C-terminus by 
Atg4 to generate the LC3-I isoform.  LC3-I is present throughout the cytoplasm of cells that are 
not undergoing autophagy.  Once phagophore formation has been initiated, LC3-I is conjugated 
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to phosphatidylethanolamine (PE) to form LC3-II by Atg7 and the E2-like protein Atg3.  LC3-II is 
incorporated into each of the membranes of the expanding phagophore, with internal LC3-II being 
degraded in the autolysosome and cytoplasmic LC3-II being delipidated by Atg4 and recycled.  
The formation of LC3-II specifically in cells undergoing autophagy, and its association with the 
autophagosome, make it an excellent marker for studying autophagy75.  LC3-II also recruits 
adaptor proteins, such as p62, to autophagosomes so that ubiquitin-conjugated proteins can be 
selectively degraded through autophagy93. 
Lastly, autophagosomes must move bidirectionally along microtubules to areas where 
lysosomes are enriched and then fuse with them to form autolysosomes.  Proteins including 
ESCRT, SNAREs, Rab7, and the class C Vps proteins are involved in autophagosome/lysosome 
fusion73.  Additionally, PI3K complexes distinct from those necessary for autophagosome 
formation play a role in fusion.  UVRAG, when in complex with Vps34, Vps15, and Beclin 1, 
promotes fusion by recruiting the class C Vps proteins to the autophagosome94.  Alternatively, 
Rubicon inhibits autophagosome fusion when it interacts with this UVRAG-containing PI3K 
complex81,82.  Once fusion is complete, lysosomal H+-ATPases degrade the cytoplasmic contents 
so their building blocks can be recycled for reuse by the cell. 
 
Regulation of Autophagy 
 There are several signaling pathways that have been found to regulate autophagy in 
mammalian cells.  First, and the most studied, is the mTOR pathway95.  mTOR is a 
serine/threonine kinase that regulates multiple cellular functions, including cell survival, protein 
and lipid synthesis, energy metabolism, cytoskeleton reorganization, and autophagy.  
Accordingly, mTOR activity is regulated by growth factors, amino acids, glucose, energy status, 
and cellular stresses.  mTOR exists within 2 complexes, mTORC1 and mTORC2, that are 
functionally distinct.  mTORC1 regulates autophagy through inhibition of the ULK1/Atg1 
complex77,78,96.  ULK1 is constitutively complexed with Atg13, FIP200, and Atg101.  Under 
nutrient rich conditions, mTORC1 suppresses autophagy by phosphorylating ULK1 and Atg13, 
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rendering them catalytically inactive and unable to initiate autophagosome formation.  During 
starvation, mTORC1 dissociates from the ULK1 complex and no longer phosphorylates ULK1 or 
Atg13.  ULK1 then phosphorylates Atg13, Atg101, and itself to induce autophagy. 
 The PI3K-Akt pathway is upstream of mTORC1 and negatively regulates autophagy97.  
Growth factors activate PI3K, inducing the conversion of phosphatidylinositol (4,5)-bisphosphate 
(PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3).  This recruits phosphoinositide-
dependent kinase 1 (PDK1) and Akt to the plasma membrane.  Akt is activated by 
phosphorylation at serine 473 by mTORC2, followed by phosphorylation by PDK1 at threonine 
308.  In contrast, Akt activity is negatively regulated by PTEN.  Once Akt is activated, it can 
positively regulate mTORC1 through two mechanisms.  First, Akt phosphorylates and inactivates 
TSC1/2.  Tuberous sclerosis 1 (TSC1) and TSC2 form a heterodimer that functions as a GTPase 
activating protein (GAP) for the GTPase Ras homolog enriched in brain (Rheb).  Rheb stimulates 
mTORC1 activity by direct interaction98,99.  Additionally, Akt can promote mTORC1 activity by 
inactivating PRAS40, an mTORC1 inhibitor100. 
There are signaling events besides PI3K-Akt that regulate mTORC1 and autophagy.  
Amino acids activate mTORC1 and must be present for any other upstream signal to activate the 
complex.  In response to amino acids, the GTPases RagA/B bind GTP, permitting them to 
interact with the raptor component of mTORC1.  This stimulates translocation of mTORC1 to the 
lysosome where it comes in contact with Rheb and is activated101,102.  5’ adenosine 
monophosphate-activated protein kinase (AMPK) inhibits mTORC1 and therefore induces 
autophagy103.  Under conditions where the intracellular AMP/ATP ratio is increased, AMPK 
becomes active and phosphorylates raptor, a component of mTORC1, resulting in the 
dissociation of this complex.  Furthermore, AMPK, IKKβ, and canonical Wnt signaling can inhibit 
TSC1/2104-106. 
 The regulation of mTORC1 by p53 is complex.  Under conditions of genotoxic or 
oxidative stress, p53 is stabilized and inhibits mTOR signaling in either a transcription-dependent 
mechanism through up-regulation of AMPK and PTEN, or a transcription-independent 
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mechanism through the activation of AMPK107,108.  This results in the activation of autophagy.  
Paradoxically, p53 loss has been reported to induce autophagy.  Genetic or chemical inhibition of 
p53, or p53 depletion due to starvation or ER stress, inhibits mTORC1 through AMPK activation.  
p53 loss can also activate autophagy by directly inducing ER stress signaling through IRE-1α109.  
It is currently unclear how to reconcile these conflicting effects of p53 on autophagy. 
In addition to the ULK1 complex, the PI3K complex required for autophagosome 
elongation is regulated by upstream signaling pathways, but this regulation does not involve 
mTOR.  During starvation, JUN N-terminal kinase 1 (JNK1) induces autophagy by 
phosphorylating Bcl-2110.  Phospho-Bcl-2 can no longer bind to the BH3 domain of Beclin 1, 
rendering Beclin 1 free to form the PI3K complex and stimulate autophagy.  Expression of Beclin 
1 and BNIP3, an additional positive autophagy regulator, can also be up-regulated by Ras 
signaling111,112. 
Additional signaling pathways can regulate mammalian autophagy independently of 
mTORC1.  AMPK has recently been shown to directly phosphorylate ULK1 and regulate the 
ULK1 complex to induce autophagy113,114.  In the phosphoinositol signaling pathway, G protein-
coupled receptors activate phospholipase C (PLC), which hydrolyzes PIP2 to inositol 1,4,5-
trphosphate (IP3) and diacylglycerol (DAG).  IP3 is a second messenger that is believed to inhibit 
autophagy by mediating the release of the endoplasmic reticulum Ca2+ store into the 
cytoplasm115. 
 
Functions of Autophagy 
Under normal physiological conditions, autophagy can promote cell survival or maintain 
cellular homeostasis.  Basal autophagy occurs in all cell types and functions to eliminate protein 
aggregates and damaged organelles.  Peroxisomes can be removed through autophagy116.  
Abnormal proteins and organelles, such as ubiquitinated protein aggregates and deformed 
organelles, accumulate in autophagy-deficient hepatocytes, neurons, and cardiomyocytes117-120.  
Defective mitochondria are removed through autophagy to limit the production of reactive oxygen 
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species (ROS) before extensive genomic damage can occur121.  Likewise, autophagy can 
sequester intracellular pathogens and degrade them through fusion with the lysosome122,123. 
Autophagy is also required during development.  Degradation of components of the 
ooycyte cytoplasm through autophagy is necessary following fertilization during the pre-
implantation period in mice124.  Also, post-fertilization, paternal mitochondria are eliminated 
through autophagy in C. elegans125,126.  Autophagy is involved in the differentiation of 
erythrocytes, lymphocytes, and adipocytes as well by remodeling the cytoplasm127.  Other 
standard functions of autophagy include anti-ageing and regulation of the innate immune system 
by promoting antigen presentation128. 
Autophagy can also be stimulated in response to multiple cellular stresses, the most 
studied being starvation.  Autophagy allows cells to adapt to low nutrient availability through the 
degradation of proteins, carbohydrates, and lipids to maintain cellular metabolism and generate 
energy72,128.  For example, autophagy has been shown to support the viability of a hematopoietic 
cell line as inhibition of this process increased cell death upon growth factor deprivation129.  
Autophagy inhibition plus the addition of methylpyruvate, a tricarboxcylic acid (TCA) cycle 
substrate, rescued the decrease in viability upon withdrawal of growth factors, suggesting 
autophagy is necessary to generate energy in these cells.  Studies in mice add further evidence 
for the need of autophagy to generate energy.  The induction of autophagy is critical for 
maintaining energy levels in various tissues after loss of maternal food supply130.  AMPK was 
found to be activated in the hearts of starved autophagy-deficient mice, suggesting that 
autophagy is necessary to maintain a low AMP/ATP ratio within the cell.  
Autophagy is also a survival mechanism employed by cells facing periods of hypoxia or 
that experience ER stress.  Hypoxia, or conditions of approximately 0.5-3% oxygen, can induce 
cell death through decreased mitochondrial metabolism131.  However, cells can survive this stress 
by stabilizing the hypoxia-inducible factor-1 (HIF-1) complex, up-regulating the transcription of 
autophagy regulators BNIP3 and BNIP3L, and inducing autophagy132,133.  When ER stress, 
brought on by conditions such as ER-Ca2+-depletion, oxidative injury, or hypoglycemia, becomes 
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too great or persists for long periods of time, cell death can occur134.  Autophagy allows cells to 
adapt by contributing to the elimination of unfolded or aggregated proteins and promoting cell 
survival135,136.   
 Autophagy has been found to be dysregulated in multiple disorders, such as metabolic 
diseases, neurodegenerative disorders, infectious disease, and cancer128,137.  Specifically in 
regards to cancer, the role autophagy plays is controversial as it has been shown to both 
suppress and promote tumorigenesis.  However, it is beginning to become clear that autophagy is 
a tumor suppressive process that inhibits the initiation of malignant disease, but is also survival 
pathway that allows cells in primary tumors to avoid death due to metabolic stress and currently 
used chemotherapeutic agents128.  This has led to the evaluation of autophagy as a potential 
target in several types of cancers138-140.  However, unlike primary tumor growth, there is little 
known about the role of autophagy during tumor dormancy and recurrence.  Using genetically 
engineered mice, we set out to determine if autophagy promotes tumor recurrence by supporting 
the survival of dormant tumor cells, or alternatively suppresses mammary recurrent tumor 
formation. 
 
Autophagy is Tumor Suppressive 
Autophagy is widely accepted to constitute a tumor suppressive process.  The positive 
regulator of autophagy, Beclin 1, is monoallelically deleted in 50% of sporadic human breast 
carcinomas and is associated with increased susceptibility to ovarian and prostate cancer in 
humans141.  Additionally, frameshift mutations in the UVRAG gene occur in colon and gastric 
cancers142.  Lower Beclin 1 levels correspond to poor prognosis in patients with esophageal 
squamous cell carcinoma (ESCC)143, colon cancer144, and pancreatic ductal carcinoma145.  High 
levels of Beclin 1 correspond to increased survival in high grade gliomas146, hepatocellular 
carcinoma147, and large B-cell lymphoma148. 
Autophagy-deficient mouse lines have been generated and support the conclusion that 
autophagy inhibits tumorigenesis.  Beclin 1+/- mice develop spontaneous liver and lung cancers 
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as well as lymphomas, in addition to displaying hyperproliferation of mammary epithelial 
cells149,150.  Bif-/- mice have increased incidence of multiple spontaneous malignancies86 and 
Atg4C-deficient mice are more susceptible to chemically-induced fibrosarcoma151.  Liver-specific 
deletion of Atg7 leads to spontaneous benign liver adenomas as does mosaic deletion of Atg5152.  
Moreover, over-expression of Beclin 1 in the human breast cancer cell line MCF-7, which 
otherwise does not express Beclin 1, impairs its growth in vitro and tumorigenicity in vivo153.   
There is also a great deal of overlap between oncogenic signaling and suppression of 
autophagy.  As described above, several tumor suppressors stimulate autophagy, such as PTEN, 
TSC1/2, p53, and LKB1 (an activator of AMPK).  Conversely, multiple oncogenes, including PI3K, 
Akt, and Bcl-2, inhibit autophagy154. 
The precise mechanisms by which autophagy suppresses tumor formation are not 
completely understood.  One possibility is that autophagy defects promote tumorigenesis through 
increased mutagenesis and chronic inflammation155-158.  Loss of one allele of Beclin 1 increases 
chromosome instability and accelerates the growth of tumor xenografts generated from 
immortalized baby mouse kidney cells (iBMKs)157 and immortalized mouse mammary epithelial 
cells (iMMECs)155.  Additionally, Atg5-/- iBMKs showed increased p62 levels along with increased 
genomic instability, suggesting a role for this molecule in promoting tumorigenesis158.  Also, in 
autophagy-deficient iBMK tumor allografts, tissue damage stimulated a chronic inflammatory 
response that fueled tumor growth156.  Another potential mechanism is that autophagy promotes 
oncogene-induced senescence to inhibit tumorigenesis159 
 
Autophagy is Pro-Tumorigenic 
Alternatively, increasing evidence suggests autophagy is required for tumor progression.  
Monoallelic deletion of Beclin 1 decreased renal tumor formation in Tsc2+/- mice and delayed the 
onset of spontaneous T-cell lymphoma in ATM-/- mice160,161.  In the MMTV-PyMT mouse model of 
breast cancer, FIP200 deletion delayed the formation of mammary tumors162.  Also, knockdown 
of essential autophagy genes impaired the growth of human pancreatic ductal carcinoma 
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tumors163.  Interestingly, autophagy was recently found to promote tumorigenesis of Ras-
transformed iBMKs in vivo164.  It is currently unclear whether this requirement is specific to Ras-
driven tumors or will be observed in the context of tumors driven by other oncogenes. 
Maintaining cellular metabolism and homeostasis by recycling cellular components 
through autophagy can create a survival mechanism for tumor cells facing different types of 
stress.  For example, Beclin 1+/- iBMKs and iMMECs are more sensitive to metabolic stress in 
vitro, albeit more tumorigenic in vivo, than their Beclin 1+/+ counterparts155,156,158.  Deletion of 
essential autophagy genes also results in tumor cell death specifically in hypoxic regions of the 
tumor128.  Furthermore, autophagy has been shown to promote the survival of tumor cells from a 
Myc-induced mouse model of lymphoma in response to p53 activation or chemotherapy139.  
Autophagy can also provide resistance to cell death induced by multiple cytotoxic agents137,138.  
Accordingly, many clinical trials have been initiated to test autophagy inhibitors in combination 
with standard of care agents for the treatment of human malignancies138,140. 
More studies need to be conducted to reconcile these apparently contradictory roles, but 
the above evidence supports autophagy as a tumor cell survival mechanism and as a tumor 
suppressive process in primary mammary tumors.  However, the role of autophagy in cellular 
dormancy and recurrence is largely unexplored.  One study does suggest that autophagy may 
promote tumor mass dormancy165.  Using a human ovarian cancer cell line, induction of 
autophagy by ectopic expression of the Ras-related gene ARHI in established xenografts was 
able to induce tumor dormancy.  It was proposed that a balance between cell death and 
proliferation exists once autophagy is stimulated in these tumors.  This is an important finding 
regarding autophagy and tumor mass dormancy, but the function of autophagy in cellular 
dormancy is undetermined.   
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THESIS OBJECTIVES 
 
We hypothesize that dormant mammary tumor cells survive through the use of 
autophagy, the process of degrading cytoplasmic proteins and organelles within the lysosome.  
Autophagy sustains cell viability by recycling these components to maintain metabolism and 
homeostasis.   Several lines of evidence support autophagy as a survival and/or tumor 
suppressive process in primary tumors, however, the role of autophagy in cellular tumor 
dormancy and recurrence has not been explored.  Therefore, the goal of this thesis is to 
determine whether autophagy is a mechanism by which dormant mammary tumor cells escape 
death or an activity that is detrimental to continued tumor cell growth by addressing the following 
specific aims: 
 
I.  Test the effect of inhibiting autophagy on mammary tumor dormancy and recurrence   
We will test if autophagy is required for tumor dormancy and recurrence by monoallelic 
deletion of the tumor suppressor Beclin 1 and conditional shRNA-mediated down-regulation of 
the essential autophagy genes Atg5, Atg7, and Beclin 1 in the MTB/TAN mouse model of breast 
cancer.  Using this same mouse model, we will administer the lysosomotropic drugs chloroquine 
and Lys05 to determine the effects of autophagy inhibition on tumor dormancy and recurrence.  
We will investigate the effects of autophagy inhibition on tumor recurrence by measuring the 
incidence, timing, and rate of growth of recurrent tumors.  Additionally, we will determine the 
number of dormant tumor cells that survive autophagy inhibition by flow cytometry.  We expect a 
decrease in dormant tumor cell number and a decrease in incidence and an increase in time to 
recurrence in treated animals compared to controls if autophagy is required for tumor cell 
survival.  Conversely, an increase in the number of dormant tumor cells and an increase in 
incidence and growth of recurrent tumors following inhibition of autophagy would suggest that 
autophagy suppresses tumorigenesis. 
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II.  Test the effect of promoting autophagy on mammary tumor dormancy and recurrence 
To determine whether autophagy is sufficient to promote mammary tumor cell dormancy 
and recurrence, we will induce autophagy in our MTB/TAN mouse model by administration of the 
mTOR inhibitor rapamycin or the anti-diabetic drug metformin.  The experiments to test the 
effects on tumor dormancy and recurrence will be analogous to those in Aim I.  If autophagy is 
sufficient to promote dormant tumor cell survival, we expect an increase in the number of dormant 
tumor cells and an increase in recurrence when autophagy is induced.  On the other hand, if 
dormant tumor cell number decreases and recurrence is slowed in treated animals compared to 
controls, autophagy may be acting as a tumor suppressive mechanism. 
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CHAPTER II:  Autophagy is Required for HER2/neu-Induced Mammary Tumor Recurrence 
by Promoting the Survival of Dormant Tumor Cells 
 21 
   
INTRODUCTION 
 
 Breast cancer is the leading cause of cancer death among women worldwide1.  Mortality 
from breast cancer is principally due to tumor recurrence following a period of clinical remission 
after surgical removal of the primary tumor and adjuvant therapy.  This latent period, which can 
last up to 20 years, is thought to reflect the survival and persistence of residual cancer cells in a 
quiescent state11,35.  Ultimately, these surviving cells, termed minimal residual disease, re-emerge 
from their dormant state and resume growth, leading to cancer recurrence.  At present, the 
mechanisms that enable dormant tumor cells to survive and recur are poorly understood.  Since 
recurrent breast cancer is typically an incurable disease, understanding the biology of dormant 
tumor cells is of paramount clinical importance.   
 Little is known about the biology of dormant tumor cells, either in patients or in animal 
models, primarily due to the difficulty in identifying, isolating, and analyzing dormant tumor cells in 
vivo.  To address this critical gap, we have developed a genetically engineered mouse model for 
HER2/neu-induced mammary tumorigenesis that faithfully recapitulates key features of the 
natural history of human breast cancer, including minimal residual disease, tumor dormancy, and 
recurrence68-71.  In this model, bitransgenic MMTV-rtTA;TetO-HER2/neu (MTB/TAN) mice 
conditionally express the HER2/neu oncogene in a mammary epithelial-specific and doxycycline-
dependent manner.  Following primary tumor development, HER2/neu down-regulation triggered 
by doxycycline withdrawal results in the regression of primary mammary tumors to a non-palpable 
state, as a consequence of their “addiction” to the oncogenic signaling pathways that led to their 
formation.  However, analogous to the phenomena of tumor dormancy and recurrence in breast 
cancer patients, a small population of tumor cells survives oncogene down-regulation and 
persists in the mammary gland in a dormant state.  After a variable latency period, these residual 
cells spontaneously give rise to actively growing recurrent tumors in a stochastic manner that 
results in the death of the animal.  These models enable mechanistic approaches to elucidating 
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the molecular and cellular pathways and processes that contribute to the survival and recurrence 
of dormant residual tumor cells.  
 One such candidate process is macroautophagy.  Macroautophagy (referred to hereafter 
as autophagy) is an evolutionarily conserved catabolic process involving the lysosomal 
degradation of organelles and proteins that serves to recycle damaged cellular components and 
generate energy72.  Notably, the Beclin 1 tumor suppressor (also known as Atg6) is required for 
autophagy and monoallelically deleted in 50% of sporadic human breast carcinomas, suggesting 
that autophagy is tumor suppressive141.  Consistent with this, overexpression of Beclin 1 impairs 
the growth of breast cancer cell lines in vitro as well as their tumorigenicity in vivo153.   
 Paradoxically, autophagy can promote the survival of transformed mammary epithelial 
cells in vivo and in vitro, while at the same time inhibiting their tumorigenicity155,156.  Based on 
these and other observations, autophagy has been proposed to constitute a survival mechanism 
for cancer cells subjected to a variety of cellular stresses by providing these cells with an 
alternate energy source through controlled cellular autodigestion and recycling of damaged 
cellular components129.  Nevertheless, while accumulating evidence supports a role for 
autophagy in primary tumorigenesis, the role of autophagy in cellular tumor dormancy and 
recurrence is unknown. 
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RESULTS 
 
Dormant mammary tumor cells undergo autophagy in vivo 
 The anti-HER2 targeted therapy trastuzumab has been reported to induce autophagy in 
breast cancer cell lines in vitro166.  To confirm that genetic down-regulation of HER2/neu 
recapitulates the effects of pharmacological HER2/neu inhibition, tumor cells from a primary 
mammary adenocarcinoma in an MTB/TAN mouse70 were cultured in the presence of doxycycline 
to maintain HER2/neu levels.  Doxycycline withdrawal induced acute HER2/neu down-regulation, 
which was accompanied by an acute increase in levels of LC3-II, the cleaved, lipidated form of rat 
microtubule-associated protein 1 light chain 3 (LC3) that serves as a marker for autophagy 
(Figure 1A and ref. 92).  Consistent with the induction of autophagy, electron microscopy revealed 
an increased number of double-membraned autophagosomes in tumor cells following doxycycline 
withdrawal (Figure 1B, C).   
 To confirm these results, we generated a MTB/TAN primary tumor cell line stably 
expressing the autophagy marker EGFP-LC3.  Induction of autophagy induces the incorporation 
of cleaved, lipidated LC3-II into autophagosomes, which alters LC3 subcellular localization from 
diffusely cytoplasmic to punctate92.  Doxycycline withdrawal from EGFP-LC3 expressing primary 
tumor cells resulted in an increase in the number of EGFP-positive punctae per cell compared to 
cells grown in the presence of HER2/neu (Figure 1D, E).  Together, these results indicate that 
acute HER2/neu down-regulation triggers autophagy in vitro. 
 To determine whether cytoplasmic contents sequestered in autophagosomes reached 
the lysosome and were degraded in primary MTB/TAN tumor cells, acute doxycycline withdrawal 
was combined with chloroquine treatment.  Chloroquine (CQ) raises lysosomal pH and inhibits 
protein degradation within the autolysosome such that cells with flux through the autophagic 
pathway show additional increases in LC3-II levels when treated with chloroquine129,167.  Indeed, 
combined chloroquine treatment and HER2-neu down-regulation in primary MTB/TAN tumor cells 
further augmented LC3-II levels beyond those in cells subjected to HER2/neu down-regulation 
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alone (Figure 1A).  These findings suggest that acute HER2/neu down-regulation induces 
autophagy as well as flux through the autophagic pathway. 
We next asked whether acute HER2/neu down-regulation induces autophagy in vivo.  
Doxycycline was withdrawn from MTB/TAN mice bearing primary mammary tumors for 48 hours 
to down-regulate HER2/neu expression and immunoblotting was used to analyze levels of p62 
(also known as SQSTM1), which recognizes ubiquitin-marked proteins and sequesters them for 
degradation through autophagy.  As a consequence, p62 itself is degraded in cells undergoing 
autophagy158,168.  Consistent with our in vitro observations, acute HER2/neu down-regulation 
resulted in a rapid reduction in p62 protein levels (Figure 2A).  Furthermore, primary orthotopic 
tumors generated from MTB/TAN tumor cells expressing EGFP-LC3 exhibited an increase in the 
number of EGFP-positive punctae per tumor cell following acute doxycycline withdrawal (Figure 
2B).  These results suggest that autophagy is induced in primary tumor cells following acute 
HER2/neu down-regulation.  
While autophagy has been shown to occur in vitro in actively growing tumor cells 
subjected to a number of different cellular stresses, whether autophagy occurs in dormant tumor 
cells in vivo is unknown.  We have found that a small number of neoplastic cells from MTB/TAN 
primary mammary tumors survive HER2/neu down-regulation and persist in a dormant state in 
residual lesions within the mammary gland (Figure 3A, B).  These cells are quiescent, yet remain 
competent to resume growth, resulting in recurrent tumors70.  Fluorescence microscopy 
performed on dormant EGFP-LC3-labeled tumor cells within residual lesions in mice harboring 
fully regressed orthotopic tumors revealed an increase in the number of EGFP-positive punctae 
per tumor cell compared to actively growing orthotopic primary tumors (Figure 2B).  Together, 
these observations suggest that autophagy is triggered in tumor cells following acute HER2/neu 
down-regulation in vivo and in vitro and that dormant residual tumor cells undergo autophagy in 
vivo. 
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Pharmacological inhibition of autophagy inhibits mammary tumor recurrence 
Our observations that autophagy occurs in vivo, is triggered by acute HER2/neu down-
regulation in actively growing primary tumor cells, and persists in dormant mammary tumor cells 
were equally consistent with models in which autophagy is tumor suppressive or tumor 
promoting.  To begin to distinguish between these possibilities, we treated MTB/TAN tumor-
bearing mice with chloroquine.  As chloroquine has been used safely in millions of people 
worldwide for the prevention and treatment of malaria and has a favorable therapeutic index, this 
drug represents an attractive approach to inhibiting autophagy in vivo169.   
To determine the effect of chloroquine treatment on mammary tumor recurrence, female 
nu/nu mice maintained on doxycycline were injected orthotopically with primary MTB/TAN tumor 
cells.  Following primary tumor formation, tumor regression was induced by doxycycline 
withdrawal and HER2/neu down-regulation70.  Daily treatment with chloroquine was initiated 
coincident with HER2/neu down-regulation (Figure 4A).  Mice bearing fully regressed primary 
tumors were then monitored for recurrence.  Daily chloroquine administration markedly delayed 
the onset of tumor recurrence in mice, with the median latency for tumor recurrence increasing 
from 84 to 140 days (H.R. = 3.12, 95% CI 1.45 - 6.72, p = 0.004; Figure 4B).  This finding 
suggests that autophagy promotes, rather than inhibits, mammary tumor recurrence. 
 
Atg5 and Atg7 are required for mammary tumor recurrence 
To confirm these results, since pharmacological agents may have off-target effects, we 
determined the effect on tumor recurrence of genetically inhibiting autophagy by knocking down 
the expression of Atg5 or Atg7, each of which is required for autophagy.  Atg5 and Atg7 are 
components of an ubiquitin-like conjugation system wherein the E1-like molecule Atg7 and the 
E2-like molecule Atg10 covalently link Atg5 to Atg12.  Atg5-Atg12 then forms a complex with 
Atg16 that is required for formation of the autophagosome74.   
To determine if genetically inhibiting autophagy delays tumor recurrence, primary 
MTB/TAN tumor cells were generated that expressed shRNAs targeting either Atg5 or Atg7.   
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qRT-PCR and immunoblotting confirmed knockdown of Atg5 and Atg7 (Figure 5A-D).  These 
cells were then injected orthotopically into the mammary glands of nu/nu mice on doxycycline, as 
were cells transduced with a vector control, to form primary tumors.  As above, doxycycline was 
withdrawn from mice bearing orthotopic tumors to induce HER2/neu down-regulation, which 
resulted in the regression of the tumors to a non-palpable state.  Mice were then monitored for 
recurrence.   
This analysis revealed that genetic inhibition of autophagy by knocking down either Atg5 
or Atg7 dramatically impaired tumor recurrence (H.R. = 5.35, 95% CI 1.72 - 16.62, p = 0.004; 
H.R.= 7.56, 95% CI 2.33 - 24.58, p < 0.001; Figure 5E).  These results are consistent with the 
effects of autophagy inhibition by chloroquine and further suggest that autophagy is required for 
the recurrence of HER2/neu-induced tumors. 
 
Beclin 1 is required for mammary tumor recurrence 
The observations that Atg5 knockdown, Atg7 knockdown, and chloroquine treatment 
each result in a delay in mammary tumor recurrence is consistent with a model in which 
autophagy plays a pro-tumorigenic role in breast cancer recurrence.  However, multiple lines of 
evidence suggest that autophagy is tumor suppressive, several of which were garnered from 
studies analyzing mice, or tumor cells, in which Beclin 1 is monoallelically deleted149,150,153,155,156.   
Beclin 1 is a haploinsufficient tumor suppressor whose heterozygous loss in mice results 
in increased susceptibility to lymphomas, liver cancer, lung cancer, and mammary epithelial 
hyperplasias149,150.  Beclin 1 is also essential for the initiation of autophagosome formation by 
means of its ability to form a complex with the Vps34 PI3 kinase and other proteins74.  Since 
knockdown or loss of Beclin 1 inhibits autophagy while increasing susceptibility to primary tumor 
formation, these data suggest a tumor suppressive role for Beclin 1 and autophagy.   
In light of these conflicting data, we wished to determine whether – consistent with a 
tumor suppressive role for Beclin 1 and autophagy – loss of Beclin 1 would accelerate mammary 
tumor recurrence or whether – consistent with a tumor promoting role for autophagy as 
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suggested by the effects of chloroquine treatment and Atg5/Atg7 knockdown – loss of Beclin 1 
would inhibit mammary tumor recurrence.  To address this question, Beclin 1+/- mice were 
crossed to MTB/TAN inducible bitransgenic mice to generate cohorts of MTB/TAN;Beclin 1+/+ and 
MTB/TAN;Beclin 1+/- female mice.  Primary mammary tumors were then induced by chronic 
activation of HER2/neu via doxycycline administration.   
The incidence, latency, multiplicity and growth rate of primary HER2/neu-induced tumors 
did not differ between Beclin 1+/+ and Beclin 1+/- mice (Figure 6A and data not shown).  Tumor-
bearing mice were then deinduced and mice bearing fully regressed tumors were monitored for 
recurrence.  The rate of primary tumor regression was unaffected by Beclin 1 genotype (data not 
shown).  In contrast, deletion of one allele of Beclin 1 markedly delayed tumor recurrence with 
the median latency for tumor recurrence increasing from 77 days to 131 days (H.R. = 2.38, 95% 
CI 1.15 - 4.94, p = 0.019; Figure 6B).  These results demonstrate that Beclin 1 is required for 
mammary tumor recurrence and further support our findings based on Atg5/Atg7 knockdown and 
chloroquine treatment that autophagy is required for mammary recurrence. 
 
Selection against dormant tumor cells with impaired autophagy 
Having established a role for autophagy in the recurrence of HER2/neu-induced 
mammary tumors, we wished to determine the cellular basis for this requirement.  Based on 
evidence supporting a role for autophagy in responses to cellular stress, we considered the 
possibility that autophagy contributes to the survival of tumor cells subjected to HER2/neu 
pathway inhibition.  To test this hypothesis, HER2/neu was down-regulated for 24 hours in vitro in 
MTB/TAN primary tumor cells expressing an shRNA targeting Atg5 or a control vector and the 
percentage of viable cells was determined.  The survival of tumor cells transduced with a control 
vector was not altered by HER2/neu down-regulation in the presence of 10% serum (Figure 7A).  
In contrast, a substantial increase in cell death was observed in tumor cells expressing HER2/neu 
when Atg5 was knocked down, and the combination of Atg5 knockdown with HER2/neu down-
regulation resulted in a dramatic impairment in cell survival (Figure 7A).  These findings suggest 
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that autophagy is required for the survival of primary mammary tumor cells subjected to acute 
HER2/neu down-regulation in vitro, which is consistent with a prior report166. 
We next wished to test the role of autophagy in promoting tumor cell survival in vivo 
during the process of mammary tumor recurrence.  MTB/TAN primary tumor cells expressing an 
shRNA targeting Atg5 were labeled with an H2B-mCherry reporter, whereas MTB/TAN primary 
tumor cells transduced with an empty vector were labeled with an H2B-EGFP reporter.  These 
two fluorescent populations of isogenic cells were admixed in equal parts (Figure 7B), injected 
into the mammary glands of nu/nu mice maintained on doxycycline, and allowed to generate 
orthotopic primary tumors.  Doxycycline was then withdrawn to initiate the process of tumor 
regression and fluorescence microscopy was used to determine the ratio of mCherry-labeled 
Atg5 knockdown cells to EGFP-labeled control cells in primary tumors, residual tumor lesions 14 
days following HER2/neu down-regulation, residual tumor lesions 28 days following HER2/neu 
down-regulation, and recurrent tumors (Figure 7C).   
As predicted based on the unperturbed nature of primary tumorigenesis in Beclin 1+/- 
mice, we observed no selection for or against cells with Atg5 knockdown in primary tumors 
(Figure 7D, E).  Furthermore, we observed no selection for or against cells expressing an Atg5 
shRNA in residual lesions 14 days post-HER2/neu down-regulation, a time point that roughly 
corresponds to the completion of tumor regression and onset of tumor dormancy (Figure 7D, E 
and Figure 3A, B).  In contrast, cells with Atg5 knockdown were present at a lower than expected 
ratio in residual lesions 28 days following HER2/neu down-regulation, a time point at which 
residual tumor cells have been in a dormant state for approximately 2 weeks (Figure 7D, E and 
Figure 3A, B).  This competitive disadvantage was even more pronounced in recurrent tumors, in 
which only 1% of fluorescent cells were mCherry-positive (Figure 7D, E).   
To rule out differential effects of the H2B-mCherry and H2B-EGFP reporters, this 
experiment was repeated after swapping fluorescent protein labels between Atg5 shRNA and 
control cells.  Similar results were observed (Figure 7F).  Together, these data indicate that 
primary tumor cells in which autophagy is impaired are at a strong, cell-intrinsic selective 
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disadvantage following HER2/neu down-regulation, but not until tumor cells have entered a 
dormant state.   
 
Autophagy is required for dormant tumor cell survival 
Our observations to this point suggested the possibility that autophagy is required for the 
survival of dormant tumor cells following oncogene down-regulation.  To test directly whether 
tumor dormancy represents a cellular state in which cells are particularly reliant upon autophagy 
for their survival, we determined the impact of chloroquine treatment on dormant tumor cells 
generated by HER2/neu down-regulation.  Primary MTB/TAN tumor cells were grown in 10% 
serum plus doxycycline, 1% serum plus doxycycline, or 1% serum in the absence of doxycycline.  
After 3 weeks, cells grown in 1% serum in the absence of doxycycline were Ki67-negative, but 
could be induced to re-enter the cell cycle solely by the re-addition of doxycycline, demonstrating 
that these cells are reversibly growth arrested (Figure 8A-C).   
After 3 weeks in the above media, cells were treated with chloroquine for 1 week and cell 
viability was assessed.  Dormant tumor cells maintained in 1% serum in the absence of 
HER2/neu expression were markedly more sensitive to chloroquine treatment than proliferating 
cells expressing HER2/neu maintained in either 1% serum or 10% serum (Figure 9A).  These 
findings suggest that dormant tumor cells are more dependent upon autophagy for survival than 
actively growing cells. 
We next wished to determine whether dormant mammary tumors cells are dependent 
upon autophagy for survival in vivo.  To address this, mice harboring orthotopic EGFP-labeled 
dormant residual tumor cells were treated with chloroquine for 2 weeks beginning 21 days after 
HER2/neu down-regulation.  Mammary glands were then harvested, digested to form a single-cell 
suspension, and the number of EGFP-positive residual tumor cells was determined by flow 
cytometry (Figure 9B).  This analysis revealed that mice treated with chloroquine for 2 weeks 
within the period of dormancy harbored 38% fewer dormant tumor cells (p < 0.05) than mice 
treated with a vehicle control (Figure 9C).  Given the absence of tumor cell proliferation at these 
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time points, these data strongly suggest that autophagy is required for the survival of dormant 
mammary tumor cells in vivo. 
 
Autophagy inhibition in mice bearing dormant minimal residual disease impairs 
recurrence 
Our findings to this point suggested that dormant tumor cells may be uniquely dependent 
upon autophagy for their survival.  If correct, our data would predict that inhibitors of autophagy 
would be most effective not in actively growing tumors, but in dormant residual tumor cells.  If so, 
chloroquine could be used on that basis to reduce the pool of viable dormant residual tumor cells 
and thereby prevent or delay tumor recurrence.   
To test this hypothesis, we again employed chloroquine in an orthotopic recurrence 
assay, except instead of initiating chloroquine treatment at the time of HER2/neu down-
regulation, chloroquine treatment was initiated 28 days following doxycycline withdrawal when 
residual tumor cells already exist in a dormant state (Figure 3A, B and Figure 10A).  Mice were 
then monitored for tumor recurrence.   
This analysis revealed that autophagy inhibition restricted specifically to the period of 
tumor dormancy markedly delayed recurrence (H.R. = 2.88, 95% CI 1.39 - 5.98, p = 0.005; 
Figure 10B).  Notably, the magnitude of the effect of chloroquine administration beginning 28 
days after HER2/neu down-regulation was nearly identical to that observed for the effect of 
chloroquine administration beginning immediately at the time of HER2/neu down-regulation 
(Figure 4A, B).  This finding was consistent with results from the fluorescent cell competition 
assay (Figure 7B-F), indicating that cells with impaired autophagy are not selected against during 
primary tumor formation or within the first 14 days following HER2/neu down-regulation.  
Accordingly, these observations provide further support for a model in which the effects of 
autophagy inhibition on tumor cell survival are largely confined to the phase of tumor dormancy. 
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DISCUSSION 
 
While accumulating evidence supports a role for autophagy in primary tumorigenesis and 
the acute response to cytotoxic and targeted therapies, the role of autophagy in cellular tumor 
dormancy and recurrence has yet to be defined.  The clinical relevance of this question is 
highlighted by the fact that disseminated tumor cells, referred to as minimal residual disease, are 
detectable in the bone marrow of more than 30% of early stage breast cancer patients and 
reportedly exist in a non-proliferative state44,45.  At least some of these cells retain the ability to 
resume growth, suggesting cellular dormancy.  In this regard, two distinct modes of tumor 
dormancy have been characterized: tumor mass dormancy, in which a population of residual 
tumor cells does not increase in size as a consequence of balanced rates of proliferation and 
apoptosis due to host immune responses or the absence of an angiogenic switch39,40; and cellular 
dormancy, in which a population of solitary tumor cells exists in a quiescent state in the absence 
of proliferation and apoptosis42.   
At present, the role of autophagy in cellular dormancy is unknown.  However, ectopic 
expression of the Ras-related gene ARHI in xenografts from a human ovarian cancer cell line has 
been reported to induce reversible tumor mass dormancy that is associated with PI3K pathway 
inhibition, increased autophagy, and suppression of net tumor growth165.  It was suggested that 
ARHI-induced suppression of VEGF expression in this context may have inhibited angiogenesis 
in xenografts, consistent with tumor mass dormancy.  The proliferative status of tumor cells was 
not investigated.   
In the present study, using genetic and pharmacological approaches, we have addressed 
the role of autophagy in cellular dormancy.  Specifically, we have demonstrated that inhibition of 
autophagy by chloroquine administration, Atg5 or Atg7 knockdown, or deletion of a single allele of 
the tumor suppressor Beclin 1 is sufficient to inhibit mammary tumor recurrence.  This 
requirement for autophagy in tumor recurrence was attributable to its ability to serve as a survival 
mechanism for the small number of primary tumor cells that survive HER2/neu pathway inhibition 
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and exist in a dormant state as minimal residual disease.  Consistent with this cellular mechanism 
of action, autophagy was induced in dormant residual tumor cells in vivo following HER2/neu 
down-regulation, and pharmacological inhibition of autophagy in mice bearing dormant minimal 
residual disease significantly decreased the number of surviving dormant tumor cells and 
substantially delayed mammary tumor recurrence.  In aggregate, these findings support a pro-
tumorigenic role for autophagy and Beclin 1 in breast cancer recurrence by promoting the survival 
of dormant residual tumor cells. 
Knockdown or loss of Beclin 1 inhibits autophagy while increasing susceptibility to 
primary tumor formation; conversely, overexpression of Beclin 1 – as well as ARHI – inhibits 
tumor growth.  These observations suggest a tumor suppressive role for autophagy.  In contrast, 
as we found that the inhibition of autophagy by either pharmacological or genetic means 
significantly delayed tumor recurrence in mice bearing minimal residual disease and resulted in 
the death of dormant tumor cells, our results indicate that autophagy is pro-tumorigenic in the 
context of tumor dormancy and recurrence.  This finding contrasts with multiple lines of evidence 
suggesting that autophagy is a tumor suppressive mechanism during primary 
carcinogenesis149,150,153,155,156.  These context-specific, seemingly opposing functions of 
autophagy highlight the differing biological properties – and therefore therapeutic targets – of 
primary tumor cells compared to dormant residual tumor cells.   
Notably, we found that dormant mammary tumor cells are uniquely reliant on autophagy 
for their survival compared to actively growing tumor cells.  Indeed, primary tumorigenesis 
induced by HER2/neu was unaffected in Beclin 1+/- mice and we observed no selection for or 
against cells with Atg5 knockdown during primary orthotopic tumor outgrowth.  More surprisingly, 
and contrary to findings that autophagy supports cell survival in response to acute cellular stress, 
we observed no selection for or against cells with Atg5 knockdown within the first 14 days 
following HER2/neu down-regulation, during which time the vast majority of tumor cells die 
secondary to oncogene addiction.  In contrast, selection against tumor cells with Atg5 knockdown 
was readily apparent during the period of cellular dormancy, and chloroquine administration killed 
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dormant residual tumor cells while having little, if any, effect on actively growing recurrent tumor 
cells (Figure 11A, B).  Consistent with this, the magnitude of recurrence inhibition in mice 
chronically treated with chloroquine beginning at the time of HER2/neu down-regulation and 
tumor regression was essentially identical to that observed for chloroquine administration 
restricted to the period of tumor dormancy.  This suggests that the clinically meaningful effects of 
autophagy inhibition may result from effects on dormant tumor cells rather than tumor cells 
responding to the acute stress of HER2/neu pathway down-regulation.  To our knowledge, this is 
the first evidence to identify a potential therapeutic target that is specific to dormant minimal 
residual disease.   
Most anti-neoplastic therapeutic modalities preferentially target actively proliferating 
cancer cells.  In light of our identification of cellular dormancy as a stage of tumor progression 
that is particularly reliant upon autophagy for survival, our findings suggest that dormant residual 
tumor cells may be uniquely susceptible to agents, such as hydroxychloroquine, that inhibit this 
process.  To date however, pre-clinical and clinical trials have principally, if not exclusively, 
employed autophagy inhibitors to target actively proliferating stages of disease that our findings 
predict may be intrinsically resistant to autophagy inhibition138,139,165.  Accordingly, our results 
suggest that autophagy inhibitors may be more effective in clinical contexts characterized by 
cellular tumor dormancy, and support autophagy inhibition as a tractable therapeutic strategy for 
preventing breast cancer recurrence. 
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METHODS 
 
Cell culture 
The doxycycline inducible MTB/TAN primary tumor cell line was generated and cultured as 
described70.  Cells were cultured at 37 °C in 5% CO 2 and maintained in DMEM (MediaTech) 
supplemented with 10% Super Calf Serum (Gemini Bio-Products), 5 µg/ml insulin (Gemini Bio-
Products), 10 ng/ml EGF (Sigma-Aldrich), 5 µg/ml prolactin (National Institute of Diabetic and 
Digestive and Kidney Diseases), 1 µM progesterone (Sigma-Aldrich), 1 µg/ml hydrocortisone 
(Sigma-Aldrich), 2 µg/ml doxycycline (Research Products International), 200 nM glutamine 
(Gibco), and 1% penicillin/streptomycin (Gibco) unless otherwise indicated.  Chloroquine 
disphosphate salt was purchased from Sigma-Aldrich.  Viability was calculated using Vi-CELL 
(Beckman Coulter). 
 
Immunoblotting 
Protein lysates were prepared by homogenizing tumors or cell lines in lysis buffer (50 mM Tris-
HCl, pH 7.5; 150 mM NaCl; 1% Triton X-100) supplemented with HaltTM Protease and 
Phosphatase Inhibitor Cocktail (Thermo Scientific).  For Western blot analysis, membranes were 
probed with Alexa-Fluor-conjugated secondary antibodies (Molecular Probes).  Bound antibodies 
were detected using the Odyssey detection system (LI-COR Biosciences).  The following primary 
antibodies were used for Western blotting: anti-ErbB2 (Cell Signaling), anti–LC3 (Cell Signaling), 
anti–β-tubulin (Biogenex), anti–p62 (Progen Biotechnik), anti-Atg12 (Cell Signaling), and anti-
Atg7 (Cell Signaling). 
 
Microscopy 
For transmission electron microscopy, cells for electron microscopic examination were fixed with 
2.5% glutaraldehyde, 2.0% paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, 
overnight at 4 oC.   After subsequent buffer washes, the samples were post-fixed in 2.0% osmium 
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tetroxide for 1 h at RT, and rinsed in DH2O prior to en bloc staining with 2% uranyl acetate.  After 
dehydration through a graded ethanol series, the tissue was infiltrated and embedded in EMbed-
812 (Electron Microscopy Sciences).  Thin sections were stained with uranyl acetate and lead 
citrate and examined with a JEOL 1010 electron microscope fitted with a Hamamatsu digital 
camera and AMT Advantage image capture software.  At least 25 cells were analyzed for each 
condition. 
For fluorescence microscopy, cells were seeded onto 2-well chamber glass slides.  
Tissue was snap-frozen in O.C.T. (TissueTek) and cut into 8 µM frozen sections.  Samples were 
fixed in 4% paraformaldehyde for 10 min then stained with Hoechst 33258 (Sigma-Aldrich) to 
visualize nuclei.  For EGFP-LC3 expressing cells, at least 25 cells for each condition were 
analyzed by quantifying EGFP-LC3 punctae using Cell Profiler170.  Briefly, nuclei were 
segmented, and the number of punctae per nucleus was determined.  Manual validation of 
nuclear segmentation and punctae quantification were performed on a training set prior to the 
automated analysis of samples.  For EGFP-LC3-labeled tissues, four tumors were analyzed per 
time point and at least three non-consecutive slides per tumor were imaged.  For the orthotopic 
fluorescent cell competition assay, the admixture of cells was plated onto 2-well chamber glass 
slides and six fields were quantified prior to injection into nu/nu mice for tumor generation.  For 
each tumor or residual tissue sample, four non-serial sections per tumor and six images per 
section were obtained.  The number of fluorescently labeled cells per image was determined 
using Image-Pro Plus 7 (Media Cybernetics). 
For immunofluorescence analysis, cells were seeded on 2-well chamber glass slides, 
fixed in 4% paraformaldehyde for 10 min, and permeabilized with 0.5% Triton/PBS for 20 min.  
For tissue, 8 µM paraffin tissue sections were prepared using a standard xylene-based de-waxing 
procedure. Sections were subjected to antigen retrieval in the 2100 Retriever (Electron 
Microscopy Sciences).  Cell and tissue samples then were blocked in 10% goat serum/4% 
BSA/PBS for 1 h and incubated overnight at 4 °C wit h primary antibody diluted in 4% BSA/PBS.  
Samples were stained with Alexa-Fluor-conjugated secondary antibodies (Molecular Probes) 
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diluted in 4% BSA/PBS for 1 h at RT in addition to Hoechst 33258 (Sigma-Aldrich) to visualize 
nuclei.  Anti-Ki67 (DAKO) and anti-EGFP (Novus Biologicals) primary antibodies were used for 
immunofluorescence.  Fluorescence and immunofluorescence microscopy were performed on a 
DM 5000B Automated Upright Microscope (Leica) and images were captured using a DFC350 FX 
monochrome digital camera (Leica).  
 
Retrovirus production and infection 
H2B-EGFP and EGFP-LC3 (Tamotsu Yoshimori, Ph.D., National Institute of Genetics, Shizouka-
ken, Japan) were subcloned into pK1 retroviral vector as previously described70.  
Oligonucleotides for shRNAs targeting Atg5 and Atg7 were obtained from Open Biosystems.  The 
following sequences were used:  Atg5 shRNA: 
TGCTGTTGACAGTGAGCGCAGAACCTGCCTTCTCACAAACTAGTGAAGCCACAGATGTAGTT
TGTGAGAAGGCAGGTTCTTTGCCTACTGCCTCGGA; Atg7 shRNA:  
TGCTGTTGACAGTGAGCGCTGCTACTAGATGAAGACAATATAGTGAAGCCACAGATGTATAT
TGTCTTCATCTAGTAGCAATGCCTACTGCCTCGGA.  Oligonucleotides were cloned into the 
LMP vector (Open Biosystems) as described171.  LMP vectors were generated that expressed 
H2B-EGFP or H2B-mCherry in place of EGFP by subcloning.  The oligonucleotide targeting Atg5 
was also cloned into these vectors for use in the orthotopic competition assay.   
Retroviruses were generated by transfection of Plat-E cells172.  In brief, Plat-E cells were 
plated at 5x106 cells per 10-cm dish 1 d before transfection.  Lipofectamine® 2000 transfection 
reagent (Life Technologies) plus 24 µg of the retroviral plasmid of interest was added to cells.  
Media was changed 6 h later and replaced with 5 ml fresh media.  Viral supernatants were 
harvested 2 d later, centrifuged at 2,000 r.p.m., split into 1 ml aliquots, and snap frozen at -80 °C.    
 MTB/TAN primary tumor cells were plated at 1x105 cells per well in 6-well plates.  The 
following day, 1 ml of viral supernatant, 3 ml of media, and 8 µg/ml polybrene were added to each 
well.  Cells were then centrifuged at 2,000 r.p.m. for 2 h at RT and then incubated overnight at 37 
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°C.  Media was changed the following day.  Selectio n with 1 µg/ml puromycin was initiated 24 h 
later to isolate stable transfectants. 
 
Mice and recurrence assays   
Animal care and all animal experiments were performed with the approval of, and in accordance 
with, guidelines of the University of Pennsylvania IACUC.  Orthotopic recurrence assays were 
performed as described68.  1x106 cells were injected into the inguinal mammary fat pads of 
athymic nu/nu mice (Taconic) maintained on 2 mg/ml doxycycline (Research Products 
International) and 5% sucrose in drinking water.  For fluorescent cell competition assays, H2B-
EGFP and H2B-mCherry-labeled cells were admixed in a 1:1 ratio and 1x106 cells of the resulting 
mixture were injected into the inguinal mammary fat pads of nu/nu mice.  Animals were monitored 
twice per week for primary or recurrent tumor formation.  For chloroquine treatment, animals were 
matched based on time of deinduction and then randomly assigned to a treatment cohort.  Tumor 
volume was calculated using the formula (W2*L)/2 where L≥W.  Area under the curve (AUC) was 
calculated using the formula [(vol1+vol2)/2]*(day2-day1).  Mean recurrent tumor growth rate was 
calculated using this formula [(sumAUC)-(vol1*(dayn-day1))]/(dayn-day1)2. 
Beclin 1+/- C57BL/6 mice (Zhenyu Yue, Ph.D., Mount Sinai School of Medicine, New 
York, New York, USA) were backcrossed 6 generations onto the FVB background.  These 
animals were then crossed to MTB/TAN mice.  6-wk-old female offspring of the desired 
genotypes from each litter were induced with 2 mg/ml doxycycline (Research Products 
International) and 5% sucrose in the drinking water.  Animals were monitored for mammary tumor 
development and recurrence once per week. 
 
RNA isolation and qRT-PCR 
RNA was isolated from cells using RNeasy® RNA Mini Kit (Qiagen) and reverse transcription was 
performed using the SuperScript® First-Strand Synthesis System for RT-PCR (Life Technologies) 
according to manufacturer’s instructions.   qRT-PCR was performed on the 7900 HT Fast Real-
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Time PCR system using 6-carboxyfluorescein–labeled Taqman probes (Applied Biosystems) 
specific for Atg5, Atg7, and Tbp as a reference.  Relative expression levels were calculated using 
the comparative Ct method173. 
 
Flow cytometry 
Mammary glands were harvested, manually minced, and incubated at 37 °C for 1 h in MEGM 
(Lonza), 1X B-27 (Gibco), 20 ng/ml bFGF (Sigma-Aldrich), 4 µg/ml heparin (Stem Cell 
Technologies), 5% Super Calf Serum (Gemini Bio-Products), and 1X Collagenase/Hyaluronidase 
(Stem Cell Technologies).  Tissue was then suspended in red blood cell lysis buffer for 5 min, 
washed with 1X DPBS (cellgro), digested in 0.25% trypsin-EDTA (Gibco) for 2 min, washed, and 
digested in 1X DPBS (cellgro), 2% Super Calf Serum (Gemini Bio-Products), 1 mM EDTA, 1 
mg/ml dispase II (Stem Cell Technologies), and 100 mg/ml DNAse I (Qiagen) for 5 min.  After 
washing, cells were resuspended in 1X DPBS (cellgro), 2% Super Calf Serum (Gemini Bio-
Products), and 1 mM EDTA and analyzed for EGFP-fluorescence using a FACSCaliburTM flow 
cytometer (BD Biosciences).  Total fluorescently-labeled cell number was calculated using 
CountBrightTM Absolute Counting Beads for flow cytometry (Molecular Probes). 
 
Statistical analyses 
We used Student's unpaired t-test for statistical analysis or Mann-Whitney U test when data was 
not normally distributed.  Log-rank test was used when analyzing survival curves.  p value < 0.05 
was considered statistically significant.  Hazard ratio with 95% confidence interval was calculated 
for survival curves. 
  
  
Figure 1 
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Figure 1.  HER2/neu down-regulation induces autophagy in primary tumor cells in vitro.  
(A-E) MTB/TAN primary tumor cells subjected to doxycycline (dox) withdrawal for 24 h.  
Treatment with 50 µM chloroquine (CQ) for 24 h was used as a positive control for the induction 
of autophagy.  (A) HER2/neu levels and conversion of LC3-I to LC3-II determined by western 
blotting.  β-tubulin is shown as a loading control.  (B) Representative images of double-
membraned autophagosomes (arrows) visualized by electron microscopy.  Bar = 500nm.  (C) 
Quantification of autophagosomes per cell in (B).  (D) Representative images of subcellular 
localization of EGFP-LC3 visualized by fluorescence microscopy.  Original magnification, x400.  
(E) Quantification of average EGFP-LC3 punctae per cell in (D).  Data represent mean ± SEM.  
**p < 0.001, ***p < 0.0001. 
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  HER2/neu down-regulation induces autophagy in primary and dormant tumor 
cells in vivo.  (A) HER2/neu and p62 levels evaluated by western blotting in orthotopic MTB/TAN 
primary tumors in the presence of doxycycline (dox) or following dox withdrawal for 2 d.  β-tubulin 
is shown as a loading control.  (B) Representative images of subcellular localization of EGFP-
LC3 in MTB/TAN primary orthotopic tumors or orthotopic tumors subjected to 2 d or 28 d of dox 
withdrawal.  Original magnification, x400. 
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Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  A subset of MTB/TAN primary tumor cells becomes dormant upon HER2/neu 
down-regulation in vivo.  (A) Representative immunofluorescence images of orthotopic 
MTB/TAN tumors and residual lesions.  Original magnification, x200.  (B) The percentage of 
EGFP-positive cells that were also Ki67-positive (red) was determined in primary tumors (n = 2), 
residual lesions 14 d post-doxycycline (dox) withdrawal (n = 4), and residual lesions 28 d post-
dox withdrawal (n = 4) from (A).  Data represent mean ± SEM. 
  
 43 
 
Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Chloroquine inhibits mammary tumor recurrence.  (A) Schematic of orthotopic 
MTB/TAN recurrence model and timing of chloroquine treatment.  (B) Recurrence-free survival of 
female nu/nu mice harboring MTB/TAN orthotopic primary tumors induced to regress by 
doxycycline (dox) withdrawal and treated with vehicle (n = 24) or 60 mg/kg/d chloroquine (n = 26) 
as described in (A).  Median recurrence latencies are indicated. 
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Figure 5 
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Figure 5.  Atg5 and Atg7 are required for mammary tumor recurrence.  (A,B) qRT-PCR 
analysis of (A) Atg5 or (B) Atg7 expression levels in parental primary MTB/TAN tumor cells or 
MTB/TAN tumor cells expressing a vector control or shRNAs targeting Atg5 or Atg7 (shAtg5 or 
shAtg7).  Expression is normalized to Tbp.  Data represent mean ± SEM.  (C,D) Western blot 
analysis of (C) Atg5-Atg12 and (D) Atg7 levels in parental primary MTB/TAN tumor cells, vector 
control, shAtg5, or shAtg7-expressing MTB/TAN tumor cells.  β-tubulin is shown as a loading 
control.  (E) Recurrence-free survival of female nu/nu mice harboring fully regressed orthotopic 
MTB/TAN tumors derived from vector control (n = 14), shRNA targeting Atg5 (shAtg5; n = 9), or 
shRNA targeting Atg7 (shAtg7; n = 11)-expressing MTB/TAN tumor cells.  Median recurrence 
latencies are indicated. 
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Figure 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Beclin 1 is required for mammary tumor recurrence in intact mice.  (A) Primary 
tumor-free survival of female MTB/TAN;Beclin 1+/+ (n = 38) and MTB/TAN;Beclin 1+/- mice (n = 
40) administered doxycycline (dox) to induce HER2/neu beginning at 6 wk of age.  (B) 
Recurrence-free survival of female MTB/TAN;Beclin 1+/+ (n = 18) and MTB/TAN;Beclin 1+/- mice 
(n = 18) that harbored fully regressed primary tumors following dox withdrawal.  Median 
recurrence latencies are indicated. 
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Figure 7 
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Figure 7.  Atg5 is required for dormant mammary tumor cell survival.  (A) Viability of primary 
MTB/TAN tumor cells expressing an shRNA targeting Atg5 (shAtg5) or empty vector grown in 
0.5% serum with or without doxycycline (dox) for 24 h.  Data represent mean ± SEM.  *p < 0.05.  
(B) H2B-EGFP and H2B-mCherry-labeled tumor cells were counted, admixed in a 1:1 ratio, 
seeded onto chamber slides, and the ratio of H2B-EGFP and H2B-mCherry-labeled tumor cells 
was determined by fluorescent microscopy immediately prior to injection into female nu/nu mice 
as described in (C).  (C-E) Mammary fat pads of female nu/nu mice on dox were injected with an 
equal ratio of primary MTB/TAN tumor cells that were either transduced with shAtg5 and labeled 
with H2B-mCherry or were transduced with a vector control and labeled with H2B-EGFP.  (C) 
Schematic of orthotopic MTB/TAN competition assay and timing of tumor harvest.  (D) 
Representative fluorescence microscopy images of orthotopic MTB/TAN primary tumors (n = 6), 
residual lesions 14 d post-dox withdrawal (n = 5), residual lesions 28 d post-dox withdrawal (n = 
5), and recurrent tumors (n = 3) from (C).  Original magnification, x400.  (E) Percentage of H2B-
EGFP-positive and H2B-mCherry-positive tumor cells was determined at each time point in (C).  
Data represent mean ± SEM.  ***p < 0.0001. (F) Fluorescent cell competition assay as shown in 
(C-E), but with swapped fluorescent reporters.  Percentage of H2B-EGFP-positive and H2B-
mCherry-positive tumor cells was determined in orthotopic MTB/TAN primary tumors (n = 5), 
residual lesions 14 d post-dox withdrawal (n = 4), residual lesions 28 d post-dox withdrawal (n = 
6), and recurrent tumors (n = 3).  Data represent mean ± SEM.  **p < 0.001 ***p < 0.0001. 
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Figure 8 
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Figure 8.  Induction of dormancy in MTB/TAN primary tumor cells in vitro.  (A) Primary 
MTB/TAN tumor cells were cultured in 1% serum in the absence of doxycycline (dox) for 3 wk.  A 
subset of cells was then analyzed by immunofluorescence for Ki67 (center panel).  Dox was then 
added to the remaining cells and culture continued for 1 wk prior to analysis by 
immunofluorescence for Ki67 staining (right panel).  Actively proliferating MTB/TAN primary tumor 
cells cultured in 10% serum plus dox (left panel) served as a positive control for proliferation.  
Representative images shown.  Original magnification, x400.  (B) Representative 
immunofluorescence images of primary MTB/TAN tumor cells cultured in 10% serum plus dox, 
1% serum plus dox, or 1% serum in the absence of dox for 3 wk stained for Ki67.  Original 
magnification, x200.  (C) Quantification of the percentage of Ki67-positive cells from (B). 
  
 51 
 
Figure 9 
 
Figure 9.  Chloroquine decreases the survival of dormant mammary tumor cells.  (A) 
Viability of primary MTB/TAN tumor cells grown in 10% serum plus doxycycline (dox), 1% serum 
plus dox, or 1% serum without dox for 3 wk, then treated with 50 µM chloroquine (CQ) or vehicle 
control for 1 wk.  Data represent mean ± SEM.  *p < 0.05.  (B) Schematic of orthotopic MTB/TAN 
dormancy model and timing of chloroquine treatment.  (C) Female nu/nu mice harboring primary 
orthotopic tumors generated from primary MTB/TAN cells were deinduced for 21 d and then were 
treated daily with chloroquine 60 mg/kg (n = 21) or vehicle control (n = 23) for 2 wk.  At 35 d post-
dox withdrawal, the number of EGFP-positive tumor cells per gland was determined using flow 
cytometry.  Data represent mean ± SEM.  *p < 0.05. 
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Figure 10 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.  Chloroquine treatment of mice bearing dormant minimal residual disease 
impairs recurrence.  (A) Schematic of orthotopic MTB/TAN recurrence model and timing of 
chloroquine treatment.  (B) Recurrence-free survival of female nu/nu mice bearing fully regressed 
orthotopic MTB/TAN tumors that were treated daily with vehicle control (n =  22) or 60 mg/kg 
chloroquine (n =  24) as described in (A).  Median latencies for tumor recurrence indicated. 
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Figure 11 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.  Chloroquine treatment has no effect on actively growing recurrent tumors.  (A) 
Schematic of orthotopic MTB/TAN recurrence model and timing of chloroquine treatment.  (B) 
Mean tumor growth rates of MTB/TAN orthotopic recurrent tumors treated with vehicle or 60 
mg/kg/d chloroquine from a size of 63 mm3 to 382 mm3.
 54 
   
CHAPTER III:  Additional Studies to Determine the Effects of Inhibiting Autophagy on 
HER2/neu-Induced Mammary Tumor Dormancy and Recurrence 
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INTRODUCTION 
 
 It is well established that there is a context-specific role for autophagy in tumor 
progression.  Using multiple model systems and cancer therapies, autophagy has been shown to 
be both tumor suppressive and tumor promoting140.  In the previous chapter, we have provided 
evidence that autophagy is pro-tumorigenic in the context of HER2/neu-driven mammary tumor 
recurrence due to its role in promoting the survival of dormant tumor cells.  In addition, we 
demonstrated that this requirement for autophagy in tumor cell survival is limited to the stage of 
tumor progression in which residual tumor cells exist in a dormant state.   This suggests the 
potential utility of autophagy inhibitors to target minimal residual disease in the clinic.  However, 
critical questions remain unanswered. 
 First, interest in developing more specific and potent autophagy inhibitors is rising.  It has 
been reported that the concentrations of chloroquine necessary to inhibit autophagy in preclinical 
models are very difficult to achieve in patients because of the low potency of this drug.  Plus, it 
can take weeks to achieve peak concentrations of chloroquine in patients because of its long half-
life174.  Additionally, chloroquine and hydroxychloroquine have been found to cause toxicity175.  
For these reasons, efforts are underway to develop and test improved autophagy inhibitors for 
use in the clinic. 
Even so, chloroquine and its analog hydroxychloroquine are currently being tested in 
clinical trials for the treatment of a variety of refractory malignancies as supported by positive 
preclinical findings using inhibitors of autophagy139,176-178.  For example, inhibition of autophagy 
enhanced tumor regression resulting from p53 activation or chemotherapy in a Myc-induced 
mouse model of lymphoma139.  Additionally, the anti-neoplastic therapy suberoylanilide 
hydroxamic acid, when combined with autophagy inhibition, showed increased anti-cancer effects 
in primary chronic myelogenous leukemia (CML) cells176.  These and other encouraging results 
have led to the initiation of more than 20 clinical trials involving chloroquine in combination with 
standard of care agents138,140. 
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 In contrast to these data, we found that HER2/neu-driven primary tumors do not respond 
to the combination of autophagy inhibition and targeted therapy.  While we did see a delay in 
recurrence when chloroquine treatment was administered concurrently with doxycycline 
withdrawal, we found that this was not caused by an increased response to the down-regulation 
of HER2/neu since autophagy inhibition did not increase the amount of cell death that occurred 
post-HER2/neu down-regulation.  Rather, delayed recurrence upon chloroquine treatment was 
instead due to decreased survival of dormant tumor cells that are no longer reliant on HER2/neu 
signaling.  These results described in Chapter II, combined with the increasing interest in 
autophagy inhibitors as cancer therapies, warrant further studies into the specific stage of tumor 
progression most likely to require autophagy and to respond to treatment with autophagy 
inhibitors. 
 Here, we discuss our attempts to further determine the optimal stage of tumor 
progression at which autophagy inhibition will be effective.  First, we examine a new autophagy 
inhibitor, Lys05, and show that it inhibits mammary tumor recurrence to a similar extent as 
chloroquine treatment, supporting the further development of this more potent autophagy 
inhibitor.  We then describe an attempt to confirm our finding that the tumor suppressor Beclin 1 
is required for mammary tumor recurrence using the orthotopic MTB/TAN model of breast cancer 
recurrence.  Next, we demonstrate that autophagy inhibitors are ineffective when targeting 
actively growing stages of tumorigenesis as previously suggested.  Lastly, we describe an 
orthotopic MTB/TAN recurrence model that does not require the formation of primary tumors that 
was generated as a new resource for the laboratory. 
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RESULTS 
 
Lys05, a novel inhibitor of autophagy, delays mammary tumor recurrence 
It has been shown that large micromolar concentrations of chloroquine achieved in 
preclinical models to inhibit autophagy are not often achieved in patients174.  Thus, there is 
increased interest in developing more potent autophagy inhibitors.  We were fortunate to obtain 
one of these new autophagy inhibitors, Lys01, and its trihydrochloride salt Lys05, from Dr. Jeffrey 
Winkler at the University of Pennsylvania179.  Lys01 is a dimeric form of chloroquine, with the 
spacer N,N-bis(2-aminoethyl) methylamine 5 connecting two chloroquine moieties.  Drs. 
Amaravadi and Winkler found that Lys01/Lys05 inhibited autophagy to a greater degree than 
chloroquine, and at a 10-fold lower concentration, in vitro.  When tested in a HT-29 colon cancer 
xenograft model, Lys05 significantly decreased tumor growth compared to tumors treated with 
vehicle control.  Although some toxicity was observed in mice treated with Lys05, this occurred at 
concentrations substantially higher than necessary to achieve anti-tumor activity. 
Given the increased reported potency of Lys05 compared to chloroquine, we wished to 
treat animals that harbored minimal residual disease with Lys05 to determine if increased 
inhibition of autophagy would translate into a further delay in tumor recurrence, or, possibly, 
prevent recurrence altogether.  We initiated treatment with Lys05 or vehicle control in mice 
bearing dormant minimal residual disease composed of tumor cells that survived HER2/neu 
down-regulation and recurrent tumor latency was measured (Figure 1A).   
As observed with chloroquine treatment and consistent with our model, both 
concentrations of Lys05 studied significantly delayed recurrence compared to controls (H.R. = 
3.04, 95% CI 1.52 – 6.09, p = 0.0015; H.R. = 3.59, 95% CI 1.74 – 7.42, p = 0.0006; Figure 1B).  
However, the delay in recurrence seen when animals were treated with Lys05 was not greater 
than the delay observed in mice treated with chloroquine.  The median recurrence latency for 
treatment with 40 mg/kg Lys05 was 145 days, compared to 144 days for chloroquine treatment 
(Figure 1B).  Despite the fact that Lys05 did not increase the time to tumor recurrence beyond 
 58 
 
that seen with chloroquine treatment, these data further confirm a role for autophagy in tumor 
recurrence and support the continued development of Lys05 for use in the clinic, since Lys05 
significantly delays recurrence at a much lower concentration than chloroquine.  
 
shRNA-mediated knockdown of Beclin 1 promotes mammary tumor recurrence 
 Beclin 1 is an essential autophagy gene that has been shown to be a tumor suppressor in 
both mice and humans141,149,150,155,156.  However, our studies using MTB/TAN;Beclin 1+/+ and 
MTB/TAN;Beclin 1+/- mice suggested that both Beclin 1 and autophagy are required for tumor 
recurrence.  In light of the conflicting data regarding Beclin 1 loss and tumorigenesis, we wished 
to confirm the requirement of Beclin 1 and autophagy for mammary tumor recurrence using the 
MTB/TAN orthotopic mouse model of breast cancer recurrence.   
Autophagy was inhibited in primary MTB/TAN tumor cells by shRNA-mediated 
knockdown of Beclin 1.  Using this method, we were able to achieve an approximate 75% 
decrease in expression of Beclin 1 mRNA and protein (Figure 2A, B).  Cells that expressed an 
shRNA targeting Beclin 1 or a control vector were then injected into the mammary fat pads of 
female nu/nu mice on doxycycline.  As seen in the intact model, primary tumors with decreased 
Beclin 1 expression grew at the same rate as control tumors (Figure 2C).  These results support 
the model that Beclin 1 and autophagy do not play a role in primary tumorigenesis.   
Next, doxycycline was withdrawn to initiate primary tumor regression and then time to 
tumor recurrence was measured.  Surprisingly, recurrent tumor latency was marginally decreased 
when Beclin 1 was knocked down compared to the latency observed in control animals (H.R. = 
0.44, 95% CI 0.20 - 0.94, p = 0.0347; Figure 2D).  This is the opposite of what we observed in 
intact MTB/TAN;Beclin 1+/+ and MTB/TAN;Beclin 1+/- mice in which deletion of one allele of Beclin 
1 suppressed mammary tumor recurrence.   
 
 
 
 59 
 
Chloroquine does not affect the growth of actively growing mammary tumors 
 Despite this conflicting data regarding Beclin 1 expression and cancer, preclinical 
evidence suggests that autophagy promotes tumorigenesis and that inhibition of autophagy using 
chloroquine can augment the efficacy of anti-neoplastic agents176,177.  Therefore, clinical trials are 
being conducted to test chloroquine as a treatment for multiple types of cancers.  The vast 
majority of these studies use chloroquine to target advanced, actively growing tumors.  However, 
based on our findings that dormant residual tumor cells are preferentially sensitive to inhibition of 
autophagy, patients with minimal residual disease are the specific patient subpopulation expected 
to be sensitive to autophagy inhibitors.    Rapidly growing primary or recurrent tumors are not 
predicted to respond to chloroquine treatment. 
 We chose to determine if autophagy inhibition affects the growth of actively proliferating 
tumors by treating animals bearing orthotopic MTB/TAN primary or recurrent tumors with 
chloroquine.  Once tumors reached target size, two doses of vehicle control or chloroquine were 
administered to animals (Figure 3A, B).  Tumors were then harvested and analyzed for changes 
in proliferation and apoptosis by immunofluorescence for Ki67 and cleaved caspase-3.  In both 
primary and recurrent tumors, no difference was observed in the percentage of Ki67-positive 
tumors cells between vehicle control or chloroquine treated tumors (Figure 3C, D).  Similarly, no 
difference was observed in cleaved caspase-3 staining (Figure 3E, F).  This suggests that acute 
chloroquine treatment of actively growing primary or recurrent tumors does not alter the rate of 
proliferation or apoptosis of tumor cells. 
 Next, we calculated the mean tumor growth rate of primary and recurrent tumors treated 
chronically with chloroquine or vehicle control (Figure 4A, B).  Because we found that Atg5/7 
knockdown or monoallelic loss of Beclin 1 did not change the growth rate of actively growing 
primary tumors as described in Chapter II, we did not expect to see a difference in growth rates 
between vehicle control or chloroquine treated tumors.  As anticipated, primary tumors treated 
with chloroquine grew at the same rate as tumors treated with vehicle control (Figure 4C).  As 
discussed previously, recurrent tumor growth rate was also not affected by chloroquine treatment. 
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(Figure 4D).  Together, these results suggest that actively growing tumors may be less sensitive 
to autophagy inhibition than dormant tumor cells.  These findings add further support for the 
concept that dormant tumor cells exhibit increased reliance on autophagy for their survival 
compared to actively growing primary or recurrent tumors. 
 
Generation of an orthotopic MTB/TAN mouse model of mammary tumor recurrence that 
does not require the formation of primary tumors 
As outlined in the previous chapter, we performed multiple experiments to inhibit 
autophagy genetically in both the intact and orthotopic MTB/TAN mouse models of breast cancer.  
In both systems, autophagy was inhibited throughout tumorigenesis, potentially confounding any 
effects of autophagy inhibition observed specifically during mammary tumor dormancy and 
recurrence.  We found that autophagy wasn’t required for HER2/neu-driven primary 
tumorigenesis, so the effects of inhibiting autophagy during dormancy and recurrence were likely 
not confounded by effects of autophagy inhibition on primary tumor formation.  Nevertheless, we 
could not rule out this possibility.  Moreover, there could be experimental scenarios that would 
require a way to distinguish between the different roles of a molecule or cellular process during 
distinct stages of tumorigenesis.   
To address this concern, we developed an orthotopic MTB/TAN mouse model of 
mammary tumor recurrence that does not require the formation of a primary tumor.  In brief, 
primary MTB/TAN tumor cell lines were injected into female nu/nu mice maintained on 
doxycycline in the same manner as previously described, but instead of waiting for the 
development of primary tumors, doxycycline was withdrawn 48 hours after tumor cell injection 
(Figure 5A).  At this time no palpable primary tumors were detectable (data not shown). 
We tested the utility of this “no primary tumor” orthotopic MTB/TAN recurrence model 
using five different primary tumor cell lines.  We used two MTB/TAN primary tumor cell lines 
transduced to express a H2B-EGFP reporter (99142, 54074) as well as a new cell line that was 
generated from a primary MTB/TAN tumor that expressed EGFP driven by the β-actin promoter 
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(184665).  In addition, since p53 signaling is inactivated in most human cancers180, we also 
tested the 99142 and 54074 cell lines that had been transduced to express an shRNA targeting 
p53 (Figure 6A-D). 
These five cell lines were individually injected into mice and 48 hours later animals were 
deinduced.  Then animals were monitored for tumor recurrence.  Despite the absence of primary 
tumor formation, recurrent tumors did arise in these mice.  The median time to recurrence in the 
54074 tumors was 275 days when animals were deinduced 48 hours post-injection (Figure 5B).  
Recurrent tumor latency was decreased from 275 days to 130 days by knocking down p53 in the 
54074 cell line (Figure 5B).  In contrast, p53 knockdown did not significantly change the time to 
recurrence in the 99142 cell line (Figure 5B).  The 99142 and 18665 cell lines had similar 
recurrent tumor latencies, 42 and 53 days, respectively (Figure 5B).  Mean recurrent tumor 
growth rates were also included as a reference (Figure 5C).  Taken together, this data suggests 
that this “no primary tumor” orthotopic MTB/TAN recurrence model is a viable system to study 
dormancy and recurrence without confounding influences from primary tumorigenesis.  However, 
this mouse model was never used to determine if autophagy was required for mammary tumor 
recurrence because, as discussed in Chapter II, knockdown of Atg5/7 or monoallelic loss of 
Beclin 1 did not alter primary tumor growth and Atg5 knockdown cells were not selected against 
during primary tumorigenesis, suggesting there were not confounding influences of autophagy 
inhibition during primary tumorigenesis. 
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DISCUSSION 
 
The inhibition of autophagy as a strategy to treat patients with various types of cancer is 
currently being tested in many clinical trials. However, determining the multiple roles of autophagy 
in malignant pathogenesis has the potential to better inform the design of these trials and the use 
of autophagy inhibitors in the clinic.  Autophagy has been shown to either promote or suppress 
tumorigenesis depending on the tumor type, model system, and biological context.  Therefore, we 
wished to determine the role of autophagy in the context of HER2/neu-induced tumor recurrence 
using multiple approaches.  As discussed in the previous chapter, we found that autophagy is 
required for mammary tumor recurrence.  Specifically, we found that monoallelic loss of the tumor 
suppressor Beclin 1 significantly delayed tumor recurrence.  This result conflicts with the multiple 
lines of evidence that suggest Beclin 1 loss promotes primary tumorigenesis141,149,150,155,156.  We 
believe that these opposing functions of Beclin 1 highlight the different biological properties of 
primary compared to dormant tumor cells. 
Nevertheless, we wanted to further support the model that autophagy and Beclin 1 
promote mammary tumor recurrence.  We chose to do so by shRNA-mediated knockdown of 
Beclin 1 in our orthotopic MTB/TAN mouse model.  As observed in MTB/TAN;Beclin 1+/- mice, 
Beclin 1 knockdown did not impair orthotopic primary tumor growth.  However, decreased 
expression of Beclin 1 achieved by shRNA-mediated knockdown marginally accelerated tumor 
recurrence, conflicting with our previous work.  It is important to note that only one shRNA 
targeting Beclin 1 was tested in this experiment.  Therefore, we cannot rule out that potential off-
targets effects of this shRNA are responsible for the minor acceleration of tumor recurrence 
observed upon Beclin 1 knockdown. 
Another explanation for this discrepancy involves the different expression levels of Beclin 
1 in the intact model compared to the orthotopic model.  We achieved 75% knockdown of Beclin 
1 in our MTB/TAN primary tumor cell line, and this is much greater than the loss seen in Beclin 
1+/- mice149,150.  As such, one possibility is that the greater knockdown of expression achieved by 
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shRNA-mediated knockdown may have affected autophagy-independent functions of Beclin 1.  
These autophagy-independent functions of Beclin 1 were first suggested to exist when it was 
observed that Beclin 1-/- mice had a much more severe embryonic phenotype than that of other 
autophagy gene-deficient mice130,149.  The alternative functions of Beclin 1 are still unclear.  
However, an autophagy-independent tumor suppressive effect of Beclin 1 has been described 
that involves the regulation of apoptosis by Beclin 1.  In multiple cancer cell lines, increased 
Beclin 1 levels enhanced the sensitivity of cells to chemotherapy or proteasome inhibition181-183.  
This cytotoxicity was reduced upon knockdown of Beclin 1183.  Therefore, by significantly 
decreasing Beclin 1 expression in MTB/TAN tumor cells, the amount of cell death upon 
HER2/neu down-regulation may have been decreased compared to what was observed in 
MTB/TAN cells expressing vector control in vivo.  This may then have resulted in the survival of a 
greater number of recurrent tumor-initiating cells and may have translated into accelerated 
mammary tumor recurrence upon Beclin 1 knockdown.  If true, this hypothesis would predict that 
knockdown of Beclin 1 levels by 50% in the orthotopic MTB/TAN recurrence model would 
phenocopy the loss of one allele on Beclin 1 on the latency of tumor recurrence. 
More work needs to be done to reconcile the different effects of autophagy on 
tumorigenesis, but there are data that demonstrate that targeting this process may be a sound 
strategy for the treatment of some cancers139,176-178.  Currently, chloroquine and 
hydroxychloroquine are the only autophagy inhibitors being investigated in the clinic, but both 
drugs have caused toxicity175.  Additionally, the high concentrations of chloroquine needed to 
inhibit autophagy in vitro do not appear to be attained in patients174.  As a result there is a critical 
need for the development of safer, more potent inhibitors of autophagy. 
Two such compounds are currently being tested in preclinical models.  Lucanthone is an 
agent approved for the treatment of schistosomal parasites.  Lucanthone has recently been 
shown to cause tumor cell death by inhibiting autophagy through the disruption of lysosomal 
function.  Lucanthone was found to be approximately 10-fold more potent than chloroquine and 
lacks obvious toxicity184.  The second agent is known as Lys05.  Through increased 
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deacidification of the lysosome, Lys05 inhibited autophagy and displayed increased anti-cancer 
activity compared to chloroquine in tumor cell lines and xenograft tumor models.  Very little 
toxicity was seen with Lys05 treatment as well179. 
We were interested in testing these more potent autophagy inhibitors in the MTB/TAN 
mouse models.  Our hope was that we would achieve a greater delay in mammary tumor 
recurrence with these agents, or perhaps prevent recurrent tumor formation.  When Lys05 was 
administered to animals bearing minimal residual disease, both low and intermediate doses of 
Lys05 significantly delayed recurrence.  Unfortunately, the increased inhibition of autophagy 
reported for Lys05 treatment compared to chloroquine did not translate into a further delay in 
recurrence.  Nevertheless, this study suggests that Lys05 has potential as an anti-neoplastic 
agent in the setting of dormant residual disease or, possibly, tumor recurrence. 
Virtually all studies to date have focused on testing the efficacy of autophagy inhibition in 
actively growing tumors.  In contrast, we found that quiescent residual tumor cells were 
preferentially sensitive to autophagy inhibition in comparison to actively growing recurrent tumors.  
To extend these results, we determined that actively growing primary tumors, like recurrent 
tumors, were largely unresponsive to autophagy inhibition.  Specifically, chloroquine did not affect 
mean tumor growth rates, proliferation, or apoptosis in primary or recurrent MTB/TAN tumors.  
Taken together, our findings support autophagy inhibition as a promising therapeutic strategy for 
the prevention of breast cancer recurrence and predict that autophagy inhibitors may be most 
effective in the context of dormant minimal residual disease.   
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METHODS 
 
Cell culture 
Inducible MTB/TAN primary tumor cell lines were generated as previously described70.  Cells 
were cultured at 37 °C in 5% CO 2 and maintained in DMEM (MediaTech) supplemented with 10% 
Super Calf Serum (Gemini Bio-Products), 5 µg/ml insulin (Gemini Bio-Products), 10 ng/ml EGF 
(Sigma-Aldrich), 5 µg/ml prolactin (National Institute of Diabetic and Digestive and Kidney 
Diseases), 1 µM progesterone (Sigma-Aldrich), 1 µg/ml hydrocortisone (Sigma-Aldrich), 2 µg/ml 
doxycycline (Research Products International), 200 nM glutamine (Gibco), and 1% 
penicillin/streptomycin (Gibco) unless otherwise indicated. 
 
Plasmid generation 
Oligonucleotide for shRNA targeting p53 was obtained from Ross Dickens (Cold Spring Harbor 
Laboratory, Cold Spring Harbor, New York, USA).  Oligonucleotide for shRNA targeting Beclin 1 
was obtained from Open Biosystems.  The following sequences were used:  p53 shRNA:  
TGCTGTTGACAGTGAGCGCCCACTACAAGTACATGTGTAATAG 
TGAAGCACAGATGTATTACACATGTACTTGTAGTGGATGCCTACTGCCTCGGA; Beclin 1 
shRNA:  TGCTGTTGACAGTGAGCGAGCCAATAAGATGGGTCTGAAATAGTG 
AAGCCACAGATGTATTTCAGACCCATCTTATTGGCCTGCCTACTGCCTCGGA 
Oligonucleotides were cloned into the LMP vector (Open Biosystems) as described171.  H2B-
EGFP was previously cloned into pk170. 
 
Retrovirus production and infection 
Retroviruses were generated by transfection of Plat-E cells172.  Plat-E cells were plated at 5x106 
cells per 10-cm dish 1 d before transfection.  Lipofectamine® 2000 transfection reagent (Life 
Technologies) plus 24 µg of the retroviral plasmid of interest was added to cells.  Media was 
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changed 6 h later and replaced with 5 ml fresh media.  Viral supernatants were harvested two 
days later, centrifuged at 2,000 r.p.m., split into 1 ml aliquots, and snap frozen at -80°C.    
 MTB/TAN primary tumor cells were plated at 1x105 cells per well in 6-well plates.  The 
following day, 1 ml of viral supernatant, 3 ml of media, and 8 µg/ml polybrene were added to each 
well.  Cells were then centrifuged at 2,000 r.p.m. for 2 h at RT and then incubated overnight at 
37°C.  Media was changed the following day.  Select ion with 1 µg/ml puromycin was initiated 24 h 
later to isolate stable transfectants. 
 
RNA isolation and qRT-PCR 
RNA was isolated from cells using RNeasy® RNA Mini Kit (Qiagen) and reverse transcription was 
performed using the SuperScript® First-Strand Synthesis System for RT-PCR (Life Technologies) 
according to manufacturer’s instructions.   qRT-PCR was performed on the 7900 HT Fast Real-
Time PCR system using carboxyfluorescein-labeled Taqman probes (Applied Biosystems) 
specific for Beclin 1, p53, and Tbp as a reference.  Relative expression levels were calculated 
using the comparative Ct method173.  
 
Immunoblotting 
Protein lysates were prepared by homogenizing tumors or cell lines in lysis buffer (50 mM Tris-
HCl, pH 7.5; 150 mM NaCl; 1% Triton X-100) supplemented with HaltTM Protease and 
Phosphatase Inhibitor Cocktail (Thermo Scientific).  For Western blot analysis, membranes were 
probed with Alexa-Fluor-conjugated secondary antibodies (Molecular Probes).  Bound antibodies 
were detected using the Odyssey detection system (LI-COR Biosciences).  The following primary 
antibodies were used for Western blotting: anti-Beclin 1 (Cell Signaling), anti–p53 (Cell 
Signaling), anti–β-tubulin (Biogenex). 
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Mice and recurrence assays 
Animal care and all animal experiments were performed with the approval of, and in accordance 
with, guidelines of the University of Pennsylvania IACUC.  Orthotopic recurrence assays were 
performed as described70.  1x106 cells were injected into the inguinal mammary fat pads of 
athymic nu/nu mice (Taconic) maintained on 2 mg/ml doxycycline (Research Products 
International) and 5% sucrose in drinking water.  Animals were monitored twice per week for 
primary or recurrent tumor formation.  Lys05 was obtained from Ravi Amaravadi (University of 
Pennsylvania).  For Lys05 treatment, animals were matched based on time of deinduction and 
then randomly assigned to a treatment cohort.  Lys05 was dissolved in 1x PBS before 
intraperitoneal injection179.  Tumor volume (vol) was calculated using the formula (W2*L)/2 where 
L≥W.  Area under the curve (AUC) was calculated using the formula [(vol1+vol2)/2]*(day2-day1).  
Mean recurrent tumor growth rate was calculated using this formula [(sumAUC)-(vol1*(dayn-
day1))]/(dayn-day1)2. 
 
Immunofluorescence 
8 µM paraffin tissue sections were prepared using a standard xylene-based de-waxing 
procedure. Sections were subjected to antigen retrieval in the 2100 Retriever (Electron 
Microscopy Sciences).  Samples then were blocked in 10% goat serum/4% BSA/PBS for 1 h and 
incubated overnight at 4 °C with primary antibody d iluted in 4% BSA/PBS.  Samples were stained 
with Alexa-Fluor-conjugated secondary antibodies (Molecular Probes) diluted in 4% BSA/PBS for 
1 h at RT in addition to Hoechst 33258 (Sigma-Aldrich) to visualize nuclei.  Anti-Ki67 (DAKO), 
anti-cleaved caspase 3 (Cell Signaling), and anti-EGFP (Novus Biologicals) primary antibodies 
were used for immunofluorescence.  For each tumor sample, four non-serial sections per tumor 
and six images per section were obtained.  The number of red pixels per cell per image was 
determined using Image-Pro Plus 7 (Media Cybernetics).  Immunofluorescence microscopy was 
performed on a DM 5000B Automated Upright Microscope (Leica) and images were captured 
using a DFC350 FX monochrome digital camera (Leica). 
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Statistical analyses 
We used Student's unpaired t-test for statistical analysis.  Log-rank test was used when analyzing 
survival curves.  p value < 0.05 was considered statistically significant.  Hazard ratio with 95% 
confidence interval was calculated for survival curves. 
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Lys05, a novel inhibitor of autophagy, delays mammary tumor recurrence.  (A) 
Schematic of orthotopic MTB/TAN recurrence model and timing of Lys05 treatment.  (B) 
Recurrence-free survival of female nu/nu mice harboring fully regressed primary orthotopic 
MTB/TAN tumors that were treated with vehicle control (n = 26), 10 mg/kg Lys05 (n = 26) daily, or 
40 mg/kg Lys05 (n = 26) 5 d a week starting 14 d after HER2/neu down-regulation as described 
in (A).  Median latencies for tumor recurrence are 84 d post-deinduction for controls, 129 d post-
deinduction for tumors treated with 10 mg/kg Lys05, and 145 d post-deinduction for tumors 
treated with 40 mg/kg Lys05.  
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Figure 2  
 
Figure 2.  shRNA-mediated knockdown of Beclin 1 promotes mammary tumor recurrence.  
(A) qRT-PCR analysis of Beclin 1 expression levels in parental MTB/TAN primary tumor cells, 
cells expressing a control vector, or cells expressing an shRNA targeting Beclin 1 (shBeclin 1).  
(B)  Western blot analysis of Beclin 1 protein levels in parental MTB/TAN primary tumor cells, 
cells expressing a vector control, or cells expressing shBeclin 1.  β-tubulin is shown as a loading 
control.  (C) Mean tumor growth rates of MTB/TAN orthotopic primary tumors expressing a 
control vector (n = 17) or shBeclin1 (n = 16) calculated from time of MTB/TAN primary tumor cell 
injection until tumors reached 14 mm3.  (D) Recurrence-free survival of female nu/nu mice 
harboring fully regressed orthotopic MTB/TAN tumors derived from vector control (n = 14) or 
shBeclin1 (n = 25)-expressing MTB/TAN tumor cells.  Median recurrence latencies are indicated. 
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Figure 3 
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Figure 3.  Chloroquine does not affect proliferation or apoptosis of actively growing tumor 
cells.  (A, B)  Schematics of orthotopic MTB/TAN model and timing of chloroquine treatment.  (C, 
D) The percentage of Ki67-positive orthotopic MTB/TAN (C) primary or (D) recurrent tumor cells 
treated with 2 doses of vehicle control or 60 mg/kg chloroquine on consecutive days starting once 
tumors reached 63 mm3.  (E, F) The percentage of cleaved caspase 3 (CC3)-positive orthotopic 
MTB/TAN (E) primary or (F) recurrent tumor cells treated with 2 doses of vehicle or 60 mg/kg 
chloroquine on consecutive days starting once tumors reached 63 mm3.  Data expressed as 
mean ± SEM.  
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Figure 4  
 
 
Figure 4.  Chloroquine does not affect the growth rate of primary or recurrent tumors.  (A, 
B)  Schematics of orthotopic MTB/TAN model and timing of chloroquine treatment.  (C, D) Mean 
tumor growth rates of orthotopic MTB/TAN (C) primary or (D) recurrent tumors treated with 
vehicle or 60 mg/kg/d chloroquine from a size of 63 mm3 to 382 mm3. 
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Figure 5  
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Figure 5.  Generation of an orthotopic MTB/TAN mouse model of mammary tumor 
recurrence that does not require the formation of primary tumors.  (A) Schematic of 
orthotopic MTB/TAN recurrence model without primary tumor formation.  Tumor cells were 
injected into the mammary fat pad of female nu/nu mice on doxycycline (dox).  48 hr later, before 
the formation of palpable primary tumors, the animals were deinduced and recurrence was 
measured.  (B) Recurrence-free survival of female nu/nu following injection of primary MTB/TAN 
tumor cell lines expressing H2B-EGFP (99142; n = 16, 54074; n =17), a newly generated primary 
MTB/TAN tumor cell line with β-actin-driven  GFP expression (184665; n = 18), or the primary 
MTB/TAN tumor cell lines that express an shRNA targeting p53 (99142 shp53; n = 17, 54074 
shp53; n = 17).  Median latencies for tumor recurrence are 294 d post-deinduction for 54074 
H2B-EGFP, 42 d post-deinduction for 99142 H2B-EGFP, 53 d post-deinduction for 184665, 46 d 
post-deinduction for 99142 shp53, and 130 d post-deinduction for 54074 shp53.  (C) Mean tumor 
growth rates of recurrent tumors generated from primary MTB/TAN tumor cell lines 99142 (n = 7), 
54074 (n =7), 184665 (n = 13), 99142 shp53 (n = 13), or 54074 shp53 (n = 8).  MGR was 
calculated from when tumors reached 4 mm3 until 382 mm3 in size. 
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Figure 6  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Knockdown of p53 in MTB/TAN primary tumor cells.  (A, B)  p53 mRNA levels 
evaluated by qRT-PCR in parental primary MTB/TAN tumor cells, cells expressing a control 
vector, and cells expressing shRNA targeting p53 (shp53).  Expression is normalized to Tbp.  (C, 
D)  p53 levels evaluated by western blotting in parental MTB/TAN primary tumor cells, cells 
expressing a control vector, and cells expressing shp53.  HC11 cells were used as a positive 
control for p53 expression.  β-tubulin is shown as a loading control. 
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INTRODUCTION 
 
Activation of the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt) signaling 
pathway contributes to the pathogenesis of multiple tumor types.  PIK3CA, the gene encoding a 
subunit of PI3K, is the most frequently mutated kinase in cancer185.  Moreover, the gene encoding 
phosphatase and tensin homolog (PTEN), a negative regulator of Akt, is frequently deleted or 
inactivated in tumor cells186.  Stimulation of the PI3K-Akt pathway in cancers results in increased 
activity of the mammalian target of rapamycin (mTOR) pathway, a central regulator of protein 
translation, cell growth, and metabolism.  Because of the importance of elevated mTOR signaling 
in cancer, analogs of the mTOR inhibitor rapamycin have shown anti-neoplastic activity in 
patients with advanced-stage renal cell carcinoma, pancreatic neuroendocrine tumors, as well as 
advanced hormone receptor-positive breast cancer187.  These successes have led to additional 
clinical trials designed to block the mTOR signaling pathway and evaluate the effectiveness of 
mTOR inhibitors in other cancers188. 
Another consequence of mTOR activation in cancer cells is the inhibition of autophagy.  
mTOR inhibits autophagy to promote the growth of cancer cells so they can subsequently 
divide95.  However, the role of mTOR-mediated autophagy suppression in cancer is not clear.  
The role of mTOR signaling in tumor dormancy and recurrence is also undefined.  Therefore, we 
wished to determine the effects of promoting autophagy, as well as investigate the role of mTOR 
signaling, in breast cancer dormancy and recurrence by pharmacological inhibition of mTORC1 
using rapamycin. 
Rapamycin promotes autophagy, and regulates many other cellular processes, through 
the inhibition of mTOR.  TOR1 and TOR2 were first discovered in genetic screens to identify 
mediators of the effects of rapamycin in Saccharomyces cerevisiae189,190.  The mammalian 
equivalent, mTOR, was discovered shortly thereafter191-193.  mTOR is an atypical serine/threonine 
kinase and a member of the PI3K-related family.  It exists in 2 independent complexes within the 
cell, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).  These complexes contain 
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differing components and have different sensitivities to rapamycin and upstream and downstream 
effectors.  mTORC1 consists of the catalytic subunit mTOR, mammalian lethal with sec-13 
protein 8 (mLST8, also known as GβL), DEP domain containing mTOR-interacting protein 
(DEPTOR), the Tti1/Tel2 complex, regulatory-associated protein of mammalian target of 
rapamycin (raptor), and proline-rich Akt substrate 40 kDa (PRAS40).  Like mTORC1, mTORC2 
also contains mTOR, mLST8, DEPTOR, and the Tti1/Tel2 complex, but contains the rapamycin-
insensitive companion of mTOR (rictor), as opposed to raptor, as well as mammalian stress-
activated map kinase-interacting protein 1 (mSin1), and protein observed with rictor 1 and 2 
(protor1/2)95. 
The mTORC1 complex has been shown to inhibit autophagy through at least two 
mechanisms.  First, mTORC1 directly phosphorylates and suppresses unc-51-like kinase 1 
(ULK1), a kinase that forms a complex with focal adhesion kinase family-interacting protein of 200 
kDa (FIP200), Atg13, and Atg101, and the active form of this ULK1 complex is required to initiate 
autophagosome formation77,78,96.  mTORC1 may also inhibit autophagy by negatively regulating 
lysosome biogenesis through the transcription factor EB (TFEB).  Phosphorylation of TFEB 
sequesters it in the cytoplasm, rendering it unable to activate transcription of its target genes, 
many of which are involved in lysosomal function and autophagosome formation and fusion194,195. 
Beyond its role in suppressing autophagy, mTORC1 also regulates protein synthesis, 
lipid synthesis, and energy metabolism.  For example, protein synthesis is regulated by the 
mTORC1 target 4E-binding protein 1 (4E-BP1)196,197.  Phosphorylation of 4E-BP1 on threonines 
37 and 46 by mTORC1 primes 4E-BP1 to be phosphorylated at subsequent sites.  
Hyperphosphorylation of 4E-BP1 decreases its binding to eukaryotic translation initiation factor E 
(eIF4E).  This allows eIF4E to recruit the other members of the eIF4F translation initiation 
complex to the 5’ cap structure of mRNA to initiate translation.   
40S ribosomal protein S6 kinase 1 (S6K1) activation by mTORC1 also leads to an 
increase in cap-dependent translation initiation and elongation, as well as ribosome and mRNA 
biogenesis and transcription of rRNA196,198-200.  mTORC1 phosphorylates S6K1 on threonine 389 
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in the linker domain, priming it for phosphorylation of threonine 229 in the catalytic domain by 
phosphate-dependent kinase-1 (PDK1).  These phosphorylation events are required for S6K1 
activity.  Some important targets of S6K1 are S6, eIF4B, and tripartite motif-containing protein 24 
(TIF-1A).   
In addition, lipid synthesis is controlled by mTORC1 through its activation of sterol 
regulatory element-binding protein 1/2 (SREBP1/2) to increase transcription of genes involved in 
generating fatty acids and cholesterols201,202.  Lastly, mTORC1 can increase the expression of 
genes involved in glucose metabolism by regulating HIF-1α202,203. 
Upstream of mTORC1, the signaling pathway is just as complicated.  Growth factors, 
stress, energy status, oxygen, and amino acids have all been shown to control the activity of 
mTORC1.  The majority of these inputs signal through tuberous sclerosis proteins 1 and 2 
(TSC1/2).  The TSC1/2 complex inhibits mTORC1 activity by regulating the Ras homolog 
enriched in brain small GTPase (Rheb) through its GTPase-activating protein (GAP) activity.  
Rheb is converted into its inactive GDP-bound state by TSC1/2, and as a result it can no longer 
interact with and activate mTORC198,99.  There are also upstream signals that act independently 
of TSC1/2.  Protein kinase B (Akt) can activate mTORC1 by phosphorylating PRAS40100 and 
adenosine monophosphate-activated protein kinase (AMPK) can inhibit the complex by 
phosphorylating raptor103.  Additionally, amino acids have been shown to regulate mTORC1 by 
relocating the complex to the lysosomal surface where it can be activated by Rheb101,102. 
In comparison to mTORC1, relatively little is known about the mTORC2 signaling 
pathway.  Unlike mTORC1, mTORC2 is insensitive to nutrients, but responds to growth factors in 
an unclear manner204.  mTORC2 regulates metabolism, survival, and cytoskeletal organization 
through control of the AGC subfamily of kinases including Akt, serum- and glucocorticoid-induced 
protein kinase 1 (SGK1), and protein kinase C-α (PKC-α)205-207. 
To determine the effects of autophagy promotion on mammary tumor dormancy and 
recurrence, we chose in inhibit mTORC1, and induce autophagy, using the drug rapamycin.  
Rapamycin regulates mTOR signaling by forming a gain-of-function complex with 12-kDa FK506-
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binding protein (FKBP12)191,193.  This complex then inhibits mTORC1, but not mTORC2, possibly 
by compromising the formation of mTORC1208,209 as well as inhibiting the activity of the kinase 
domain of mTOR210,211.  Chronic treatment with rapamycin can also inhibit the activity of mTORC2 
in a cell type-specific manner by disrupting its formation; although, the details of this phenomenon 
are unclear212,213.   
Here we discuss the results obtained from attempts to promote autophagy using the drug 
rapamycin.  Studies outlined in previous chapters focused on inhibiting autophagy in dormant 
tumor cells to determine if autophagy is required for mammary tumor dormancy and/or 
recurrence.  These experiments determined that autophagy is required for HER2/neu-induced 
mammary tumor recurrence by promoting the survival of dormant tumor cells.  To complement 
this work, we wished to determine if autophagy is sufficient to promote recurrence in MTB/TAN 
mice.  Based on our initial hypothesis, we anticipated that promoting autophagy would accelerate 
recurrence, possibly by enhancing the survival of dormant tumor cells.  Surprisingly, treatment 
with rapamycin delayed HER2/neu-induced recurrence and decreased dormant mammary tumor 
cell survival.  Though unexpected, these findings are the first to demonstrate that dormant 
mammary tumor cells are especially susceptible to rapamycin treatment, thus raising the 
possibility that this drug might have clinical utility in the context of patients with minimal residual 
disease.  
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RESULTS 
 
Rapamycin treatment delays mammary tumor recurrence 
Based on our findings that autophagy inhibition delays mammary tumor recurrence, 
coupled with the fact that rapamycin induces autophagy by inhibiting the mTORC1 complex, we 
hypothesized that rapamycin treatment would increase the number of dormant mammary tumor 
cells surviving HER2/neu down-regulation and thereby accelerate mammary tumor recurrence.   
To determine the effect of rapamycin treatment on recurrence, MTB/TAN primary tumor 
cells labeled with H2B-EGFP were injected into mammary fat pads of nu/nu mice maintained on 
doxycycline.  Once primary tumors formed, mice were deinduced and HER2/neu expression was 
down-regulated.  Treatment with rapamycin or vehicle control began at 28 days post-deinduction, 
when primary tumors had regressed to a non-palpable state and a small population of quiescent 
residual tumor cells remained in the mammary gland (Figure 1A).   
In contrast to our expectations, treatment with rapamycin markedly delayed the latency of 
tumor recurrence compared to treatment with a vehicle control (H.R. = 23.26, 95% CI 8.06-67.19, 
p < 0.0001; Figure 1B).   
 
Rapamycin treatment does not affect recurrent tumor growth 
Although the finding that rapamycin delays recurrence was unexpected, given the 
magnitude of this effect, we wished to determine its cellular mechanism.  Based on knowledge of 
the mTOR signaling pathway, at least three different type of cell-autonomous mechanisms could 
contribute to this effect.  First, rapamycin could decrease proliferation and/or decrease survival of 
recurrent tumor cells, and the resulting slower tumor growth rate could be responsible for an 
increase in the time to the detection of palpable recurrent tumors.  Second, rapamycin could 
decrease the survival of dormant mammary tumor cells within the mammary gland.  If fewer 
residual tumor cells are present in the gland, each of which has a similar (but low) probability of 
re-entering the cell cycle, recurrence would be expected to be delayed.  Third, rapamycin 
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treatment could inhibit the re-entry of dormant tumor cells into the cell cycle and, thereby, 
increase the time to recurrence.  Beyond these hypothetical mechanisms, or a combination of 
these mechanisms, tumor cell non-autonomous effects of rapamycin treatment could also 
contribute. 
To distinguish between these possible mechanisms of action of rapamycin, we set out to 
determine if the mean growth rate of recurrent tumors was altered by rapamycin treatment.  In 
addition, as a control we analyzed the effects of rapamycin on primary tumor growth.  Rapamycin 
or vehicle control was administered to animals harboring orthotopic MTB/TAN primary or 
recurrent tumors starting from a size of 62.5 mm3 to 381.5 mm3 and changes in mean tumor 
growth rate were calculated over this time (Figure 2A, B).  In primary tumors, rapamycin 
treatment marginally decreased the mean growth rate from 6 mm3 per day to 3 mm3 per day 
(Figure 2C).  However, analogous to observations in cancer patients treated with rapalogs188,214, 
tumors rapidly became resistant to treatment (Figure 2E).  For the first 12 days of rapamycin 
treatment, primary tumors grew more slowly than control tumors.  Subsequent to that, however, 
primary tumors treated with rapamycin began to grow rapidly, suggesting they had escaped the 
inhibitory effects of rapamycin treatment (Figure 2E).   
In contrast to what was observed in primary tumors, the mean growth rate of recurrent 
tumors was not significantly affected by treatment with rapamycin (Figure 2D), and there was no 
significant difference between the tumor volumes of vehicle control and rapamycin treated mice at 
any time point examined (Figure 2F).  This suggests that actively growing and proliferating 
MTB/TAN recurrent tumors are not affected by rapamycin treatment and argues against the 
possibility that rapamycin treatment decreases recurrent tumor cell growth and, therefore, 
increases the time to recurrent tumor detection. 
 
Rapamycin decreases survival of dormant mammary tumor cells 
Since rapamycin had little effect on the growth of recurrent tumors, we next wished to 
determine if rapamycin delayed mammary tumor recurrence by decreasing the survival of 
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dormant tumor cells in vivo.  To do so, we treated mice bearing dormant residual disease with 
rapamycin or vehicle control for 2 weeks (Figure 3A, B).  Mammary glands from these mice were 
then harvested, digested to form a single cell suspension, and the number of H2B-EGFP-labeled 
dormant tumor cells was determined using flow cytometry.  Rapamycin treatment resulted in a 
30% decrease in the number of dormant residual cells present after 2 weeks compared to 
treatment with control (Figure 3C).  Since dormant MTB/TAN tumor cells exist in the absence of 
proliferation, the decrease in dormant tumor cell number observed following rapamycin treatment 
suggests that mTOR activity is required for the survival of dormant tumor cells.   
We next wished to determine if this decrease in dormant tumor cell number is responsible 
for the delay of tumor recurrence observed upon treatment with rapamycin or if rapamycin 
treatment delays recurrence by inhibiting cell cycle re-entry of dormant tumor cells.  To 
distinguish between these two possibilities, we treated animals that harbored dormant residual 
disease with rapamycin for 2 weeks.  Treatment was then stopped and the formation of recurrent 
tumors was monitored (Figure 4A).  As observed with chronic rapamycin treatment, treatment 
with rapamycin for 2 weeks significantly delayed tumor recurrence (H.R. = 2.29, 95% CI 1.27-
5.17, p = 0.0088; Figure 4B).  While significant, treating mice for 2 weeks with rapamycin did not 
delay tumor recurrence as greatly as when treatment was continued until sacrifice of the mouse 
due to recurrent tumor burden (Figure 1B).  Therefore, this result is consistent with a model in 
which rapamycin treatment decreases the survival of dormant tumor cells and that treatment with 
rapamycin for longer than 2 weeks is necessary to cause greater dormant tumor cell death and 
increase the latency of tumor recurrence.  On the other hand, this result is also consistent with a 
model in which rapamycin both decreases dormant tumor cell survival and delays the re-entry of 
dormant tumor cells into the cell cycle. 
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Evaluation of potential mechanisms of rapamycin resistance in recurrent mammary 
tumors 
Having observed that rapamycin treatment inhibits recurrence, and that this is associated 
with a decrease in the number of surviving dormant tumor cells, we wished to investigate the 
molecular mechanisms underlying this phenomenon.  Even though recurrence is delayed in 
response to rapamycin treatment, tumor cells do escape rapamycin treatment and ultimately 
recur (Figure 1B).  We chose to look for any differences between these recurrent tumors that 
formed in the presence of rapamycin treatment and recurrent tumors that formed while being 
treated with control to determine the mechanism of rapamycin resistance.  It was our hope that 
this would provide insight into the components of the mTOR signaling pathway that are involved 
in delaying mammary tumor recurrence.   
 Mutations in mTOR and FKBP12 have been reported to confer resistance to rapamycin.  
Mutations in mTOR that convert serine 2035 to an isoleucine abolish FKBP12-rapamycin binding 
to mTORC1215,216.  In a similar manner, FKBP12 mutations that substitute arginine 42 for 
glutamine or tryptophan 59 for leucine abrogate sensitivity to rapamycin as well217.  Therefore, 
genomic DNA from 16 recurrent tumors harvested from mice in Figure 1B treated with vehicle 
control or rapamycin was sequenced for the reported mutations.  No mutations were identified in 
control or rapamycin treated recurrent tumors (data not shown). 
We next investigated the activity of mTORC1 in these same recurrent tumors by 
determining the phosphorylation state of its targets.  The mTOR signaling pathway is complex; 
therefore, the phosphorylation status of multiple downstream effectors may be altered in order for 
tumor cells to escape rapamycin treatment.  One of the most commonly measured mTORC1 
targets is S6K1.  Upon rapamycin treatment, S6K1 becomes hypophosphorylated and inactive.  
As a result, the ribosomal protein S6, a direct target of S6K1, is no longer phosphorylated198-200.  
To determine the activity of the mTORC1-S6K1 pathway, we tested the phosphorylation status of 
both S6K1 and S6 in recurrent tumors that had escaped rapamycin treatment, as well as vehicle 
control tumors, by western blotting.  In control tumors, phosphorylation of both S6K1 and S6 was 
 86 
 
evident, suggesting that the mTORC1 pathway was active (Figure 5A, B).  Rapamycin treatment 
was associated with a marked decrease in phosphorylation of S6K1 compared to recurrent 
tumors treated with vehicle control (Figure 5A).  Consistent with this, S6 phosphorylation was 
dramatically inhibited in all recurrent tumors that escaped rapamycin treatment (Figure 5B).  This 
result implies that the S6K1 arm of mTORC1 signaling remains intact in tumors that recur and 
grow despite rapamycin treatment.  This, in turn, suggests that the S6K pathway is not 
responsible for promoting tumor cell escape from rapamycin treatment.  
Another well defined target of mTORC1 is 4E-BP1.  Upon mTORC1 inhibition by 
rapamycin, 4E-BP1 becomes hypophosphorylated.  This results in the continued association of 
4E-BP1 and eIF4E and decreased protein translation197.  It has been shown, in some cell types, 
that 4E-BP1 phosphorylation recovers after chronic treatment with rapamycin218.  Therefore, we 
evaluated the phosphorylation status of 4E-BP1 as a potential mechanism of rapamycin 
resistance in recurrent tumors.  Using western blotting, we evaluated 4E-BP1 phosphorylation at 
mTORC1 target residues in recurrent tumors that formed in the presence of rapamycin or vehicle 
control.  As was observed for S6K1, 4E-BP1 phosphorylation was decreased in recurrent tumors 
that formed in the presence of rapamycin compared to control tumors (Figure 5C).  This implies 
that the 4E-BP1 arm of mTORC1 signaling is intact and not responsible for the escape of 
recurrent tumors from rapamycin treatment.  Taken together, these results suggest that mTORC1 
activity is inhibited by rapamycin, even in recurrent tumors that have escaped from the effects of 
rapamycin treatment. 
In addition to testing the phosphorylation status of direct mTORC1 targets in rapamycin-
resistant recurrent tumors, we were also interested in assessing Akt activity to determine if this 
molecule was involved in the escape of recurrent tumors from the effects of rapamycin treatment.  
An autoinhibitory feedback loop in mTORC1 signaling has been described where S6K1 can 
phosphorylate insulin receptor substrate-1 (IRS1), promoting IRS1 proteolysis.  Loss of this 
scaffold protein then results in a decrease in PI3K-Akt-mTOR pathway activity.  Rapamycin can 
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block this autoinhibitory feedback loop, causing activation of PI3K-Akt signaling and subsequent 
resistance to the drug219.   
To determine whether the PI3K-Akt pathway was affected by rapamycin treatment, we 
probed for phosphorylated Akt at serine 473 and total Akt levels in recurrent tumors that formed in 
the presence of rapamycin treatment or vehicle control.  In contrast to the increase in 
phosphorylated Akt that would be expected if the above IRS1 feedback loop was active, we 
observed lower levels of phospho-Akt in rapamycin-resistant recurrent tumors compared to 
control recurrent tumors (Figure 5D).  This result does not support a role for the S6K1-IRS1 
feedback loop in escape from rapamycin treatment.    
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DISCUSSION 
 
Disseminated tumor cells are detectable in the bone marrow of greater than 30% of 
breast cancer patients and these cells are believed to exist in a non-proliferative state44,45,220.  At 
least some of these dormant cells retain the ability to resume growth, resulting in tumor 
recurrence and death from breast cancer.  As such, understanding the mechanisms by which 
dormant tumor cells survive is of clinical importance.   
We chose to investigate the PI3K-Akt-mTOR signaling pathway as a potential 
mechanism of dormant tumor cell survival because its regulation of autophagy, as well as its 
control of cell survival, is well characterized95.  Although PI3K-Akt-mTOR signaling has been 
implicated in the progression of a number of different primary malignancies, the role of this 
pathway in tumor dormancy and recurrence is unclear.  Using an inducible bitransgenic mouse 
model of breast cancer dormancy and recurrence, we found that inhibiting mTOR through the use 
of the drug rapamycin significantly delayed tumor recurrence by decreasing the survival of 
dormant tumor cells. 
Based on our previous work supporting a pro-tumorigenic role for autophagy in mammary 
tumor recurrence, this result was unexpected.  We had predicted that rapamycin would 
accelerate tumor recurrence by inducing autophagy and enhancing the ability of dormant tumor 
cells to survive.  Instead, we observed that rapamycin treatment increased the time to recurrence 
and decreased the number of dormant tumor cells surviving within residual lesions.  Taken 
together, these results suggest that the mechanism by which rapamycin prevents tumor 
recurrence in MTB/TAN mouse model is via a mechanism other than autophagy. 
Despite evidence that mTORC1 inhibits autophagy, data exist suggesting that rapamycin 
does not promote this process in all cellular contexts.  The Sabatini group discovered rapamycin-
resistant functions of mTORC1, one of which is the inhibition of autophagy.  They observed that 
in MEFs, rapamycin slightly increased the number of GFP-LC3 punctate per cell compared to 
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controls, but the use of a new ATP-competitive inhibitor of mTORC1 named Torin1 markedly 
induced autophagy221.   
An alternate possibility is that rapamycin inhibits, rather than promotes, autophagy in 
dormant tumor cells as mTOR has recently been shown to inactivate the death associated protein 
1 (DAP1), a known inhibitor of autophagy222.  While we have not yet elucidated the basis for this 
unexpected result, our evidence does suggest that rapamycin does not delay mammary tumor 
recurrence by promoting autophagy. 
We found that rapamycin reduced the number of dormant tumor cells within residual 
lesions, suggesting that rapamycin delays recurrence by decreasing the survival of cells with the 
potential to form tumors.  Additionally, treating animals that harbored residual tumor cells with 
rapamycin for 2 weeks significantly delayed recurrence, further suggesting that rapamycin delays 
recurrence by reducing dormant tumor cell survival.  Yet, treating mice for 2 weeks with 
rapamycin did not result in the more that 2-fold delay in recurrence we observed when animals 
bearing minimal residual disease were treated until sacrifice.  Taken together, these results are 
consistent with a model in which rapamycin increases recurrent tumor latency by reducing 
dormant tumor cell survival, but periods of rapamycin treatment longer than 2 weeks are 
necessary to give rise to greater dormant tumor cell death and a greater delay in recurrence.  
Another possible explanation for the shorter time to tumor recurrence observed in mice 
that were treated with rapamycin for 2 weeks compared to chronic treatment is that, in addition to 
inhibiting dormant tumor cell survival, rapamycin delays re-entry of dormant tumor cells into the 
cell cycle.  However, until we are able to determine the time point in tumor progression where 
dormancy ends and tumor cells reinitiate cell proliferation, we will not be able to test this. 
In addition to uncovering a cellular mechanism of action for rapamycin treatment, we 
were also interested in determining a molecular mechanism.  As mTOR signals through a variety 
of effectors, multiple cellular processes and signaling components downstream of mTORC1 could 
be involved in promoting mammary tumor dormancy and recurrence.  Since interrogating 
signaling pathways in residual dormant tumor cells is technically challenging, we chose to first 
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determine the activity of the mTORC1 pathway in recurrent tumors that had escaped rapamycin 
treatment.  We anticipated that changes observed between rapamycin-resistant tumors and 
controls would potentially provide insight into mTORC1 effectors that are important during 
mammary tumor dormancy.  We first investigated the phosphorylation state of S6K1 and 4E-BP1, 
direct targets of mTORC1.  Each of these molecules were hypophosphorylated in recurrent 
tumors treated with rapamycin, suggesting that tumor recurrence is not explained by escape from 
rapamycin-mediated inhibition of these downstream signaling arms of mTORC1.  This, in turn, 
suggests that other mTOR effectors, such as HIF1α, Lipin-1, SREBP1, and PGC1α,  may be 
involved in escape from rapamycin treatment and – by extension – dormant tumor cell survival95. 
Next, we shifted our focus upstream of mTORC1.  Rapamycin can increase Akt activity in 
tumor cells through inhibition of the S6K1-IRS1 feedback loop219,223, raising the possibility that 
this could serve as a mechanism for tumor cells to escape rapamycin treatment.  We instead 
found a loss of Akt phosphorylation in rapamycin-resistant tumors.  One possible explanation for 
the loss of Akt activity is that in addition to mTORC1, mTORC2 is inhibited by rapamycin.  
Chronic rapamycin treatment of tumor cells has been shown to inhibit both mTORC1 and 
mTORC2 activity and consequently decrease the size of tumor xenografts213,224.  As Akt is a 
direct target of mTORC2205, the loss of Akt phosphorylation in rapamycin-resistant recurrent 
tumors suggests that both mTOR complexes may be inhibited in MTB/TAN recurrent tumor cells 
as well.  This suggests that mTORC2 signaling may be a potential mechanism of tumor cell 
escape from rapamycin treatment. 
These potential explanations for the delay in tumor recurrence seen with rapamycin 
treatment all assume that rapamycin inhibits mTORC1 activity within MTB/TAN tumor cells and 
therefore delays recurrence in a tumor cell-autonomous manner.  It is also possible that tumor 
cell non-autonomous effects are responsible for the delay in recurrence we observed as the 
majority of cell types within the mouse are exposed to rapamycin and may be affected by the 
drug.   
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Despite the mechanistic questions that remain, we show that rapamycin exerts its anti-
tumor effects specifically during dormancy, a stage in breast cancer progression most often 
resistant to targeted therapy or cytotoxic agents.  It is notable, then, that most, if not all, clinical 
trials that are underway using rapamycin and its analogs to target cancers are in the context of 
actively proliferating cancers that our findings would predict will not respond to rapamycin 
treatment188,225.  Rather, our results suggest that the use of rapamycin in patients with dormant 
minimal residual disease at high risk for relapse would be a successful therapeutic approach for 
the prevention of breast cancer recurrence. 
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METHODS 
 
Cell culture 
Inducible MTB/TAN primary tumor cell lines were generated as previously described70.  Cells 
were cultured at 37 °C in 5% CO 2 and maintained in DMEM (MediaTech) supplemented with 10% 
Super Calf Serum (Gemini Bio-Products), 5 µg/ml insulin (Gemini Bio-Products), 10 ng/ml EGF 
(Sigma-Aldrich), 5 µg/ml prolactin (National Institute of Diabetic and Digestive and Kidney 
Diseases), 1 µM progesterone (Sigma-Aldrich), 1 µg/ml hydrocortisone (Sigma-Aldrich), 2 µg/ml 
doxycycline (Research Products International), 200 nM glutamine (Gibco), and 1% 
penicillin/streptomycin (Gibco) unless otherwise indicated. 
 
Immunoblotting 
Protein lysates were prepared by homogenizing tumors or cell lines in lysis buffer (50 mM Tris-
HCl, pH 7.5; 150 mM NaCl; 1% Triton X-100) supplemented with HaltTM Protease and 
Phosphatase Inhibitor Cocktail (Thermo Scientific).  For Western blot analysis, membranes were 
probed with Alexa-Fluor-conjugated secondary antibodies (Molecular Probes).  Bound antibodies 
were detected using the Odyssey detection system (LI-COR Biosciences).  The following primary 
antibodies were used for Western blotting: anti-phospho S6K Thr 389 (Cell Signaling), anti-S6K 
(Cell Signaling), anti–phospho S6 Ser 235/236 (Cell Signaling), anti-S6 (Cell Signaling), anti-
phospho 4E-BP1 Thr 37/46 (Cell Signaling), anti-4E-BP1 (Cell Signaling), anti-phospho Akt 
Ser473 (Cell Signaling), anti-Akt (Cell Signaling), anti–β-tubulin (Biogenex). 
 
Immunofluorescence 
Tissue was either snap-frozen in O.C.T. (TissueTek) and cut into 8 µM frozen sections.  Samples 
were fixed in 4% paraformaldehyde for 10 min and then permeabilized with 0.5% Triton/PBS for 
20 min.  All samples then were blocked in 10% goat serum/4% BSA/PBS for 1 h and incubated 
overnight at 4 °C with primary antibody diluted in 4% BSA/PBS.  Samples were stained with 
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Alexa-Fluor-conjugated secondary antibodies (Molecular Probes) diluted in 4% BSA/PBS for 1 h 
at RT in addition to Hoechst 33258 (Sigma-Aldrich) to visualize nuclei.  The following primary 
antibodies were used for IF:  anti-Ki67 (Dako).  Microscopy was performed on a DM 5000B 
Automated Upright Microscope (Leica) and images were captured using a DFC350 FX 
monochrome digital camera (Leica).  4 residual lesions were sectioned the entire way through the 
mammary gland and 4-6 non-serial slides from each lesion were analyzed. 
 
Retrovirus production and infection 
H2B-EGFP was previously cloned into pk170.  Retroviruses were generated by transfection of 
Plat-E cells172.  Plat-E cells were plated at 5x106 cells per 10-cm dish 1 d before transfection.  
Lipofectamine® 2000 transfection reagent (Life Technologies) plus 24 µg of the retroviral plasmid 
of interest was added to cells.  Media was changed 6 h later and replaced with 5 ml fresh media.  
Viral supernatants were harvested two days later, centrifuged at 2,000 r.p.m., split into 1 ml 
aliquots, and snap frozen at -80°C.    
 MTB/TAN primary tumor cells were plated at 1x105 cells per well in 6-well plates.  The 
following day, 1 ml of viral supernatant, 3 ml of media, and 8 µg/ml polybrene were added to each 
well.  Cells were then centrifuged at 2,000 r.p.m. for 2 h at RT and then incubated overnight at 
37°C.  Media was changed the following day.  Select ion with 1 µg/ml puromycin was initiated 24 h 
later to isolate stable transfectants. 
 
RNA isolation and DNA sequencing 
RNA was isolated from cells using RNeasy® RNA Mini Kit (Qiagen) and reverse transcription was 
performed using the SuperScript® First-Strand Synthesis System for RT-PCR (Life Technologies) 
according to manufacturer’s instructions.   cDNA surrounding the suspected mutations was 
amplified by PCR, and fragments were sequenced using the same primers.  Primers used for 
mTOR:  cacaatgcagccaacaagat, tttcgacaccattcttgtgc.  Primers used for FKBP12:  
ggtggagaccatctctcctg, aacaagagtggcatgtggtg. 
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Mice and recurrence assays 
Animal care and all animal experiments were performed with the approval of, and in accordance 
with, guidelines of the University of Pennsylvania IACUC.  Orthotopic recurrence assays were 
performed as described70.  1x106 cells were injected into the inguinal mammary fat pads of 
athymic nu/nu mice (Taconic) maintained on 2 mg/ml doxycycline (Research Products 
International) and 5% sucrose in drinking water.  Animals were monitored twice per week for 
primary or recurrent tumor formation.  For rapamycin treatment, animals were matched based on 
time of deinduction and then randomly assigned to a treatment cohort.  Rapamycin (LC 
Laboratories) was dissolved in DMSO and mixed with a 0.2% Sodium 
Carboxymethylcellulose/0.25% Polysorbate 80/PBS vehicle buffer before intraperitoneal injection 
every other day.  Tumor volume (vol) was calculated using the formula (W2*L)/2 where L≥W.  
Area under the curve (AUC) was calculated using the formula [(vol1+vol2)/2]*(day2-day1).  Mean 
recurrent tumor growth rate was calculated using this formula [(sumAUC)-(vol1*(dayn-
day1))]/(dayn-day1)2. 
 
Flow cytometry 
Mammary glands were harvested, manually minced, and incubated at 37°C for 1 h in MEGM 
(Lonza), 1X B-27 (Gibco), 20 ng/ml bFGF (Sigma-Aldrich), 4 µg/ml heparin (Stem Cell 
Technologies), 5% Super Calf Serum (Gemini Bio-Products), and 1X Collagenase/Hyaluronidase 
(Stem Cell Technologies).  Tissue was then suspended in red blood cell lysis buffer for 5 min, 
washed with 1X DPBS (cellgro), digested in 0.25% trypsin-EDTA (Gibco) for 2 min, washed, and 
digested in 1X DPBS (cellgro), 2% Super Calf Serum (Gemini Bio-Products), 1 mM EDTA, 1 
mg/ml dispase II (Stem Cell Technologies), and 100 mg/ml DNAse I (Qiagen) for 5 min.  After 
washing, cells were resuspended in 1X DPBS (cellgro), 2% Super Calf Serum (Gemini Bio-
Products), and 1 mM EDTA and analyzed for EGFP-fluorescence using a FACSCaliburTM flow 
cytometer (BD Biosciences).  Total fluorescently-labeled cell number was calculated using 
CountBrightTM Absolute Counting Beads for flow cytometry (Molecular Probes). 
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Statistical analyses 
We used Student's unpaired t-test for statistical analysis.  Log-rank test was used when analyzing 
survival curves.  p value < 0.05 was considered statistically significant.  Hazard ratio with 95% 
confidence interval was calculated for survival curves. 
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Rapamycin treatment delays mammary tumor recurrence.  (A) Schematic of 
orthotopic MTB/TAN recurrence model and timing of rapamycin treatment.  (B) Recurrence-free 
survival of female nu/nu mice harboring fully regressed orthotopic MTB/TAN tumors that were 
treated with control (n = 20) or 4 mg/kg rapamycin (n = 22) starting 28 d after HER2/neu down-
regulation as described in (A).  Median latencies for tumor recurrence indicated. 
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Figure 2 
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Figure 2.  Rapamycin treatment does not affect recurrent tumor growth.  (A, B) Schematics 
of orthotopic MTB/TAN model and timing of rapamycin treatment.  Female nu/nu mice harboring 
MTB/TAN orthotopic (A) primary or (B) recurrent tumors were treated with vehicle control or 4 
mg/kg rapamycin starting when tumors were 62.55 mm3 until tumors reached 381.5 mm3.  Mean 
growth rates of orthotopic MTB/TAN (C) primary and (D) recurrent tumors were calculated.  
Average tumor volumes were calculated for orthotopic MTB/TAN (E) primary (n = 18) and (F) 
recurrent tumors (n = 22) during treatment.  Data represent mean ± SEM.  
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Figure 3 
 
Figure 3.  Rapamycin decreases survival of dormant mammary tumor cells.  (A) Schematic 
of orthotopic MTB/TAN dormancy model and timing of rapamycin treatment.  (B) Representative 
immunofluorescence images of untreated MTB/TAN residual lesions (n = 6) stained for Ki67 
harvested 36 d post-doxycycline (dox) withdrawal.  An orthotopic primary MTB/TAN tumor was 
used as a positive control for Ki67 staining.  Original magnification, 630x.  (C) Female nu/nu mice 
harboring fully regressed orthotopic MTB/TAN primary tumors were treated with vehicle control (n 
= 22) or 4 mg/kg rapamycin (n = 21) for 2 wks as described in (B).  At 36 d post-dox withdrawal, 
the number of EGFP-positive tumor cells per gland was calculated by flow cytometry.  Data 
represent mean ± SEM.  *p < 0.05.   
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Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Rapamycin delays recurrence by decreasing the number of dormant tumor cells.  
(A) Schematic of orthotopic MTB/TAN recurrence model and timing of rapamycin treatment.  (B) 
Recurrence-free survival of female nu/nu mice bearing fully regressed orthotopic MTB/TAN 
primary tumors that were treated with vehicle control (n = 24) or 4 mg/kg rapamycin (n = 24) for 2 
wks as described in (A).  Median latencies for tumor recurrence indicated. 
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Figure 5 
 
Figure 5.  Evaluation of potential mechanisms of rapamycin resistance in recurrent 
mammary tumors.  (A-D) Orthotopic recurrent MTB/TAN tumors harvested from the experiment 
outlined in Figure 1B that formed in the presence of vehicle control or 4mg/kg rapamycin 
treatment were analyzed by western blot for mTORC1 pathway activity.  β-tubulin is used as a 
loading control.  (A)  Levels of p70 S6 kinase 1 (S6K1) phosphorylated at threonine 389 and total 
S6K1 were assessed.  An additional isoform of S6K1, p85, phosphorylated at threonine 412 is 
also detected.  (B) Levels of ribosomal protein S6 phosphorylated at serine 235/236 and total S6 
were measured.  (C) Phosphorylation of 4E-BP1 at threonine 37/46 and total 4E-BP1 protein 
levels were assessed.  (D) The feedback loop between S6K1 and Akt was assessed by probing 
for levels of phosphorylated Akt at serine 473 in addition to total levels of Akt.
 102 
   
CHAPTER V:  Determining if Metformin Promotes HER2/neu-Induced Mammary Tumor 
Recurrence
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INTRODUCTION 
 
Metformin is a biguanide widely prescribed as a first-line anti-diabetic drug in type 2 
diabetes mellitus patients.  In addition to its anti-diabetic properties, metformin may also have 
potential as a cancer therapy.  Observational studies have shown that metformin treatment is 
associated with reduced cancer incidence and cancer-related mortality for a variety of 
malignancies226-228.  In studies of breast cancer, metformin use was associated with a lower risk 
of developing the disease229-231.  An association was also seen between metformin usage and 
decreased mortality due to breast cancer232.   
Initial studies showing an association between metformin and decreased cancer risk led 
to the widespread initiation of preclinical studies to better understand the effects of metformin on 
tumor cells233.  Metformin treatment reduces the risk of animals developing carcinogen-induced 
liver cancer and decreases the growth of gastric and liver tumors in mice234-236.  Metformin also 
delayed the onset of mammary tumors induced by chemical carcinogens or HER2/neu 237,238.  
Furthermore, metformin may improve the efficacy of chemotherapy.  Metformin showed 
synergetic anti-tumor activity with doxorubicin, paclitaxel, and trastuzumab in several mouse 
tumor models239-242.  Taken together, these findings in preclinical models are consistent with the 
possibility that metformin has anti-neoplastic properties. 
On the other hand, preclinical studies have found that metformin can increase the 
survival of tumor cells.  In multiple cancer cell lines, metformin reduced tumor cell death mediated 
by cisplatin treatment, and this was later found to be due to the induction of autophagy243,244.  
Furthermore, metformin treatment of mice bearing p53+/+ HCT116 tumor xenografts resulted in 
the induction of autophagy and increased tumor cell survival compared to p53-/- tumors245.  These 
studies were performed in primary tumor cells in vitro and in vivo and the results are consistent 
with our previous work showing autophagy promotes the survival of dormant tumor cells. 
Despite the conflicting reports on the effects of metformin on primary tumorigenesis, no 
studies have been done to determine the effects of metformin treatment on tumor dormancy or 
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recurrence.  Therefore, we wished to determine the effects of metformin treatment during this 
period in tumor progression using the MTB/TAN mouse model of breast cancer.  In light of our 
work supporting a pro-tumorigenic role for autophagy in dormant tumor cell survival and 
recurrence, we predicted that metformin would accelerate mammary tumor recurrence through 
the induction of autophagy and the increased survival of dormant tumor cells.   
Whether metformin has pro-tumorigenic or tumor suppressive effects on cancer, it is now 
understood that metformin acts through activation of AMPK246.  5’ adenosine monophosphate-
activated protein kinase (AMPK) is a highly conserved serine/threonine kinase that plays an 
important role in cancer cell metabolism because of its regulation of cellular energy homeostasis.  
Under conditions of cellular stress where the ratio of AMP/ATP becomes elevated, AMPK is 
activated and decreases ATP-consuming processes while inhibiting proliferation.  An important 
upstream kinase of AMPK, liver kinase B1 (LKB1), phosphorylates the α subunit of AMPK, and 
this event is required for AMPK activation247. 
Regulation of AMPK by metformin is indirect and suspected to be due to the inhibition of 
respiratory chain complex I of the mitochondrial electron-transport chain and the resulting 
increase in the intercellular AMP/ATP ratio248.  The consequences of AMPK activation by 
metformin are still unclear, but potential mechanisms of the anti-neoplastic activity of metformin 
have been proposed.  AMPK activation by metformin was found to inhibit mTORC1 and S6K1 
activity and decrease protein synthesis and proliferation of breast cancer cells in vitro249.  
Additionally, treatment with metformin activated AMPK and down-regulated fatty-acid synthase 
(FAS) expression, resulting in decreased fatty-acid synthesis and decreased growth of 
xenografted colon tumors in mice250.   
There is also evidence that metformin may act in an AMPK-independent manner234,251-260.  
Recently, metformin was shown to inhibit adenylate cyclase, reduce cyclic AMP and protein 
kinase A (PKA) activity, and block glucagon-dependent glucose output from mouse 
hepatocytes261.  Metformin was also found to decrease carcinogen-induced lung cancer by 
inhibiting the phosphorylation of insulin-like growth factor-I receptor/insulin receptor (IGF-1R/IR), 
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Akt, and ERK without activating AMPK258.  Also, metformin sensitized tumor cells to glucose 
deprivation by decreasing the transcription of genes involved in the unfolded protein response, 
even in tumor cells lacking an intact AMPK pathway259.  Lastly, metformin decreased the 
proliferation of prostate cancer cells through a decrease in cyclin D1 levels.  Inhibition of AMPK 
by siRNA did not alter the anti-proliferative effects of metformin on these cells, suggesting 
metformin decreased cyclin D1 levels independently of AMPK260. 
In contrast, AMPK activation has been shown to result in an increase in tumor cell 
survival upon metformin treatment due to the induction of autophagy.  It has been suggested that 
metformin induces autophagy through an AMPK-dependent decrease in mTOR signaling243,244. 
mTOR-mediated stimulation of autophagy by metformin has also been reported to require p53245.  
However, it was recently discovered that AMPK can directly phosphorylate ULK1, the 
downstream target of mTOR required for autophagosome formation, suggesting an alternative 
mechanism for autophagy induction by metformin113,114. 
Here we discuss our attempts to promote autophagy in dormant mammary tumor cells 
through the use of the drug metformin.  We hypothesized that metformin would induce autophagy 
and promote the survival of dormant mammary tumor cells, resulting in the acceleration of breast 
cancer recurrence.  Using multiple doses of the drug to treat MTB/TAN mice bearing minimal 
residual disease, we were unable to detect any difference in recurrence latency.  Additionally, we 
were unable to detect a change in recurrence upon metformin treatment when p53 expression 
was decreased in tumor cells.  Together, these results suggest that metformin may not affect 
mammary tumor recurrence.   
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RESULTS 
 
Metformin does not affect mammary tumor recurrence 
 To determine if metformin treatment would accelerate mammary tumor recurrence, mice 
that harbored fully regressed orthotopic MTB/TAN primary tumors were chronically treated with 
metformin or a vehicle control (Figure 1A).  No significant difference in recurrence latency was 
detected between control and metformin treated animals (Figure 1B).  There was also no change 
in recurrent tumor growth rates upon metformin treatment (Figure 1C).  This result suggests that 
metformin does not affect mammary tumor recurrence. 
 We considered the possibility that the amount of metformin administered to the mice may 
not have been high enough to activate AMPK and promote autophagy.  We observed that 
increasing the amount of metformin administered by I.P. injection resulted in toxicity (data not 
shown).  Therefore, we tested the efficacy of metformin treatment administered orally233.  Three 
oral doses, 0.25 mg/ml, 1.25 mg/ml, and 3.75 mg/ml, corresponding to 0.5 - 3 times the I.P. dose, 
were used.  Administering metformin through the drinking water did not significantly affect the 
weights of the animals and they all were in good body condition (Figure 2A).  To confirm that 
metformin was hitting its target, we looked for AMPK activation in these mice by analyzing the 
phosphorylation of AMPKα, the catalytic subunit, in liver since it is the main metformin responsive 
tissue262.  LKB1 phosphorylates AMPKα in the activation loop at threonine 172, and this 
phosphorylation is required for AMPK activation247.  We observed no detectable AMPKα 
phosphorylation, even at the highest metformin dose (Figure 2B).  This suggests that 
administering metformin orally through the drinking water may be a viable option as it did not 
cause toxicity, but the dose may need to be increased further to activate AMPK signaling. 
We decided to continue with our experiments using a higher dose of metformin, 5 mg/ml 
or 1,000 mg/kg, administered orally.  Female nu/nu mice harboring fully regressed primary tumors 
were treated with metformin or vehicle control and recurrence latency was measured (Figure 
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3A).  Even at this higher dose, however, metformin had no effect on the latency of recurrence in 
either the 99142 or 54074 orthotopic MTB/TAN models (Figure 3B, C). 
 
Metformin does not affect recurrence of mammary tumors with decreased expression of 
p53 
 It has been reported that growth of p53-deficient tumors, but not p53+/+ tumors, is 
inhibited by metformin treatment245.  In light of this finding, we hypothesized that MTB/TAN tumor 
cells, which expressed p53, might not be sensitive to metformin treatment.  We therefore knocked 
down p53 in each of these MTB/TAN primary tumor cell lines to see if metformin would affect the 
recurrence latency of these tumors (Figure 4A-D).  In addition to conferring sensitivity to 
metformin, p53 loss is often seen in breast tumors180.  As such, this is an appropriate model 
system to study the effects of metformin on breast cancer recurrence.  Treatment with metformin 
was initiated in female nu/nu mice bearing dormant residual disease and recurrence was 
monitored (Figure 5A).  As seen previously, knockdown of p53 accelerated recurrence of 54074 
MTB/TAN tumors compared to tumors generated from cells expressing endogenous levels of 
p53.  The median recurrence latency of 54074 tumors was 93 days post-deinduction (Figure 3C), 
whereas it decreased to 39 days post-deinduction for tumors expressing an shRNA targeting p53 
(Figure 5C).  However, there was no change in time to recurrence upon metformin treatment, 
even in recurrent tumors with decreased expression of p53 (Figure 5B, C).  
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DISCUSSION 
 
 Many preclinical and clinical studies have suggested that the anti-diabetic drug metformin 
reduces overall cancer risk and mortality.  On the other hand, it has been shown that metformin 
can promote the survival of tumor cells through the activation of autophagy in an AMPK and p53-
dependent manner.  Despite these contradictory hypothesized roles for metformin in primary 
tumorigenesis, the effects of AMPK activation and metformin treatment on tumor dormancy and 
recurrence have not been determined.  We hypothesized that metformin treatment would 
accelerate mammary tumor recurrence by promoting the induction of autophagy and survival of 
dormant mammary tumor cells.   
We also considered the possibility that metformin would suppress tumor recurrence 
based on the large body of work in preclinical settings reporting anti-cancer effects of the drug233.  
Furthermore, metformin has been shown to inhibit the transcription of genes involved in the 
epithelial-to-mesenchymal transition (EMT) in breast cancer stem cells263.  We previously 
reported that the EMT transcription factor Snail promotes mammary tumor recurrence70, so we 
also considered the possibility that metformin treatment would delay tumor recurrence through 
the inhibition of EMT.  However, despite multiple attempts using increasing concentrations of the 
drug, we were unable to detect a change in recurrence time in our MTB/TAN mouse model upon 
metformin treatment.   
A previous study reported that metformin and the AMPK activator AICAR decreased the 
growth rate of p53-deficient, but not p53+/+, tumors.  Therefore, we hypothesized that the negative 
results that we obtained may have been due to the fact that primary and recurrent tumor cells in 
MTB/TAN mice express p53.  To test this, we evaluated the effects of metformin in mice bearing 
dormant tumor cells expressing an shRNA targeting p53.  Despite knocking down expression of 
p53 in tumor cells, metformin had no effect on time to recurrence.  Taken together, these results 
suggest that metformin does not affect mammary tumor recurrence. 
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We originally hypothesized that metformin would increase the survival of dormant tumor 
cells through the induction of autophagy.  However, in subsequent work we determined that 
autophagy is activated in dormant mammary tumor cells in vivo.  As such, dormant mammary 
tumor cells may not have responded to metformin treatment because further induction of 
autophagy is not possible, or does not increase the number of dormant tumor cells that survive.  It 
may be helpful to determine if metformin induces autophagy in MTB/TAN cells that are not 
undergoing autophagy, such as primary tumor cells in vitro or in vivo.  
Another possible explanation for these negative results may be that metformin only 
shows anti-neoplastic activity in the context of mice that are diabetic or obese.  Previous studies 
have reported that metformin reduced tumor growth in mice with diet-induced obesity and 
diabetes, but did not affect tumors in mice receiving a control diet250,264.  It was also suggested 
that metformin might be particularly effective in patients with hyperinsulinemia, a condition 
strongly associated with insulin resistance and diabetes and a pathway that plays an important 
role in the proliferation of tumor cells228,265.  Additionally, while diabetic patients exhibit a 
decreased risk of developing breast cancer with long-term use of metformin229-231, a prospective 
study of non-diabetic women with breast cancer did not show a decrease in tumor cell 
proliferation upon treatment with metformin266.  The weight of evidence suggests that anti-
neoplastic effects of metformin are principally found in the setting of obesity and diabetes and, 
therefore, this could have contributed to the failure to observe an effect in non-obese, non-
diabetic MTB/TAN mice267-269. 
Perhaps most importantly, we may have been unable to effectively activate AMPK in 
dormant and/or recurrent tumor cells.  The doses that we administered were the same as those 
shown to be effective in preclinical studies234-236,239,245.  We reasoned that this dose of metformin, 
or the larger doses that we subsequent administered orally, would be sufficient to activate AMPK 
and induce autophagy in MTB/TAN tumors.  Moreover, this concentration of metformin is 
substantially higher than the 14-35 mg/kg administered to patients in the clinic228.  However, we 
failed to observe AMPKα activation in liver lysates of mice treated with up to 3.75 mg/ml 
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metformin in their drinking water, and we did not investigate AMPKα activation in animals treated 
with 5 mg/ml metformin.  In addition, we never assessed the levels of AMPK activation or 
autophagy in dormant tumor cells or in recurrent tumors upon metformin treatment.  It may also 
be beneficial to investigate the activity of downstream effectors of AMPK, such as mTORC1 and 
FAS, to determine if metformin activates this pathway in MTB/TAN tumors.  Before we can 
confirm that metformin does not affect mammary tumor recurrence, the status of the AMPK 
pathway must be determined in tumor cells treated with the drug. 
 Many studies suggest metformin is a viable treatment option for patients with multiple 
different cancer types.  As a result, more than 50 phase II and III clinical trials are underway to 
test the effects of metformin as a cancer therapy265.  However, the effect of metformin on tumor 
dormancy and recurrence is unknown.  We attempted to address this gap by treating animals 
from the MTB/TAN breast cancer recurrence model with metformin and measuring changes in 
recurrence latency.  Unfortunately, we were unable to detect a difference in time to recurrence 
upon metformin treatment.  While discouraging, this study leaves room for further investigation 
into the role of metformin as either pro-tumorigenic or tumor suppressive in mammary tumor 
dormancy and recurrence.  
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METHODS 
 
Cell culture 
Inducible MTB/TAN primary tumor cell lines were generated as previously described70.  Cells 
were cultured at 37 °C in 5% CO 2 and maintained in DMEM (MediaTech) supplemented with 10% 
Super Calf Serum (Gemini Bio-Products), 5 µg/ml insulin (Gemini Bio-Products), 10 ng/ml EGF 
(Sigma-Aldrich), 5 µg/ml prolactin (National Institute of Diabetic and Digestive and Kidney 
Diseases), 1 µM progesterone (Sigma-Aldrich), 1 µg/ml hydrocortisone (Sigma-Aldrich), 2 µg/ml 
doxycycline (Research Products International), 200 nM glutamine (Gibco), and 1% 
penicillin/streptomycin (Gibco) unless otherwise indicated. 
 
Immunoblotting 
Protein lysates were prepared by homogenizing tumors or cell lines in lysis buffer (50 mM Tris-
HCl, pH 7.5; 150 mM NaCl; 1% Triton X-100) supplemented with HaltTM Protease and 
Phosphatase Inhibitor Cocktail (Thermo Scientific).  For Western blot analysis, membranes were 
probed with peroxidase-conjugated secondary antibodies (Jackson Laboratories).  Bound 
antibodies were detected with an enhanced chemiluminescent system (ECL; Amersham).  The 
following primary antibodies were used: anti-phospho AMPKα Thr 172 (Cell Signaling), anti-
AMPKα (Cell Signaling), anti–p53 (Cell Signaling), anti–β-tubulin (Biogenex). 
 
Plasmid generation 
Oligonucleotide for shRNA targeting p53 was obtained from Ross Dickens (Cold Spring Harbor 
Laboratory, Cold Spring Harbor, New York, USA).  The following sequence was used:  p53 
shRNA:  TGCTGTTGACAGTGAGCGCCCACTACAAGTACATGTGTAATAG 
TGAAGCACAGATGTATTACACATGTACTTGTAGTGGATGCCTACTGCCTCGGA. 
Oligonucleotide was cloned into the LMP vector (Open Biosystems) as described171.  H2B-EGFP 
was previously cloned into pk170. 
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Retrovirus production and infection 
Retroviruses were generated by transfection of Plat-E cells172.  Plat-E cells were plated at 5x106 
cells per 10-cm dish 1 d before transfection.  Lipofectamine® 2000 transfection reagent (Life 
Technologies) plus 24 µg of the retroviral plasmid of interest was added to cells.  Media was 
changed 6 h later and replaced with 5 ml fresh media.  Viral supernatants were harvested two 
days later, centrifuged at 2,000 r.p.m., split into 1 ml aliquots, and snap frozen at -80°C.    
 MTB/TAN primary tumor cells were plated at 1x105 cells per well in 6-well plates.  The 
following day, 1 ml of viral supernatant, 3 ml of media, and 8 µg/ml polybrene were added to each 
well.  Cells were then centrifuged at 2,000 r.p.m. for 2 h at RT and then incubated overnight at 
37°C.  Media was changed the following day.  Select ion with 1 µg/ml puromycin was initiated 24 h 
later to isolate stable transfectants. 
 
Mice and recurrence assays 
Animal care and all animal experiments were performed with the approval of, and in accordance 
with, guidelines of the University of Pennsylvania IACUC.  Orthotopic recurrence assays were 
performed as described70.  1x106 cells were injected into the inguinal mammary fat pads of 
athymic nu/nu mice (Taconic) maintained on 2 mg/ml doxycycline (Research Products 
International) and 5% sucrose in drinking water.  Animals were monitored twice per week for 
primary or recurrent tumor formation.  For metformin treatment, animals were matched based on 
time of deinduction and then randomly assigned to a treatment cohort.  Metformin was dissolved 
in PBS before daily intraperitoneal injection (I.P.).  Water that contained metformin was changed 
daily for experiments where the drug was administered orally.  Metformin (dimethylbiguinide 
hydrochloride) was purchased from Sigma-Aldrich. 
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Statistical analyses 
We used Student's unpaired t-test for statistical analysis.  Log-rank test was used when analyzing 
survival curves.  p value < 0.05 was considered statistically significant.  Hazard ratio with 95% 
confidence interval was calculated for survival curves. 
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Figure 1 
 
Figure 1.  Metformin treatment does not affect recurrence of 99142 MTB/TAN tumors.  (A) 
Schematic of orthotopic MTB/TAN recurrence model and timing of metformin treatment.  (B) 
Recurrence-free survival of female nu/nu mice bearing fully regressed orthotopic 99142 
MTB/TAN primary tumors treated with control (n = 8) or 250 mg/kg/d metformin (n = 10) by I.P. 
injection.  Median tumor recurrence times indicated.  (C) Mean tumor growth rates of orthotopic 
99142 MTB/TAN recurrent tumors treated with control or 250 mg/kg/d metformin by I.P. injection 
from a size of 63 mm3 to 382 mm3. 
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Analysis of oral metformin administration ad libitum.  (A) Weights of female nu/nu 
mice treated with 0.25, 1.25, or 3.75 mg/ml metformin in drinking water (n = 3).  Data represent 
mean ± SEM.  (B) Western blot analyzing phosphorylation of AMPKα in livers from animals 
treated with control or 3.75 mg/ml metformin in drinking water.  Total AMPKα was used as a 
loading control.  C2C12 cells grown in the presence or absence of serum in the media served as 
a positive control for AMPKα phosphorylation. 
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Figure 3 
 
Figure 3.  Oral administration of metformin does not affect mammary tumor recurrence.  
(A) Schematic of orthotopic MTB/TAN recurrence model and timing of metformin treatment.  (B) 
Recurrence-free survival of female nu/nu bearing fully regressed orthotopic 99142 MTB/TAN 
primary tumors treated with control (n = 10) or 5 mg/ml metformin (n = 12) administered in 
drinking water.  (C) Recurrence-free survival of female nu/nu bearing fully regressed orthotopic 
54074 MTB/TAN primary tumors treated with control (n = 7) or 5 mg/ml metformin (n = 5) 
administered in drinking water.  Median recurrence latencies indicated. 
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Figure 4 
 
Figure 4.  Knockdown of p53 in MTB/TAN primary tumor cells.  (A, B)  p53 mRNA levels 
evaluated by qRT-PCR in parental primary MTB/TAN tumor cells, cells expressing a control 
vector, and cells expressing an shRNA targeting p53 (shp53).  Expression is normalized to Tbp.  
(C, D)  p53 levels evaluated by western blotting in parental MTB/TAN primary tumor cells, cells 
expressing a control vector, and cells expressing shp53.  HC11 cells were used as a positive 
control for p53 expression.  β-tubulin is shown as a loading control.   
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Figure 5 
 
Figure 5.  Oral administration of metformin does not affect recurrence of mammary tumors 
expressing an shRNA targeting p53.  (A) Schematic of orthotopic MTB/TAN recurrence model 
and timing of metformin treatment.  (B) Recurrence-free survival of female nu/nu bearing fully 
regressed orthotopic 99142 MTB/TAN primary tumors expressing an shRNA targeting p53 
(shp53) treated with control (n = 10) or 5 mg/ml metformin (n = 12) administered in drinking water.  
(C) Recurrence-free survival of female nu/nu bearing fully regressed orthotopic 54074 shp53 
MTB/TAN primary tumors treated with control (n = 12) or 5 mg/ml metformin (n = 10) 
administered in drinking water.  Median recurrence latencies indicated.  
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CHAPTER VI:  Summary and Future Directions 
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SUMMARY 
 
 Residual dormant tumor cells that survive treatment of the primary tumor and persist 
within a patient ultimately result in mammary tumor recurrence, currently an incurable disease.  
Consequently, understanding the mechanisms of dormant mammary tumor cell survival may 
provide insight into the development of more effective approaches for the treatment and/or 
prevention of breast cancer recurrence.  In this work, we provide evidence for two novel 
strategies for the treatment of breast cancer patients at high risk of relapse: inhibition of 
autophagy or of the mTOR signaling pathway.  Using both pharmacological and genetic 
approaches in an inducible bitransgenic MTB/TAN mouse model, inhibiting autophagy (Figure 1) 
or mTORC1 activity (Figure 2) each delayed recurrence of HER2/neu-induced primary tumors by 
causing the elimination of dormant mammary tumor cells in vivo. 
 First, we demonstrated that autophagy is triggered upon HER2/neu down-regulation at 
acute time points and remains activated in dormant residual disease.  Next, we inhibited 
autophagy by treatment with chloroquine or Lys05, Atg5/7 knockdown, or monoallelic loss of 
Beclin 1 to demonstrate that autophagy is required for recurrence in both an orthotopic and intact 
mouse model of HER2/neu-induced breast cancer.  In studies to identify a cellular mechanism for 
this requirement, we found that residual tumor cells require autophagy to survive in the dormant 
state.  In contrast, we found no requirement for autophagy in actively growing primary or recurrent 
tumors.  Together, these observations constitute the first demonstration that autophagy is 
required for breast cancer recurrence by supporting the survival of dormant tumor cells.  These 
findings conflict with multiple lines of evidence suggesting that autophagy plays a tumor 
suppressive role during primary tumorigenesis and highlight the differing biological properties of 
primary tumor cells compared to dormant residual tumor cells. 
Additionally, we found that treatment of genetically engineered mice bearing dormant 
residual disease with the mTORC1 inhibitor rapamycin significantly delayed the recurrence of 
HER2/neu-induced mammary tumors.  In what we believe to be an autophagy-independent 
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manner, rapamycin treatment impaired the survival of dormant tumor cells in vivo, without 
affecting proliferation or apoptosis in recurrent tumor cells.  We conclude that rapamycin 
treatment delays recurrence by specifically targeting quiescent dormant mammary tumor cells.  
Since rapamycin is known to promote autophagy, the effects of mTOR inhibition on dormant 
tumor cells are likely mediated by another effector pathway. 
 Lastly, we discussed our attempts to determine the effects of stimulating autophagy on 
mammary tumor dormancy and recurrence using the anti-diabetic agent metformin.  We were 
unable to detect any significant changes in the time to tumor recurrence upon metformin 
treatment, even with the use of high concentrations of this drug.  Metformin was also ineffective at 
altering the recurrence latency of tumor cells in which p53, a molecule shown to obviate 
metformin’s anti-neoplastic activity, was knocked down.  These results suggest metformin 
treatment is not sufficient to promote mammary tumor recurrence. 
 Combined, our results suggest pro-tumorigenic roles for autophagy as well as the mTOR 
signaling pathway as they both are required for the recurrence of HER2/neu-induced mammary 
tumors.  Each of these findings suggests multiple areas of further investigation as well as 
potential approaches for the treatment and prevention of breast cancer recurrence. 
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FUTURE DIRECTIONS 
 
Determine the microenvironmental stresses responsible for the induction of autophagy in 
dormant mammary tumor cells 
Autophagy is activated in response to multiple microenvironmental stresses, such as 
changes in the extracellular matrix (ECM), hypoxia, metabolic stress, and endoplasmic reticulum 
(ER) stress, that have been implicated in tumor dormancy41,270.  Therefore, it is worth 
investigating if dormant MTB/TAN tumor cells endure these stresses through the use of 
autophagy.  This may provide more insight into why autophagy is required for dormant tumor cell 
survival and how to best target this process in the clinic as a treatment for breast cancer 
recurrence. 
 
Loss of β1-integrin signaling 
 Dormant tumor cells can establish interactions with the ECM, and there is evidence that 
changes in this interaction, specifically through the loss of β1-integrin signaling, can induce 
dormancy.  In quiescent D-HEp3 squamous carcinoma cells, reduced expression of urokinase 
receptor (uPAR) compared to proliferating T-HEp3 cells deactivated α5β1 integrins, inhibiting 
integrin binding to fibronectin.  This resulted in reduced focal adhesion 1-kinase (FAK) and Ras–
extracellular signal-regulated kinase (ERK) signaling, as well as p38 activation in dormant cells41.  
Also, by down-regulating FAK, the loss of β1-integrin signaling inhibited proliferation of tumor 
cells in a MMTV-PyMT model of breast cancer61.  Additionally, type I collagen (Col-I) can initiate 
proliferation of dormant mammary tumor cells through β1-integrin activation of Src kinase and 
FAK.  Knockdown of multiple components of this signaling cascade was able to inhibit Col-I 
induced proliferation to promote dormancy59.  Evidence for the importance of β1-integrin signaling 
has also been described in the clinic, where detection of uPAR in disseminated dormant tumor 
cells predicted relapse of gastric cancer271. 
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It has also been suggested that the loss of β1-integrin signaling may stimulate 
autophagy.  Decreased β1-integrin signaling induced autophagy, and autophagy protected tumor 
cells from detachment-induced apoptosis (anoikis)272.  However, the signaling pathways 
connecting β1-integrin signaling and autophagy are unclear.  It has been shown that FAK can 
inhibit tuberous sclerosis 1/2 (TSC1/2) and inactivate mammalian target of rapamycin complex 1 
(mTORC1), possibly relieving its inhibition on autophagy273.  Furthermore, mammary epithelial 
cells treated with antibodies that block β1-integrin exhibited an increase in eukaroyotic initiation 
factor 2α (eIF2α) activity, a molecule that regulates the conversion of LC3-I to LC3-II274,275.  Loss 
of adhesion has also been shown to activate pancreatic endoplasmic reticulum kinase (PERK)276.  
PERK negatively regulates mTORC1 signaling through the activation of AMP-activated kinase 
(AMPK) and TSC2 to activate autophagy as a mechanism to survive anoikis. 
To determine if dormant MTB/TAN cells exhibit decreased β1-integrin signaling 
compared to actively proliferating primary tumor cells, we propose to assess the activity of 
multiple components of this signaling pathway previously implicated in tumor dormancy including 
FAK, ERK, p38, and eIF2α41.  Using antibodies that detect the phosphorylation state of these 
molecules, we plan to determine the activity of the β1-integin pathway by immunofluorescence 
staining of primary and dormant MTB/TAN tumor cells in vivo.  Additionally, the activity of these 
signaling molecules can be measured in primary and dormant MTB/TAN tumor cells in vitro if 
cells are cultured on plates coated with ECM proteins such as integrins and fibronectin.  This will 
enable the detection of changes in the β1-integrin signaling pathway between proliferating and 
quiescent tumor cells.  Decreased phosphorylation of FAK and/or ERK, and increased 
phosphorylation of p38 and/or eIF2α, in dormant tumor cells would be consistent with a model in 
which dormant mammary tumor cells induce autophagy to survive the loss of ECM interaction 
through decreased β1-integrin signaling.   
If we find a low ERK:p38 activity ratio in dormant tumor cells, we propose to treat mice 
harboring dormant mammary tumor cells with the p38 inhibitor SB203580277.  We plan to 
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measure recurrent tumor latency as well as dormant tumor cell number by flow cytometry in mice 
treated with SB203580 or vehicle control.  We predict that decreasing the activity of p38 will 
inhibit autophagy, decrease dormant tumor cell survival, and delay tumor recurrence if autophagy 
promotes the survival of dormant tumor cells in response to the loss of ECM interaction.  
However, inhibiting p38 may cause dormant tumor cells to resume proliferation, resulting in an 
increase in the number of dormant tumor cells and an acceleration of recurrence. 
  
Hypoxia 
 Oxygen is essential to support oxidative phosphorylation and ATP production within the 
cell.  Consequently, a poorly vascularized tumor microenvironment can limit oxygen distribution, 
leading to metabolic stress and cell death.  As a survival response to hypoxia (3 - 0.1% oxygen), 
tumor cells activate a transcriptional program via the hypoxia-inducible factor complex (HIF)131.  
HIF is a heterodimer consisting of HIF-1α, a subunit that is unstable in the presence of > 5% 
oxygen, and the β subunit ARNT.  Under hypoxic conditions, HIF-1α becomes stabilized and the 
HIF complex regulates the transcription of hundreds of genes involved in erythropoiesis, 
angiogenesis, energy metabolism, pH regulation, cell migration, and tumor invasion.   
Autophagy is also a survival response of normal and tumor cells to hypoxia.  Autophagy 
occurs in hypoxic regions of tumors, and inhibiting autophagy in low oxygen conditions results in 
tumor cell death155-157,278-280.  Hypoxia-induced autophagy has been reported to be dependent 
upon the up-regulation of BNIP3 and BNIP3L133.  These are BH3-domain containing proteins that 
sequester Bcl-2 or Bcl-XL away from Beclin 1 to induce autophagy.  Additionally, the increase in 
the AMP/ATP ratio that results from the suppression of oxidative phosphorylation by hypoxia can 
activate AMPK.  AMPK can induce autophagy by inhibiting mTORC1 or activating ULK1, an 
essential autophagy gene113,114,281.  The unfolded protein response (UPR) is also triggered by 
hypoxia and can regulate autophagy as described below131.   
To determine if the residual lesion is a hypoxic environment, we propose to treat animals 
that harbor residual lesions with pimonidazole.  This compound binds to thiol-containing proteins 
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specifically in hypoxic cells and can be detected through immunostaining282.  Additionally, we 
intend to stain for the expression of HIF-1α and its downstream targets, such as vascular 
endothelial growth factor (VEGF), pyruvate dehydrogenase kinase 1 (PDK1), and BNIP3, in 
dormant MTB/TAN tumor cells to determine if the hypoxic response is active in these cells283.  If 
we find that the residual lesion is a hypoxic microenvironment, this would suggest that autophagy 
may be a survival mechanism for dormant mammary tumor cells subjected to hypoxic stress.  We 
propose to further confirm the induction of autophagy in hypoxic dormant tumor cells by knocking 
down BNIP3 or BNIP3L in MTB/TAN tumor cells prior to the use of the cells in the orthotopic 
recurrence model.  If the hypoxic microenvironment is stimulating autophagy in dormant tumor 
cells to promote survival, knockdown of BNIP3 is predicted to result in increased dormant tumor 
cell death as assayed by flow cytometry as described in Chapters II and IV and delayed tumor 
recurrence. 
 
Metabolic Stress 
Mammalian cells depend on extracellular nutrient uptake to maintain metabolism and 
provide precursors for macromolecular synthesis, and this uptake is regulated by growth factor 
signaling cascades284.  Therefore, nutrient limitation, either through decreased nutrient availability 
or the loss of growth factors, may lead to metabolic stress.  Decreased glucose metabolism 
results in decreased ATP generation as well as the loss of many biosynthetic precursors, 
including nucleic acids, fatty acids, and acetyl CoA.  The loss of glucose can also inhibit proper 
glycosylation and protein folding in the ER.   
Autophagy is important for the reduction of metabolic stress as it can provide intracellular 
nutrients to replace extracellular nutrient consumption.  Deprivation of amino acids or glucose or 
the loss of growth factors has been shown to induce autophagy and promote survival in multiple 
cell types284.  For example, growth factor withdrawal from Bax/Bak-deficient cells resulted in the 
induction of autophagy to generate nutrients critical for survival.  These cells died upon growth 
factor deprivation if autophagy was inhibited, but the introduction of exogenous nutrients rescued 
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this effect129.  Also, using mass spectrometry, it was shown that nutrient-deprived cells can 
stimulate autophagy as an intracellular source of long-chain fatty acids285,286. 
The mTOR signaling pathway is involved in the induction of autophagy and the 
adaptation to limited nutrient availability.  The loss of amino acids induces autophagy by causing 
the mislocalization of mTORC1 away from Rheb, an activator or mTORC1, through the increased 
binding of mTORC1 to GTP-bound RagA/B102,287.  Decreases in ATP that result from nutrient 
deprivation can also stimulate AMPK signaling.  AMPK activation then induces autophagy in a 
mTOR-dependent manner281 or independently of mTOR through the direct phosphorylation of 
ULK1113,114.  Plus, the loss of growth factors inactivates the PI3K-Akt-mTOR pathway, thus 
activating autophagy284.  We currently have no data to show that the residual lesion supports the 
delivery of amino acids, glucose, or growth factors, so autophagy may be required by dormant 
MTB/TAN tumor cells to survive the metabolic stress brought on by lack of extracellular nutrient 
uptake. 
To determine if nutrients are limited within the residual lesion, we propose to first 
determine if it is well vascularized.  The presence of blood vessels can be determined by 
immunostaining for the endothelial marker CD31288.  If the residual lesion is not well vascularized 
as determined by a lack of CD31+ cells, dormant mammary tumor cells may require autophagy to 
generate energy for survival.  To determine if dormant mammary tumor cells require autophagy to 
generate energy, we propose to treat dormant MTB/TAN cells with chloroquine in the presence or 
absence of methylpyruvate in the culture media.  Methylpyruvate is the cell permeable form of 
pyruvate and is oxidized by the tricarboxylic acid (TCA) cycle to enable the production of ATP 
within a cell129.  If dormant tumor cells stimulate autophagy to generate energy and remain viable, 
the addition of this metabolite to the culture media is expected to rescue the increased cell death 
we observed when autophagy was inhibited by chloroquine. 
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Endoplasmic reticulum (ER) stress 
 Microenvironmental stresses can lead to the accumulation of unfolded or misfolded 
proteins in the lumen of the ER, a condition termed ER stress.  If proper ER homeostasis is not 
reestablished, ER stress can lead to cell death.  ER stress activates a combination of signaling 
pathways known as the unfolded protein response (UPR) to adapt to and survive restrictive 
microenvironments134.  In dormant D-HEp3 squamous carcinoma cells, all three arms of the UPR, 
including PERK, ATF6α and IRE1α, are activated and necessary for the survival of these 
dormant cells in vivo.  Inhibition of PERK, or the ER chaperone BiP, increased the sensitivity of 
D-HEp3 cells to glucose deprivation and chemotherapy65,66.  RNA interference (RNAi)-mediated 
knock down of ATF6α or XBP-1, a transcription factor activated by IRE1α, decreased the number 
of viable D-HEp3 cells in response to similar stresses67,270.  Notably, knock down of ATF6α or 
XBP-1 did not affect the survival of actively proliferating HEp3 cells (T-HEp3).  The preferential 
susceptibility of dormant tumor cells compared with proliferating cells to inhibition of the UPR is 
similar to what we have seen upon the inhibition of autophagy in the MTB/TAN system. 
 This similarity suggests that the UPR may induce autophagy in MTB/TAN dormant tumor 
cells.  Autophagy is stimulated by ER stress as a mechanism for the clearance of terminally 
misfolded proteins.  It was found that induction of the UPR induced autophagy through activation 
of PERK and subsequent phosphorylation of eIF2α275.  Autophagy is also stimulated by IRE1α 
through the activation of the JNK signaling pathway135,136.   
It is important to recognize that ER stress may also inhibit autophagy.  ATF6α has been 
reported to activate Rheb and mTORC1, and potentially inhibit autophagy, as a survival response 
of D-HEp3 cells to multiple stresses67. 
 ER stress frequently results in the release of calcium into the cytosol, and this increase is 
also capable of inducing autophagy.  Increased cytoplasmic Ca2+ following treatment with 
different ER stressors stimulated Ca2+/calmodulin-dependent kinase kinase β (CaMKKβ), leading 
to AMPK activation, inhibition of mTORC1, and the induction of autophagy289.  Additionally, Ca2+-
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dependent mechanisms of autophagy stimulation following ER stress have been described that 
involve death associated protein kinase 1 (DAPK) and PKCθ290,291. 
To determine if UPR is activated in dormant MTB/TAN tumor cells compared to actively 
proliferating primary tumor cells in vivo, we propose to perform immunostaining for activated 
forms of PERK, eIF2α, and JNK134.  An increase in phospho-PERK, phospho-eIF2α, or phospho-
JNK staining in dormant tumor cells compared to primary tumor cells suggests that the UPR is 
activated and autophagy is induced in dormant mammary tumor cells to prevent cell death due to 
ER stress.  We then propose to confirm the role of the UPR in inducing autophagy in dormant 
tumor cells by decreasing the expression of PERK, ATF6α, or XBP-1 in MTB/TAN tumor cells by 
shRNA-mediated knockdown.  These knockdown tumor cells, as well as control cells, will then be 
injected into the mammary glands of nu/nu mice.  The number of dormant tumors cells present 
within the mammary gland will be assessed and recurrent tumor latency will be measured.  We 
anticipate that inhibiting the UPR will decrease dormant tumor cell number and delay recurrence 
if autophagy is required for the survival of dormant tumor cells due to ER stress. 
 
Determine if rapamycin delays mammary tumor recurrence in an autophagy-independent 
manner 
 We favor a model in which rapamycin treatment decreases dormant tumor cell survival 
and delays recurrence through a mechanism independent of autophagy.  Since we have 
demonstrated that autophagy is required for mammary tumor recurrence, the documented ability 
of rapamycin to induce autophagy would predict that rapamycin treatment would accelerate tumor 
recurrence.  In contrast, we found that rapamycin treatment delayed the formation of MTB/TAN 
recurrent tumors.  This, in combination with the reports that in many cell types rapamycin does 
not induce autophagy221, supports the interpretation that rapamycin does not activate autophagy 
in dormant MTB/TAN tumor cells.  It is also possible that rapamycin treatment is unable to 
promote the induction of autophagy beyond what is already occurring in dormant tumor cells, or 
that further induction of autophagy by rapamycin does not result in an increase in dormant tumor 
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cell survival.  Some autophagy-independent functions of mTORC1 signaling, such as the 
promotion of cell survival and proliferation, may be involved in the effects of rapamycin treatment 
on mammary tumor dormancy and recurrence95. 
To determine if dormant MTB/TAN tumor cells are further induced to undergo autophagy 
upon rapamycin treatment, we will assess LC3 cleavage and subcellular localization in vitro and 
in vivo.  Additionally, we would propose to treat mice harboring dormant tumor cells that express 
shRNAs against autophagy genes or have monoallelic deletion of Beclin 1 with rapamycin or 
vehicle control to determine if rapamycin delays mammary tumor recurrence by promoting 
autophagy.  The observation that rapamycin is able to delay recurrence in these autophagy-
deficient mouse models of breast cancer would suggest that the mechanism of action of 
rapamycin treatment may be autophagy-independent. 
 
Determine the signaling pathways downstream of mTORC1 involved in the delay of 
mammary tumor recurrence induced by rapamycin treatment 
 We have determined that treatment with rapamycin significantly delays mammary tumor 
recurrence.  However, recurrent tumors did eventually form in the presence of the drug.  To 
provide insight into the downstream mTORC1 effectors involved in delaying mammary tumor 
recurrence, we chose to investigate potential differences in mTORC1 signaling pathways 
between rapamycin-resistant and control recurrent tumors.  Also, understanding mechanisms of 
resistance to rapamycin may lead to the generation of more effective therapies for the prevention 
of breast cancer in the clinic.   
Despite multiple attempts, we were unable to determine the molecules responsible for 
recurrent tumors becoming resistant to rapamycin treatment.  No mutations were detected in 
mTOR or FKBP12, and the phosphorylation of the mTORC1 downstream targets S6K1 and 4E-
BP1 was decreased in rapamycin-resistant recurrent tumors compared to vehicle control treated 
tumors as expected.  Activation of the Akt pathway is often a mechanism of tumor cell resistance 
to rapamycin, however phospho-Akt levels were down-regulated in rapamycin treated recurrent 
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tumors compared to controls.  An explanation for this decreased Akt activity may be that chronic 
rapamycin treatment of MTB/TAN tumor cells resulted in inhibition of mTORC1 and mTORC2 
since Akt is a direct target of mTORC2205,213.  The downstream signaling of mTORC2 is poorly 
understood, but inhibition of this complex is predicted to result in decreased proliferation and 
decreased survival of tumor cells95.  
Although mTORC2 inhibition is not thought to be a mechanism of rapamycin resistance, it 
is possible that decreased mTORC2 activity is responsible for the increased dormant tumor cell 
death that we observed upon rapamycin treatment.  To determine if this is true, we intend to 
analyze the recurrence latency of MTB/TAN tumors that express an shRNA targeting rictor, a 
molecule specific for mTORC295.  Additionally, we propose to measure the number of dormant 
tumor cells with rictor knockdown present in the residual lesion by flow cytometry as described in 
Chapters II and IV.  The observation that the delay in recurrence and loss of dormant tumor cells 
with rictor knockdown is similar to that which occurs with rapamycin treatment would be 
consistent with a model in which mTORC2 signaling is required for the recurrence of MTB/TAN 
tumors by promoting the survival of dormant tumor cells. 
 We also intend to perform qRT-PCR on rapamycin-resistant and control recurrent tumors 
to assess the activity of direct targets of mTORC1 other than those investigated in Chapter IV, 
including Lipin-1, SREBP1, and PGC1α95.  We predict that one or more of these molecules will 
remain active in the tumor cells that escaped rapamycin treatment, as measured by increased 
expression of their target genes in rapamycin-resistant recurrent tumors compared to vehicle 
control treated tumors.  The sustained activity of one or more of these targets in recurrent tumor 
cells treated with rapamycin will then suggest that these mTORC1 targets are involved in 
conferring resistance to rapamycin.   
Besides investigating the activity of the several remaining direct targets of mTORC1, 
multiple potential mechanisms of rapamycin resistance have been documented in the literature 
that involve molecules not directly regulated by this complex292.  The antiproliferative effects of 
rapamycin were impaired in p27-/- MEFs; and in tumor cells that are resistant to cell cycle arrest 
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caused by rapamycin, p27 levels were decreased compared to corresponding sensitive tumor 
cells293.  Also, overexpression of phospholipase D (PLD) in MCF-7 breast cancer cells inhibited 
growth arrest induced by rapamycin294.  Lastly, p53-/- MEFs were more susceptible to rapamycin-
induced apoptosis than p53+/+ MEFs, and p53-/- MEFs were able to continue to proliferate in the 
presence of rapamycin295.  We propose to investigate these potential mechanisms of rapamycin 
resistance by analyzing p27, PLD, and p53 levels in recurrent tumors that formed in the presence 
of rapamycin or vehicle control by western blotting.  The observation that rapamycin-resistant 
tumors have lower levels of p27 or p53, or increased levels of PLD, compared to vehicle control 
treated tumors would suggest that these molecules may be involved in the escape of tumor cells 
from rapamycin treatment. 
To confirm the requirement of the molecules found to be involved in conferring resistance 
to rapamcyin during mammary tumor dormancy and recurrence, we propose to assess the 
recurrence latency of MTB/TAN orthotopic tumors that express decreased levels of these proteins 
by shRNA-mediated knockdown as well as determine the number of dormant tumor cells with 
knockdown of these targets present within the mammary gland by flow cytometry.   If knockdown 
of these genes delays recurrence and decreases the number of dormant mammary tumor cells to 
a similar extent as to what was observed with rapamycin treatment, these results would be 
consistent with a model in which these molecules are required for MTB/TAN mammary tumor 
recurrence by promoting the survival of dormant tumor cells. 
 
Determine if rapamycin delays mammary tumor recurrence by inhibiting the re-entry of 
dormant tumor cells into the cell cycle  
We discovered that rapamycin kills dormant tumor cells after 2 weeks of treatment, yet 2 
weeks of rapamycin treatment did not delay MTB/TAN tumor recurrence as greatly as when 
treatment was continued until sacrifice of the mouse.  This result is consistent with a model in 
which rapamycin treatment delays tumor recurrence by decreasing the survival of dormant tumor 
cells.  However, treatment with rapamycin for longer than 2 weeks is necessary to cause a great 
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enough decrease in dormant tumor cell survival to result in a 2-fold increase in the latency of 
tumor recurrence.  Conversely, this result is consistent with a model in which rapamycin both 
decreases dormant tumor cell survival and delays the re-entry of dormant tumor cells into the cell 
cycle.  In addition to being cytotoxic, it has been shown that the effects of rapamycin treatment on 
tumor cells is often antiproliferative, resulting in disease stabilization188,214. 
To measure a change in the timing with which dormant tumor cells begin proliferating in 
the context of rapamycin treatment will require the development of a novel assay.  Our 
preliminary data using flow cytometry has suggested a design for such an assay.  We analyzed 
H2B-EGFP-labeled primary tumors, residual lesions harboring dormant tumor cells, and recurrent 
tumors by flow cytometry.  We found that dormant tumor cells are smaller, as determined by the 
decrease in forward scatter of tumor cells, within a residual lesion compared to actively 
proliferating primary and recurrent tumor cells (Figure 3A).  Therefore, we believe a smaller 
forward scatter correlates with quiescence.   
Next, we analyzed the forward scatter of non-palpable residual lesions at 45 days post-
deinduction.  There are residual tumor cells that are small and suspected to be quiescent (Figure 
3B, blue curve).  Yet, there is a population of dormant tumor cells within some residual lesions 
that have begun to grow in size and have possibly begun to proliferate (Figure 3B, green and 
black curves).  This suggests that 45 days post-deinduction is a time in tumor progression when a 
percentage of dormant tumor cells have re-entered the cell cycle.   
Therefore, we propose to harvest the mammary glands of animals that harbor residual 
MTB/TAN tumor cells treated with rapamycin or control from 21 to 45 days post-deinduction and 
analyze cell size and proliferation (Ki67 staining) by flow cytometry.  If rapamycin inhibits 
recurrence by delaying the re-entry of tumor cells into the cell cycle, we predict that rapamycin 
treatment will result in a larger percentage of tumor cells that have a small forward scatter and 
that are Ki67-negative compared to tumor cells treated with control. 
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Determine if tumor cell non-autonomous effects of rapamycin cause a delay in mammary 
tumor recurrence 
 With the use of a pharmacological agent like rapamycin, multiple cell types within the 
animal, not just tumor cells, are exposed to the drug and may be functionally modified.  We have 
begun experiments to determine whether rapamycin delays recurrence through tumor cell 
autonomous or non-autonomous means by generating an mTOR construct that is resistant to 
rapamycin215,216.  We would then generate MTB/TAN primary tumor cells that express rapamycin-
resistant mTOR for use in our orthotopic recurrence model.  If rapamycin directly targets tumor 
cells, we anticipate that treatment of animals bearing dormant tumor cells expressing a 
rapamycin-resistant mTOR will not result in a delay in recurrence.  However, if rapamycin 
treatment still delays recurrence of tumor cells expressing a rapamycin-resistant allele of mTOR, 
tumor cell non-autonomous effects of rapamycin are suggested to be responsible for the 
observed delay in recurrence and studies to determine the exact cell population sensitive to 
rapamycin treatment need to be conducted.   
  
Determine if promoting autophagy affects mammary tumor dormancy and recurrence 
 Conflicting reports suggest that autophagy plays a context-specific role in tumor 
development and progression, either as a tumor suppressive or pro-tumorigenic process.  
Therefore, understanding the effects of inducing autophagy on mammary tumor dormancy and 
recurrence is important to further confirm our results that autophagy promotes recurrence in the 
context of HER2/neu-induced breast cancer.  In this work, we reported two separate attempts to 
promote autophagy in dormant tumor cells to determine if autophagy was sufficient to promote 
mammary tumor recurrence.  Our findings from the first attempt, using the mTORC1 inhibitor 
rapamycin, suggest that rapamycin treatment delays MTB/TAN tumor recurrence through a 
mechanism other than autophagy.  The second attempt involved treating MTB/TAN mice that 
harbored residual tumor cells with the biguinide metformin.  We did not observe a change in 
recurrent tumor latency with metformin treatment and it is currently unclear if metformin was able 
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to promote autophagy in dormant tumor cells.  Therefore, additional methods of inducing 
autophagy are necessary to determine if promoting autophagy will accelerate mammary tumor 
recurrence.   
 
Pharmacological Induction of Autophagy 
 The recognition that rapamycin and its analogs do not inhibit all mTORC1 targets in all 
cellular contexts has driven the development of second generation mTOR inhibitors.  Catalytic 
inhibitors of mTOR that target the ATP binding site of the kinase domain have generated a great 
deal of interest188.  These mTOR kinase inhibitors block the function of both mTORC1 and 
mTORC2 and can disrupt the feedback-mediated activation of PI3K-Akt, which can be 
responsible for rapamycin resistance.  Catalytic inhibitors of mTOR have proven more efficacious 
than rapamycin in preclinical models through increased cell cycle inhibition.  Also, catalytic 
inhibitors have been shown to induce autophagy in contexts in which rapamycin does not, and 
this has led to anti-tumor activity221,296.  Because of these promising results, several mTOR 
catalytic inhibitors have entered phase I and II clinical trials188. 
Unfortunately, resistance to catalytic mTOR inhibitors can occur, also from activation of 
the PI3K-Akt pathway297.  This has formed the rationale for development of dual PI3K/mTOR 
inhibitors.  As with mTOR kinase inhibitors, dual PI3K/mTOR inhibitors have shown anti-
neoplastic effects in preclinical models188.  Additionally, one particular dual PI3K/mTOR inhibitor, 
NVP-BEZ235, was able to induce autophagy and decrease proliferation of human glioma cells298.  
Therefore, we propose to use second generation mTOR inhibitors to treat animals bearing 
minimal residual disease because they may be a more effective means to determine the effects 
of promoting autophagy on MTB/TAN mammary tumor dormancy and recurrence.  We predict 
that treatment of mice harboring minimal residual disease with second generation mTOR 
inhibitors will decrease recurrence latency by inducing autophagy and promoting the survival of 
dormant mammary tumor cells.  It is also possible that second generation mTOR inhibitors will 
delay MTB/TAN recurrence similarly to what was observed with rapamycin treatment.  This would 
 135 
 
add further support for a model in which mTORC1 inhibition delays mammary tumor recurrence in 
an autophagy-independent manner. 
 Metformin is an anti-diabetic drug that has shown promise as a cancer therapy. 
Metformin has also been shown to induce autophagy and promote tumor cell survival in vitro and 
in vivo243-245.  Consequently, we attempted to use metformin to determine the effects of inducing 
autophagy on MTB/TAN dormant tumor cell survival and recurrence.  Our initial attempts 
suggested that metformin may not affect mammary tumor recurrence.  However, we could not 
rule out that the dose of metformin we administered to mice was unable to effectively activate 
AMPK and induce autophagy in dormant tumor cells.  Verifying the activation of AMPK, by 
immunostaining for phospho-AMPK, and the induction of autophagy, by assessing LC3 cleavage 
and localization, in dormant tumor cells upon metformin treatment are the steps necessary to 
determine the effectiveness of this drug in mice. 
If we find that metformin does not effectively activate AMPK and induce autophagy, we 
propose to use other AMPK activators in MTB/TAN mice to determine the effects of promoting 
autophagy on dormancy and recurrence.  Aminoimidazole carboxamide ribonucleotide (AICAR) is 
a direct activator of AMPK that has been used clinically to treat and protect against cardiac 
ischemic injury299.  Similar to metformin, AICAR has shown anti-cancer activity in tumor 
models245,300.   
In addition, phenformin is a biguanide anti-diabetic drug being studied for its anti-
neoplastic effects.  Phenformin is approximately 50-fold more potent than metformin with broader 
tissue availability248.  Uptake of metformin by cells requires the expression of the organic cation 
transporter 1 (OCT1), whereas phenformin does not301.  These favorable attributes of phenformin 
led to experiments in preclinical models of cancer.  Phenformin delayed formation and 
progression of lymphomas and breast cancer to a greater extent than metformin302,303.  Recently, 
it was found that phenformin more effectively prolonged the survival of animals with non-small cell 
lung cancer (NSCLC) than metformin by increasing apoptosis in LKB1-deficient tumor cells.  
Notably, cells with an intact LKB1-AMPK pathway were not affected by phenformin treatment304.  
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These results suggest that phenformin may be a more effective promoter of autophagy than 
metformin with greater tissue specificity.  If promoting autophagy increases dormant tumor cell 
survival, we predict that AICAR or phenformin treatment of mice bearing residual disease will 
result in an increase in the number of dormant tumor cells as measured by flow cytometry and in 
a decrease in recurrent tumor latency. 
 
Genetic Induction of Autophagy 
 Inducing autophagy through the genetic manipulation of autophagy genes is an additional 
approach to determine the effects of promoting autophagy on tumor dormancy and recurrence.  
First, shRNA-mediated knockdown of mTOR in MTB/TAN tumor cells is anticipated to lift the 
inhibition on autophagy.  Further downstream of mTOR, over-expression of a ULK1 mutant 
unable to be phosphorylated by mTORC1 should also induce autophagy in MTB/TAN cells95,305.  
Lastly, over-expression of Beclin 1 in MTB/TAN tumor cells is anticipated to promote autophagy.  
Beclin 1 is required for autophagosome formation, and in breast cancer cell lines, over-
expression of Beclin 1 has been shown to promote autophagy153.  We intend to use these 
MTB/TAN cell lines in an orthotopic recurrence assay and predict that their recurrence latency will 
be decreased compared to controls. 
Regardless of the approach chosen, determining the effects of promoting autophagy on 
mammary tumor dormancy and recurrence is important to reconcile the conflicting roles of this 
process during tumorigenesis.  However, it is important to note that we have determined that 
dormant MTB/TAN tumor cells are autophagic, so it may not be possible to promote the process 
further in these cells.  Additionally, the induction of autophagy in cells already undergoing the 
process may not result in increased dormant tumor cell survival.  It is then a possibility that the 
experiments outlined here designed to promote autophagy will not affect mammary tumor 
dormancy and recurrence. 
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Determine if autophagy inhibition affects breast cancer metastasis 
 Mortality from breast cancer is principally caused by tumor recurrences that occur at 
either local, regional, or distant sites.  Our MTB/TAN mouse model of breast cancer primarily 
represents local recurrence since recurrent tumors typically form at a site where a primary tumor 
previously existed70.  This is because primary tumors are not removed surgically in this mouse 
model, whereas breast cancer patients undergo surgery coupled with local irradiation. While local 
recurrence alone is important to understand, there is evidence that the mechanisms of distant 
recurrence are likely to be similar to those of local recurrence. First, the timing of local breast 
cancer recurrence after primary treatment is similar to that of distant metastasis14.  Additionally, 
the transcription factor Snail promotes local recurrence in the MTB/TAN mouse model, but Snail 
expression in human primary breast cancers is also associated with an increased risk of distant 
recurrence70.  However, because of the clinical importance of breast cancer recurrence at distant 
sites, determining the role of autophagy in the survival and outgrowth of metastatic tumor cells 
may lead to a better understanding of breast cancer progression and result in increased survival 
from the disease. 
 There are reports that suggest tumor metastasis may require autophagy.  Epithelial tumor 
cells that normally require attachment to the ECM for survival undergo apoptosis upon 
detachment, a phenomenon termed anoikis.  Autophagy is activated in epithelial cells that have 
detached from the ECM, and inhibition of autophagy increases cell death due to anoikis272.  This 
suggests that MTB/TAN tumor cells that travel from the mammary gland to a distant site may 
need autophagy to survive the journey.  Additionally, the extreme conditions of the metastatic 
microenvironment may induce autophagy in tumor cells as a survival mechanism.   
Tumor-bearing MTB/TAN mice develop pulmonary metastases68.  Therefore, to 
determine if inhibition of autophagy affects metastasis, we propose to analyze the lungs of mice 
bearing orthotopic MTB/TAN recurrent tumors that were generated from control cells or Atg5/7 
knockdown cells for the presence of metastasis.  Additionally, we will monitor the occurrence of 
lung metastases in mice that were treated with chloroquine starting when the animals harbored 
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minimal residual disease until the formation of recurrent tumors.  We predict that autophagy 
inhibition will result in decreased metastasis to the lung. 
 
Determine if rapamycin treatment affects breast cancer metastasis 
Because death from breast cancer is principally due to distant recurrences, determining 
the role of mTORC1 signaling in the survival of disseminated tumor cells and the formation of 
metastasis is also important as it may lead to the improved treatment of women with this disease.  
To determine if inhibition of mTOR signaling affects distant recurrences, we propose to monitor 
the occurrence of lung metastasis in MTB/TAN mice treated with rapamycin from the time when 
dormant residual tumor cells were present until sacrifice of the animals due to recurrent tumor 
burden.  Based on the suspected similarities between local and distant recurrence, we 
hypothesize that rapamycin treatment will decrease metastasis to the lung compared to animals 
treated with vehicle control. 
 
Determine if autophagy inhibition affects the recurrence of mammary tumors driven by c-
Myc or Wnt1 
 Cellular tumor dormancy and recurrence are not phenomena limited to breast cancers 
with elevated levels of HER2/neu as HER2/neu-negative breast cancers do relapse following a 
disease free period306.  Therefore, it is important to know if the withdrawal of other oncogenic 
drivers of breast cancer would similarly lead to the requirement of autophagy during tumor 
dormancy.  Identifying the initial oncogenic driver(s) of dormant tumor cells that respond to 
autophagy inhibition may allow for proper assessment of a patient’s response to this therapy in 
the clinic.   
 We chose to conduct our studies using the MTB/TAN model because approximately 30% 
of breast cancer patients have overexpression or amplification of HER2/neu16,307.  However, we 
have also generated inducible bitransgenic mouse models of breast cancer driven by other 
oncogenes found to be important in the progression of this disease.  Amplification or 
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overexpression of c-MYC is seen in 5-15% of breast cancers and is associated with poor 
prognosis308.  The Wnt signaling pathway is also important in breast cancer as many Wnt proteins 
including Wnt2, Wnt7b, and Wnt10b are up-regulated in human breast carcinomas.  Activation of 
Wnt/β-catenin signaling is also associated with poor outcome in breast cancer patients309,310.  In 
both inducible bitransgenic mouse models generated, MMTV-rtTA/TetO-MYC (MTB/TOM)311 and 
MMTV-rtTA/TetO-Wnt1 (MTB/TWNT)69, primary adenocarcinomas that are initiated by c-Myc or 
Wnt1 fully regress once the oncogene is down-regulated upon doxycycline withdrawal.  A small 
pool of dormant neoplastic cells survives oncogene down-regulation and ultimately results in 
recurrence with kinetics similar to those observed in MTB/TAN mice. 
Analogous experiments using the intact MTB/TAN model treated with chloroquine or 
crossed to Beclin 1+/- mice could be done using MTB/TOM or MTB/TWNT animals to determine if 
the requirement of autophagy for dormant tumor cell survival is specific to HER2/neu-driven 
tumors.  To date, we have been unable to establish MTB/TOM or MTB/TWNT primary tumor cell 
lines to determine if autophagy promotes dormant tumor cell survival in vitro.  We predict that the 
inhibition of autophagy will result in a delay in the recurrence of mammary tumors driven by c-Myc 
and Wnt1.  
It is possible that autophagy will not be required for the survival for all dormant mammary 
tumor cells based on the results of studies investigating the role of autophagy in primary tumors.  
These reports suggest that the oncogene driving primary tumorigenesis dictates whether 
autophagy is tumor suppressive or pro-tumorigenic.  For example, inhibition of autophagy in 
tumor cells over-expressing Bcl-2 resulted in increased tumor growth in vivo155,156.  On the other 
hand, in Ras-activated human and mouse tumor cells, autophagy deficiency abrogated their 
tumorigenicity in vitro and in vivo163,164.  These studies suggest that, during primary 
tumorigenesis, the role autophagy plays is dependent on the initiating oncogenic pathway. 
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Determine if rapamycin treatment affects the recurrence of mammary tumors driven by c-
Myc or Wnt1 
Additionally, it is unknown whether rapamycin will delay the recurrence of mammary 
tumors induced by oncogenes other than HER2/neu.  Because of the mechanism of action of 
rapamycin, only tumor cells that require activation of the mTOR signaling pathway for survival 
and/or proliferation are anticipated to respond to treatment95.  However, if tumor cell non-
autonomous effects of rapamycin result in the delay in MTB/TAN recurrence we observed, it is 
possible that the initiating oncogene will not predict the response of dormant mammary tumor 
cells to rapamycin treatment.   
To determine if rapamycin will delay recurrence of tumors induced by an oncogene other 
than HER2/neu, we propose to chronically treat MTB/TOM or MTB/TWNT animals that harbor 
minimal residual disease with rapamycin or vehicle control and measure time to recurrent tumor 
formation.  There is evidence linking mTORC1 signaling to both c-Myc and Wnt195.  The 
canonical Wnt pathway can activate mTORC1 and mTORC1 can increase the expression of Myc.  
Therefore, we anticipate that rapamcyin treatment will delay the recurrence of tumors driven by 
these oncogenes. 
  
Determine if autophagy inhibition affects tumor recurrence in human models of breast 
cancer 
 Our work studies the role of autophagy in a mouse model of breast cancer dormancy and 
recurrence.  This model accurately recapitulates what is seen in human patients, but typically 
what is effective in mouse models will not translate well into the clinic.  It would then be beneficial 
to study autophagy in dormant mammary tumor cells obtained from human subjects.  
Unfortunately, studying tumor dormancy in patients with breast cancer is very difficult.  
Techniques for the identification and enrichment of quiescent disseminated tumor cells (DTCs) 
are improving, but there are still obstacles that need to be overcome.  DTCs need to be enriched 
because the sample size is very small.  Approximately 1 DTC per 106-107 bone marrow cells can 
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be detected.  Additionally, it is becoming clear that DTCs are a heterogeneous population, so 
accurate morphological and immunological identification of DTCs, the approach of many DTC 
detection methods, may be challenging312.   
To address the lack of knowledge of human breast cancer dormancy, we are currently 
attempting to generate in vitro and in vivo models of dormancy and recurrence using human 
breast cancer cell lines.  Using these models, we predict that autophagy will be required for the 
recurrence of human mammary tumors by promoting the survival of dormant tumor cells. 
 
Determine if rapamycin treatment affects tumor recurrence in human models of breast 
cancer 
Additionally, we propose to use these novel orthotopic mouse models of mammary tumor 
dormancy and recurrence generated using human breast cancer cell lines to determine if mTOR 
activity is required for dormant tumor cell survival and tumor recurrence.  Rapamycin treatment of 
mice bearing minimal residual disease is expected to decrease the number of dormant tumor 
cells and delay the recurrence of human orthotopic mammary tumors, further supporting the use 
of mTOR inhibitors for the prevention of breast cancer recurrence in the clinic. 
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CONCLUSIONS 
 
Death from breast cancer is principally due to tumor recurrence following successful 
treatment of primary disease.  A subset of tumor cells survives treatment and persists in a 
dormant state within a patient, and these cells ultimately give rise to recurrent tumors, currently 
an incurable disease.  Therefore, determining the mechanisms of dormant tumor cell survival is 
critical to the successful treatment of this disease.  Using a HER2/neu-inducible mouse model of 
breast cancer dormancy and recurrence, we show that autophagy inhibition or treatment with the 
mTORC1 inhibitor rapamycin delays mammary tumor recurrence by decreasing the survival of 
dormant tumor cells.   
As a whole, this work suggests that blocking autophagy or mTOR signaling in patients 
with minimal residual disease could be a successful strategy for the treatment and prevention of 
breast cancer recurrence.  As such, existing therapeutic agents, such as chloroquine and 
rapamycin, could be employed in the prevention of breast cancer recurrence.  In addition, novel 
therapies are being developed that would achieve this same goal.  The combination of these 
autophagy or mTOR inhibitors with current standard of care chemotherapeutic approaches may 
have the potential to decrease tumor recurrence, and therefore mortality, from breast cancer. 
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METHODS 
 
Cell culture 
Inducible MTB/TAN primary tumor cell lines were generated as previously described70.  Cells 
were cultured at 37 °C in 5% CO 2 and maintained in DMEM (MediaTech) supplemented with 10% 
Super Calf Serum (Gemini Bio-Products), 5 µg/ml insulin (Gemini Bio-Products), 10 ng/ml EGF 
(Sigma-Aldrich), 5 µg/ml prolactin (National Institute of Diabetic and Digestive and Kidney 
Diseases), 1 µM progesterone (Sigma-Aldrich), 1 µg/ml hydrocortisone (Sigma-Aldrich), 2 µg/ml 
doxycycline (Research Products International), 200 nM glutamine (Gibco), and 1% 
penicillin/streptomycin (Gibco) unless otherwise indicated. 
 
Mice and recurrence assays 
Animal care and all animal experiments were performed with the approval of, and in accordance 
with, guidelines of the University of Pennsylvania IACUC.  Orthotopic recurrence assays were 
performed as described70.  1x106 cells were injected into the inguinal mammary fat pads of 
athymic nu/nu mice (Taconic) maintained on 2 mg/ml doxycycline (Research Products 
International) and 5% sucrose in drinking water.  Animals were monitored twice per week for 
primary or recurrent tumor formation.  For rapamycin treatment, animals were matched based on 
time of deinduction and then randomly assigned to a treatment cohort.  Rapamycin (LC 
Laboratories) was dissolved in DMSO and mixed with a 0.2% Sodium 
Carboxymethylcellulose/0.25% Polysorbate 80/PBS vehicle buffer before intraperitoneal injection 
every other day.  Tumor volume (vol) was calculated using the formula (W2*L)/2 where L≥W.  
Area under the curve (AUC) was calculated using the formula [(vol1+vol2)/2]*(day2-day1).  Mean 
recurrent tumor growth rate was calculated using this formula [(sumAUC)-(vol1*(dayn-
day1))]/(dayn-day1)2. 
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Plasmid generation 
Plasmid containing mTOR cDNA was purchased from Open Biosystems.  mTOR was subcloned 
into the pK1 retroviral vector by cutting mTOR with the restriction enzymes SalI and NotI (NEB).  
The overhang left upon SalI digestion was blunted using DNA Polymerase I, Large (Klenow) 
Fragment (NEB).  pk1 was cut with XhoI and NotI, and the XhoI fragment was similarly blunted 
(NEB).  The fragments were then ligated together using T4 DNA Ligase (NEB) and the resulting 
plasmid mTORpk1 was sequenced.  mTOR-HA was generated by first subcloning mTOR into 
pBluescript KS (PBS/KS; Stratagene) using the restriction enzymes SalI and SspI (NEB).  Next, a 
HA linker was generated to be inserted into mTOR-PBS/KS by using SalI digestion.  mTOR-HA-
PBS/KS was cut with FseI and NotI (NEB), and the FseI fragment was blunted and subcloned 
into pk1 cut with XhoI (blunted) and NotI.  The resulting mTOR-HApk1 was sequenced.   
 
Flow cytometry 
Tumors or mammary glands were harvested, manually minced, and incubated at 37°C for 1 h in 
MEGM (Lonza), 1X B-27 (Gibco), 20 ng/ml bFGF (Sigma-Aldrich), 4 µg/ml heparin (Stem Cell 
Technologies), 5% Super Calf Serum (Gemini Bio-Products), and 1X Collagenase/Hyaluronidase 
(Stem Cell Technologies).  Tissue was then suspended in red blood cell lysis buffer for 5 min, 
washed with 1X DPBS (cellgro), digested in 0.25% trypsin-EDTA (Gibco) for 2 min, washed, and 
digested in 1X DPBS (cellgro), 2% Super Calf Serum (Gemini Bio-Products), 1 mM EDTA, 1 
mg/ml dispase II (Stem Cell Technologies), and 100 mg/ml DNAse I (Qiagen) for 5 min.  After 
washing, cells were resuspended in 1X DPBS (cellgro), 2% Super Calf Serum (Gemini Bio-
Products), and 1 mM EDTA and analyzed for EGFP-fluorescence using a FACSCaliburTM flow 
cytometer (BD Biosciences).  Total fluorescently-labeled cell number was calculated using 
CountBrightTM Absolute Counting Beads for flow cytometry (Molecular Probes).  Cells were stored 
at 4 oC in fixative (1x D-PBS, 0.2% sodium azide, 5% formaldehyde) until all samples were 
collected. 
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Figure 1 
 
Figure 1.  Autophagy inhibition delays HER2/neu-induced mammary tumor recurrence by 
eliminating dormant tumor cells in vivo.  (A) Upon HER2/neu down-regulation, the majority of 
primary MTB/TAN tumor cells (blue circles) die by apoptosis.  The cells that survive become 
dormant and undergo autophagy to survive (white circles with green punctae).  Dormant tumor 
cells then aquire additional changes that allow them to re-enter the cell cycle and form recurrent 
tumors (yellow circles).  (B) Same as in (A), except that if autophagy is inhibited in dormant tumor 
cells (green circles) by chloroquine treatment, Atg5/7 knockdown, or loss of one allele of Beclin 1, 
approximately 40% of dormant tumor cells will die.  This results in a significant delay in the onset 
of recurrent tumors. 
  
 146 
 
Figure 2 
 
Figure 2.  mTORC1 inhibition delays HER2/neu-induced mammary tumor recurrence by 
eliminating dormant tumor cells in vivo.  (A) Upon HER2/neu down-regulation, the majority of 
primary MTB/TAN tumor cells (blue circles) die by apoptosis.  The cells that survive oncogene 
down-regulation become dormant (purple circles).  Dormant tumor cells then aquire additional 
changes that allow them to re-enter the cell cycle and form recurrent tumors (yellow circles).  (B) 
Same as in (A), except that if mTORC1 signaling is inhibited in dormant tumor cells by rapamycin 
treatment, approximately one-third of dormant tumor cells will die.  This results in a significant 
delay in the onset of recurrent tumors.  
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Figure 3 
 
Figure 3.  Quiescent MTB/TAN tumor cells are smaller than actively proliferating tumor 
cells.  (A) Flow cytometry analysis of orthotopic MTB/TAN primary tumors (orange), residual 
lesions (blue), or recurrent tumors (black).  Representative curves for each tumor type shown.  
(B) Non-palpable MTB/TAN residual lesions harvested at 45 d post-deinduction were analyzed by 
flow cytometry.  Three shapes of curves were observed.  We believe the blue curve represents 
mostly quiescent dormant tumor cells, the black curve represents a residual lesion that contains a 
combination of quiescent dormant tumor cells and tumor cells that have grown and re-entered the 
cell cycle, and the green curve represents residual lesions where the majority of tumor cells have 
grown and resumed proliferation. 
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